Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/header.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/cat_index.php on line 1
About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily

In the Pipeline

Category Index
"Me Too" Drugs
Novartis Impresses Where Others Have Failed
The Hydrophobic Effect: I Don't Understand It, Either
Donald Light Responds on Drug Innovation and Costs
Getting Drug Research Really, Really Wrong
Translation Needed
Those Me-Too Drugs
Biosimilars: Not So Dang Easy
Pfizer's Future: Biotech Followups
Arzoxifene: Not the Road to Big Profits?
Now Your Liver Doesn't Have to Make It For You
How Many PPIs Does the World Need?
Bad Luck For Novartis - And For Diabetics
Godzilla vs. Mothra? Relman vs. Epstein!
By a Nose in a Head to Head
No Clear Winners
Gritting Our Teeth
An Economist Who Gets It
Alex Tabarrok on Me-Too Drugs
Blurry Copies
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Hypertension and Marketing
Merck and Its Competition
Our Buddies at the FDA
Adam Smith Goes Pharmaceutical
Innovation and Its Discontents
Claritin and Clarinex

Academia (vs. Industry)
A Day of Irreproducibility In Cambridge
Are Your Compounds Ugly? Do You Know?
The Prospects of an Academic Job
Where the Talent Comes From
Changing A Broken Science System
A Reply on Academic Alzheimer's Research
An All-In-One Alzheimer's Paper
The Seat of Learning, Indeed
Big Pharma And Its Research Publications
The NIH Takes On Reproducibility
The NIH's Drug Repurposing Program Gets Going
The Drug Industry and the Obama Administration
GSK's Published Kinase Inhibitor Set
Crowdfunding Research
The NIH, Pfizer, and Senator Wyden
Yuri Milner's Millions, And Where They're Going
Too Many Scientists: A "Pyramid Scheme"
Academia's Role in Drug Discovery
Advice For Those Trying High-Throughput Screening
Another Controversial Scaffold?
Rearrange Those Chemists
Science Fiction Gets the Upper Hand
Cheer For Good Ol' Pfizer U
Lessons For a New Medicinal Chemist
Return of the Rhodanome
Anonymous Grant Review Gets A Try
The NIH's Drug Repurposing Initiative: Will It Be a Waste?
A New Way to Kill Amoebas, From An Old Drug
A Molecular Craigslist?
Do Industrial Post-Doc Positions Work?
Different Worlds: A Last DHFR Paper Thought
Europe Wants Some of That Molecular Library Action
Merck's CALIBR Venture
Making the Move From Industry to Academia
More on the NIH's Molecular Libraries Program
That Academic-Industrial Collaboration Panel
Academia and Industry, Suing Each Other
Panel on Academic-Industrial Collaboration in Drug Discovery
Francis Collins Speaks
Does Anyone Want the NIH's Drug Screening Program?
"The Smarter You Are, The More I Will Hate You"
Publishing, Perishing, Buying and Selling
How Many New Drug Targets Aren't Even Real?
Broader Impacts Indeed
The NIH and Conflicts of Interest
What Translational Research Should Academia Do?
Academic Drug Discovery: A Survey
Roche Prevails Over Stanford
Maybe It Really Is That Hard?
Translation Needed
The PhD Problem: A Global Perspective
Nothing Personal
Roche and Stanford: Academia v. Industry?
What If Those Wonderful Results Are Wrong?
The NIH Goes For the Gusto
More On the Postdoc Situation
A Postdoc's Lament
Gonna Focus on Re-Engineering the Tools for the Process
New Cures! Faster! Faster!
The NIH's New Drug Discovery Center: Heading Into the Swamp?
Friday Mental Health Break: "Bad Project"
Chemistry Jobs Roundtable: What About Tenure?
Design Your Own Lab Course
And One Was Just Right?
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Another Set of Eyes
A Pile of Malaria Leads For the Taking
Reasons Not to Go to Grad School?
All Of You Industrial Scientists: Out Of the Room
Fear Of Academic Chemistry?
Short Topics From All Over
I'll See Your Conflicts, and Raise You?
The Grant Application Treadmill
Industrial Research: More Grounded in Reality, or Not?
To What End?
Just Give It to NIH
Wasted Money, Wasted Time?
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
More Hot Air From Me on Screening
Competing (And Competing Unethically?)
Poor Equipment Revisited
The Perils of Poor Equipment
More Than This
Lowe's Law of Diurnal Distribution
Getting To Lyrica
Scrape Off Some Attitude
Ugly, But Useful
Drugs From Where?
The Doctorate and Its Discontents
Naked Synthesis
What Can Academia Do?
Problems and Solutions
Peter Kim, So Far
Not On the Same Page
University of Drug Discovery?
The Great Divide
Mutual Suspicions
Differences Between Academia and Industry, Pt. 4
Sneaking Out for an Interview
Getting A Job
More on Question Four
Getting a Faster PhD?
The Bones of the World
Don't Become A Scientist?
Like Moving Furniture Across a Tightrope
Gumming Up the Amyloid Works
The NIH in the Clinic
One More On Basic Research and the Clinic
A Real-World Can O' Worms
How Much Basic Research?
How It Really Works
Will the Uncommon Work for the Common Good?
Industry vs. Academia: The Mental Aspect
Stuart Schreiber on Stuart Schreiber
Differences Between Academia and Industry, Pt. 2
Differences Between Industry and Academia, Pt. 1
On the Money

Aging and Lifespan
Google's Calico Moves Into Reality
Young Blood
A Sirtuin Activator Extends Lifespan in Normal Mice
Boost Your NAD And Fix It All?
Google Versus Aging
A New Pathway For Memory
How Rapamycin Extends Lifespan: Not By Slowing Down Aging
Resveratrol: What's It Do For Mitochondria?
A New Book on Longevity Research
New Sirtuin Inhibitors
Resveratrol Gets Some Details Cleared Up
Caloric Restriction Flops?
Update on the Buckyball Longevity Paper
One More on That Buckyball Longevity Paper
Buckyball Longevity: The Lead Author Replies
Resveratrol Explained. A Little Bit.
Buckyball Longevity - There's A Problem
Buckyballs Prolong Life? Really?
Would I Take Resveratrol? Would You?
Defending Das' Resvertrol Research. Oh, Come On.
A Resveratrol Research Scandal. Oh, Joy.
The Sirtuin Saga
Resveratrol in Humans: Results of a Controlled Trial
The Latest Sirtuin Controversy
Big Sirtuin News
SRT1720: Good (And Confusing) News for Obese Mice
mINDY Mice - No Obesity, No Diabetes?
Live Long and Prosper (and Be Bright Yellow at the Same Time)
Resveratrol (SRT501): Development Halted
Dapsone Prolongs Life? Well, In Nematodes It Does. . .
Does Resveratrol Really Work? And Does SRT1720?
GSK's Response to the Sirtuin Critics
Resveratrol (SRT501): Buy Now - Why Wait?
The Memory Goes Because. . .the Acetyl Groups Go?
SRT501 - A Trial Suspended
The Scent of Food Is Enough?
Sirtris's Compounds: Everyone Agrees?
Take These?
Rapamycin for Alzheimer's?
The Problem With Research on Aging
BioTime's Cellular Aging Results
A GSK/Sirtris Wrap-Up
A Storm in a Teacup
GSK and Sirtris: A Bit More
Sirtuin Scenarios
The Sirtris Compounds: Worthless? Really?
Caloric Restriction and Lifespan - Without the Caloric Restriction?
What Exactly Does Resveratrol Do?
A Nobel for Telomerase
mTOR, Rapamycin, and Lifespan: A Startling Study
Exercise and Vitamins: Now, Wait A Minute. . .
Resveratrol in Mice
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Breaking the Contract of Aging
More Sirtuins With More Effects
And Thee, O Time
Sir2 Surprise
Klotho: Sooner Than You Think?
Breathing and Aging
When Natural Selection's Through With You - Part II
After Natural Selection's Through With You

Alzheimer's Disease
Lilly Steps In for AstraZeneca's Secretase Inhibitor
TDP-43 and Alzheimer's
Targacept Fumbles the Bad News on Alzheimer's
An Alzheimer's Blood Test? Not So Fast.
Alzheimer's Bonds
Good News! Our Alzheimer's Drug Didn't Work!
Citalopram for Alzheimer's?
Alzheimer's Antibodies: Can the Current Ones Even Work?
The State of Alzheimer's Research, 2014
A Blood Test for Alzheimer's?
Alzheimer's Therapies: A Reasonably Gloomy Update
A Reply on Academic Alzheimer's Research
An All-In-One Alzheimer's Paper
David Cameron, The Press, Alzheimer's, and Hope
Lilly Goes All In on Solanezumab
A Beta-Secretase Inhibitor Hits the Skids in Alzheimer's
Update on Bexarotene for Alzheimer's
The FDA's New Alzheimer's Guidance: Wonder or Blunder?
TauRx's Funding Is Odd
CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
Eli Lilly's Brave Alzheimer's Talk
Merck Presses Ahead on Alzheimer's:
TauRx Goes Into Phase III For Alzheimer's
And Since We're Talking About Insider Trading
JNK3 - Something New for Alzheimer's?
The Coming Battle Over Alzheimer's Disease
Another Prospective Alzheimer's Trial
Lilly's Solanezumab: Did It Actually Work?
Lilly's Solanezumab: A Miss or a Win?
Bapineuzumab Still Does Not Work Against Alzheimer's
An Alzheimer's Update: Amyloid Lives?
Bapineuzumab Does Not Work Against Alzheimer's
Live By The Bricks, Die By The Bricks
Strangely Good Results in Diabetes and Cardiovascular Disease
A Preventative Trial for Alzheimer's: The Right Experiment
Bapineuzumab: An Alzheimer's Update
Bexarotene for Alzheimer's
Tau Spreads On Its Own?
Bernard Munos Rides Again
Alzheimer's: The News Is Not Getting Better
Alzheimer's: Down With Amyloid?
Lilly's Gamma Secretase Inhibitor for Alzheimer's: Worse Than Nothing
Alzheimer's Markers and Collaboration
Alzheimer's and Amyloid, Again
Alzheimer's: Extracting Data From Failed Trials
The Memory Goes Because. . .the Acetyl Groups Go?
A Brief and Not At All Intemperate Evaluation of the Current Literature
Rapamycin for Alzheimer's?
Beta-Amyloid: An Antibiotic?
Dimebon, Grasping at Straws
Dimebon Comes Crashing to Earth
A Modest Literature Proposal
Dimebon for Alzheimer's: A Black Box Indeed
Two Doses of Crazy
An Alzheimer's Compound Runs Into Big Trouble
Short Topics From All Over
Amyloid in Trouble
Does Glucophage Make Alzheimer's Worse?
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
Where Are the Drugs?
Rember for Alzheimer's: Methylene Blue's Comeback
Bapineuzumab: Good For Anything or Not?
Patents Stopping an Alzheimer's Wonder Drug?
Another Alzheimer's Compound Goes Down
Protecting Amyloid's Parent?
Elan Tries Again
In Which I Hate A Wonder Drug
Alzheimer's: A Report From the Front
ApoE4: Test or Not?
Fast Plaques in a Slow Disease
Checking The Numbers on the Alzheimer's Test
Beta-Secretase: Not So Fast?
Failure: Not Your Friend, But Definitely Your Companion
How Good Is Aricept, Anyway?
A Trial Too Far
Gumming Up the Amyloid Works
Silent Mutations and Noisy Ones
Back on the Air
Alzheimer's Vaccine Refuses to Die
Sleeping Dragons
Maybe They Can Formulate It in Madelaines
Who Dares, Wins?
Modeling the Brain?

Analytical Chemistry
Weirdly, Tramadol Is Not a Natural Product After All
Fluorinated Fingerprinting
Thalidomide, Bound to Its Target
An Alzheimer's Blood Test? Not So Fast.
Catalyst Voodoo, Yielding to Spectroscopy?
A Horrible, Expensive, and Completely Avoidable Drug Development Mixup
Xenon's Use as a Sports Drug Is Banned
A New NMR Probe Technology in the Making?
A New Way to Get Protein Crystal Structures
Crystallography Without Crystallizing: An Update
Ligands From Nothing
An HIV Structure Breakthrough? Or "Complete Rubbish"?
The 3D Fragment Consortium
New Frontiers in Analytical Chemistry
Touching Up the Spectra
Picking Out Incorrect Natural Products
GPCRs Are As Crazy As You Thought
Watching DNA Polymerase Do Its Thing
Check Out These Molecules
Underappreciated Analytical Techniques
IBM And The Limits of Transferable Tech Expertise
Mass Spec Continues Its Conquests
X-Ray Structures Of Everything. Without Crystals. Holy Cow.
Probing A Binding Tunnel With AFM
Single-Cell NMR? How About Single-Protein NMR?
Stanford's Free Electron Laser Blasts Away
Every Tiny Detail
Picosecond Protein Watching
GSK's Anti-Doping Ad
Bungled Structure, And How
Fluorine NMR: Why Not?
An NMR Poster
Proteins in a Living Cell
Fishing Around for Biomarkers
XMRV: It's Ugly, But That's Science
Detecting Single Cancer Cells
NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
Enthalpy and Entropy Again
The Latest Technology
Chemical Biology: Plastic Antibodies?
Wisterone: A Structure I Can't Believe
Chemical Biology - The Future?
Running Your Fingers Over A Single Molecule
Floyd Landis: The Isotopes Weren't Lying, After All
Masses of Data, In Every Sample
Calorimetry: What Say You?
Sequenom: Strike Up the Music, Bring On the Cream Pies
The Infinitely Active Impurity
Sure About That?
Run It Past the Chemists
GE Healthcare's Idiotic Libel Suit
Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
Water and Proteins Inside Cells: Sloshing Around, Or Not?
More Binding Site Weirdness
A Nobel for Ribosome Structure
Tie Me Molecule Down, Sport
The Great Acetonitrile Shortage
More Glowing Cells: Chemistry Comes Through Again
You Call That An X-Ray Source?
X-Ray Structures: Handle With Care
Start Small, Start Right
These Fragments I Have Shored Against My Ruins
Mass Spec on Mars
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Testosterone, Carbon Isotopes, and Floyd Landis
Doublets, Triplets, Whateverlets
Medicine Man

Animal Testing
Mouse Models of Inflammation: Wrong Or Not?
Animal Testing in the UK.
Mice Hate Men
A Call For Better Mouse Studies
Lab Mice Are Being Kept Too Cold, Apparently
Of Mice (Studies) and Men
Mouse Models of Inflammation Are Basically Worthless. Now We Know.
Lab Animals Wiped Out in Hurricane Sandy
The Mouse Trap
Reboxetine Doesn't Work. But That's Not the Real Problem.
Cancer Cells: Too Unstable For Fine Targeting?
Charles River Buys WuXi
Animal Studies: Are Too Many Never Published At All?
Fat Rats Make Poor Test Subjects?
Animal Testing: A View From the Labs
Animal Rights, You Say?
Animal Models: How High to Set the Bar?
Whose Guess Is Better?
The Animal Testing Hierarchy
Unacceptable
Less Than Zero
Worst Animal Model: Nominations Are Open
Formally Undecideable
Rats Rule, Right?
Ends, Means, Rats, and Dogs
Model Systems, From Inside and Out
Furry Judges, With Tails
What to Do When the Rats Die on You
Rats, For Fear of Worse
You'll Only Get Answers
Modeling the Brain?

Autism
More Vaccine Fearmongering
What Autism Epidemic?
MMR Vaccine and Autism: Lies, All Lies
Vaccines in the Court
Autism and Vaccines: Boiling Over Yet Again
Thimerosal. Again.
Thimerosal, Again
A Mechanism for Thimerosal
Here and There
Compare and Contrast
The Rate of Autism
Clearance Sale
Thimerosal - A Chemical Point
Thimerosal - a Chemical Point
Clearance Sale
A Quick Tour Through the Mudhole
More on Autism (And Mercury)
More on Autism and Mercury
A Quick Tour Through the Mudhole
Neurotoxins
Neurotoxins
Doing Justice to Thimerosal, And the Story
Doing Justice to Thimerosal, and the Story

Biological News
Update on Alnylam (And the Direction of Things to Come)
Proteins Grazing Against Proteins
Thalidomide, Bound to Its Target
TDP-43 and Alzheimer's
Modifying Red Blood Cells As Carriers
An Alzheimer's Blood Test? Not So Fast.
Amylin Fibrils and Aspirin: No Connection
Single-Cell Compound Measurements - Now In A Real Animal
No More Acid Stem Cells
The Science Chemogenomics Paper is Revised
DMSO Will Ruin Your Platinum Drugs. Take Heed.
Oh Brave New World
Artificial Base Pairs in Living Cells
CRISPR In the Courts
Young Blood
More on the Science Chemogenomic Signatures Paper
A Huntington's Breakthrough?
Another Target Validation Effort
Google's Big Data Flu Flop
Years Worth of the Stuff
Stem Cell Shakedown Cruise
A Close Look at Receptor Signaling
Ces3 (Ces1) Inhibition As a Drug Target
Not Again - Stem Cell Results in Trouble?
"It Is Not Hard to Peddle Incoherent Math to Biologists"
A Timeline from Cell
Irisin and Metabolism - A New Target Emerges
The Evidence Piles Up: Antioxidant Supplements Are Bad For You
The Return of Gene Therapy (And More)
Antivirals: "I Love the Deviousness of It All"
Trouble With Stapled Peptides? A Strong Rebuttal.
Boost Your NAD And Fix It All?
Cancer Cell Line Assays: You Won't Like Hearing This
Fred Sanger, 1918-2013
It Doesn't Repeat? Who's Interested?
Rewriting History at the Smithsonian?
Allosteric Binding Illuminated?
The 2013 Medicine/Physiology Nobel: Traffic
The Arguing Over PTC124 and Duchenne Muscular Dystrophy
More on Warp Drive Bio and Cryptic Natural Products
CRISPR Takes Off
GPCRs As Drug Targets: Nowhere Near Played Out
An HIV Structure Breakthrough? Or "Complete Rubbish"?
Another T-Cell Advance Against Cancer
Knockout Mice, In Detail
The Junk DNA Wars Get Hotter
More From Warp Drive Bio (And Less From Aileron?)
Corroboration for ENCODE?
GPCRs Are As Crazy As You Thought
Watching DNA Polymerase Do Its Thing
How Many Binding Pockets Are There?
GSK's Published Kinase Inhibitor Set
Another Big Genome Disparity (With Bonus ENCODE Bashing)
What The Heck Does "Epigenetic" Mean, Anyway?
IBM And The Limits of Transferable Tech Expertise
Pseudoenzymes: Back From the Dead as Targets?
Super-Enhancers in Cell Biology: ENCODE's Revenge?
Good News in Oncology: More Immune Therapy for Leukemia
AstraZeneca Makes a Deal With Moderna. Wait, Who?
More ENCODE Skepticism
Probing A Binding Tunnel With AFM
ENCODE: The Nastiest Dissent I've Seen in Quite Some Time
Mouse Models of Inflammation Are Basically Worthless. Now We Know.
Do We Really Know the Cause for Over 4500 Diseases?
Farewell to Bioinformatics
Is Obesity An Infectious Disease?
Another Reactive Oxygen Paper
Reactive Oxygen Species Are Your Friends!
The Last Thing a Professor Wants to Hear
Sue the Nobel Committee. Yeah, That'll Work.
Picosecond Protein Watching
The 2012 Nobel In Chemistry. Yes, Chemistry.
ENCODE And What It All Means
Databases and Money
Just How Do Enzymes Work?
Public Domain Databases in Medicinal Chemistry
Biomarker Caution
Europe Wants Some of That Molecular Library Action
Ciliobrevins: Digging Into Cell Biology
The Ultimate in Personalized Medicine
Roche Goes Hostile for Illumina
Fun With Epigenetics
Warp Drive Bio: Best Name or Worst?
Osiris And Their Stem Cells
Brain Cells: Different From Each Other, But Similar to Something Else?
Proteins in a Living Cell
Geron, Stem-Cell Pioneers, Drop Stem Cells
Cyclodextrin's Day in the Sun
The Latest Sirtuin Controversy
Big Sirtuin News
Merck, RNAi, Alnylam, And So On
Bait And Switch For Type B GPCRs
A First Step Toward A New Form of Life
The Histamine Code, You Say?
The Uses of Disorder
Garage Biotech: The Book
Biomarkers, Revisited. Unfortunately.
Get Yer Telomeres Measured, Step Right Up
Smell The Vibrations? Fruit Flies Might Be Able To. . .
Fishing Around for Biomarkers
Arsenic Bacteria: Does The Evidence Hold Up?
Roche Has Problems - But RNA Interference Has More
And Now, the Retractome
Epigenetics: The Code Isn't The Object
TRIM21: A Cure For the Common Cold? Maybe Not. . .
Are Genes Patentable Or Not?
Laser Nematode Surgery!
More on Garage Biotech
Chemical Biology: Engineering Enzymes
Chemical Biology - The Future?
Vinca Alkaloids, And Where They End Up
Reverse-Engineering the Human Brain? Really?
Maybe We Should Make It More of a Game
Craig Venter, Venting
XMRV and Chronic Fatigue: You Thought You Were Confused Before
Stable Helical Peptides Can Do It All?
A Synthetic Genome; A New Species
Rosetta@Home
Curse of the Plastic Tubes
The Scent of Food Is Enough?
Homemade Morphine?
Masses of Data, In Every Sample
Let's Sequence These Guys
ACC2: Great Metabolic Target, Or Total Bust?
Rapamycin for Alzheimer's?
Sickened by an Engineered Virus?
What Do Nanoparticles Really Look Like?
GeneVec's Pancreatic Cancer Therapy Crashes
Nanoparticles and RNA: Now In Humans
A Bit More Garage Biotech
BioTime's Cellular Aging Results
Stem Cell Politics
The PSA Test for Prostate Cancer: Useless
Garage Biotech
A GSK/Sirtris Wrap-Up
Your Own Personal Bacteria
The Plasmid Committee Will See You Now
Biology By the Numbers
Enzymes and Fluorines
Receptors, Moving and Shaking
Maybe You Need Some More Testosterone Over There
An Enzyme Inhibitor You Have Never, Ever, Considered
Correlations, Lovely Correlations
MAGL: A New Cancer Target
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
Extortion, Retractions, And More
Five Technologies For the Scrap Heap?
Run It Past the Chemists
Water and Proteins Inside Cells: Sloshing Around, Or Not?
What Exactly Does Resveratrol Do?
Nanotech Armor
Engineering Receptors: Not Quite There Yet. Not Exactly.
A Nobel for Ribosome Structure
A Nobel for Telomerase
Antioxidants and Cancer: Backwards?
Right Where You Want Them
Still Semaphoring, Even From the Bottom of the Swimming Pool
Schematic Notation for Biology?
Dealing With Hedgehog Screening Results
What's So Special About Ribose?
Genzyme's Virus Problems
Exercise and Vitamins: Now, Wait A Minute. . .
Niacin, No Longer Red-Faced?
No MAGIC Involved
Genes to Diseases: Hard Work, You Say?
The Motions of a Protein
Grabbing Onto A Protein's Surface
Gene Expression: You Haven't Been Thinking Big Enough?
Wash Your Tubes; Mess Up Your Data
System Biology: Ready, or Not?
Fructose In The Brain?
More Glowing Cells: Chemistry Comes Through Again
A Green Fluorescent Nobel Prize
Antipsychotics: Do They Work For A Completely Different Reason?
New, Improved DNA?
Receptors: Can't Live With 'Em, Can't Understand 'Em
Killing Proteins Wholesale
Empty As Can Be
Nanotech Stem Cells, Order Now!
RNA Interference: Even Trickier Than You Thought
Getting Real With Real Cells
Rainbows and Fishing Expeditions
Avandia: Going Under for the Third Time?
A Real Genetic Headscratcher
What We Don't Know About Enzymes
Checking The Numbers on the Alzheimer's Test
Let Us Now Turn To the Example of Yo' Mama
More Things Than Are Dreamt Of
Visfatin: Real Or Not?
It Went Up Instead of Down
Peptides as Texts
Neowater Replies
Nanotech Wonder Water?
Stem Cell Disaster
Grand Rounds Today, and Next Week
RNAi: The Awkward Age
Kinases and Their Komplications
The Vapor Trail I Referred To
It's a Bacterial Planet, You Know
There'd Better Not Be an Argon Receptor
All Bets Are Now Officially Off
A New Cancer Target - Maybe
Proteinocentrism
Gene Therapy Decisions

Birth of an Idea
Open Source Science?
Vial Thirty-Three, And More
Back on the Air
Vial Thirty-Three: Warp Drive
The Race Is On
Publish, Then Perish
The Horse Latitudes
Good News, Now That I Think About It!
Back To Life
Vial Thirty-Three: The Third Run
Vial Thirty-Three Rides Again
Vial Thirty-Three: One Up, One Down
Mid-day Update
Minute by Minute
Vial Number Thirty-Three
Cliff Diving
A Scientist's Resolutions
Report From What I Think is the Frontier
Experimental News
News Flash: I May Not Be a Fool
Data, At Last
Experimental Update
Experimental Update, For Those Who Care
Live The Stereotype!
The Consolations of Pure Research
Don't Talk To Yourself So Much
Mismatched Socks
A Little Ambiguity Would Be Welcome Right About Now
Dr. Lowe? I Have Your Hypothesis on Line Two
If This Doesn't Work, There's Only Reality To Fall Back On
Good News, Backing Slowly Through the Door?
Waiting for the Metaphorical Phone to Ring
Per Fits and Starts, Ad Astra
Here It Goes
Nature Stood Me Up
Close to the Vest
Close To the Vest
Experimental Update
In Case Anyone's Wondering
Back for More
Meanwhile, Back at the Chocolate Factory
The Nuts and Bolts of a New Idea
Measure Twice, Cut Once

Blink ›
Nature Doesn't Care: Latest in a Series
Vaccines by the Dozen
Follow Which Money Where?
An Experiment in Progress?
Alex Tabarrok on Me-Too Drugs

Blog Housekeeping
The Worst Seminar
Conference in Basel
A Last Summer Day Off
Summer Blogging Continues
Summer Blogging
Happy Fourth of July, 2014
An Early Day Off
"In the Pipeline" Will Be Moving
More Server Problems
Technical Problems
Days Off
Off To the Publishers
A Quick Clean-Up
For Some Folks, It's New Year's Day
Traveling Interruption
Out to Illinois
ACS Webinars on Drug Discovery
Back Blogging (Bonus Biographical Begging)
Cold-Weather Chicken Soup
Russian Soured Cabbage
Thanksgiving: Never Trust An Organic Chemist Who Can't Cook
Things People Won't Listen To?
Chemist At Work
Chemistry Job Postings: Worth a Try
Back to Hendrix
Travel (Back to Arkansas)
Cambridge Meetup Final Plans: Noon by Broad Canal Way
Cambridge "In the Pipeline" Reader Meetup: October 10
An "In the Pipeline" Meetup in Cambridge?
A War On Expertise?
A Quick Recipe: Lime Sorbet
Totally Off Topic: My Appearance on Jeopardy!
A Chemical Biology Conference
Comment Troubles
A Fourth of July Recipe: Pork Tenderloin and Sour Onion Salsa
A Quick Traffic Update
Travel and Upcoming Posts
New Photos, Same Blather
Best Sites for a Medicinal Chemist?
Travel (University of Wisconsin)
Not the Usual Morning Around Here
Traffic and More Traffic
A Malfunctioning Spambot
Quick E-mail Housekeeping Note
Off Topic: Happy New Year, In March
An Interview
Snow Versus Scientific Progress
A Traffic Record
Another Recipe: Cornbread
A Bean Soup Recipe, With Bonus Country Ham Talk, And a Cameo By Frederick the Great
A Christmas Break
Chemistry Software Questions Answered Monday
Thanksgiving Synthesis
Back On the Air
Blogging Outage
Travel (For C&E News)
Conference Travel
Vacation!
R. B. Woodward Does Furnish A Room
Drew University Visit
More Details
Day Off
Shortage of Blogification
Comments (And Everything Else) Are Back
Comment Trouble
Ten Years of Science Blogging. Already?
Media Note
Holiday Break
Blog Traffic: A Thank-You
A "Things I Won't Work With" Request
Happy Thanksgiving
Lab Preparation: Key Lime Pie
Conferencing
Conference Travel, With Blogging
Day Off - Some Links and Some Ancient Greek
What An Offer
Back to Blogging
On and Off
Memorial Day
Inadvertent Day Off
Conference Time
Day Off
Another Snow Day
Snow and Chance Happeneth To Them All
Another Cold-Weather Recipe: Chicken Pot Pie
A Cold-Weather Recipe, By Request: Onion Soup
Weather Delay
Holiday Break
Blogging Break
Holiday Organic Synthesis: Chocolate Pecan Pie
Open Thread
Day Off
Blogroll Update
Housekeeping Note
Lunch at the Boston ACS Meeting
By The Way. . .
Out in the Public
Back in Business
Midsummer
More From the Fourth
Holiday
Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
Coming Soon
Chemistry In (Ahem) Everyday Life
Delivery Via Kindle
Of Cambridge, MA Interest Only
More on C&E News
Day Off
More Blogroll
Blogroll Update
Blog Traffic - Thanks!
Write A Book, Why Don't You
Twitter and Science, Revisited
Sure Thing
Physics, for Dogs and Others
Holiday Time Off
Day Off!
Another Blogroll Update
Light Blogging
Applied Organic Synthesis: Chocolate Pecan Pie
More For the Blogroll
A Blogroll Update
"Back to School"
Day Off
Traveling, Updates Later
Traffic Record
Back
Time to Sing the Alma Mater
H-h-h-holy C-c-c-c-cow
Blogroll Update
Return From Travel: A Note About Cheaptickets.com
Travel Continues. . .
Travel
Day Off
Blogroll Update
Proxy Server Update
Proxies for Iran (More Politics - Mixed With Technology)
And Now Some Politics
Quick Blogroll Update
Blog Contestification
Blog Contestiness
A Science Writing Award
Still More Blogroll Additions
Blogroll Update
More Travel!
San Diego
Travel
Blogs and Journalism
Hexacyclinol - Another Request
Day Off
The Blogroll
Holiday Break
How Slow is Research Today? Here's a Recipe!
Day Off
Back
Time Off
Happy Fourth of July
Leaving Comments: A Fix
Explaining It All
Quick Note
Anonymity?
Day Off
Commenting Issues
Back On the Air
Snow Day
Synthetic Prep of the Day: Chocolate Pecan Pie
Holiday Break
Bright Lights and Applause?
Blogroll Update
Meet the Blogger?
Not Necessarily So
Two Weeks Off
Real Life, Which Costs Real Money
But Enough About You
Blogroll Update
Linkage!
Back From DC
You Want Me to Just Talk? No Problem.
Comments on Comments
Blogroll Update
Back on the Air
Work At Home! It's Easy; It's Fun!
Holiday Schedule
Shameless Self-Promotion
Elsewhere
Watch This Space
Links and Such
Darn Photons
Here and There
A Friday Linkfest
Back on the Air
Travel
Linkorama
Missed One!
A Lengthy Day
Technical Difficulties
Blogroll Revamp
Various Updates
Comments Welcome - Really
Instead of Working
Procrastination Assistance
Outside Reading, and Plenty of It
And Another Thing. . .
Blogging About Science Blogging
Even More Worthwhile Stuff
Like, Er, Fine Wine. I Hope.
Summer Hours
Continued Slacking
Outside Reading
New Address
One Problem Solved, Anyway
A Technical Question
And Now A Word. . .
Schedule Update
Holiday Blogging
Stocking Stuffers, of a Sort
Now With The Great Taste of Fish
Comment Problems
Two Days Off (From This, Anyway)
No Coming Attractions Here
A Question For the Audience
Summer Hours
The Last Word on Taste
Categories
Welcome Back!
Catching Up
Here and There

Book Recommendations
What If?
A New Med-Chem Reference
A New Book
Holiday Blogging
Science Gifts: Running Experiments at Home
The Chemistry Book
E. O. Wilson's "Letters to a Young Scientist"
The Portable Chemist's Consultant
A New Book on Longevity Research
Two New Books
Bioisosteres
Science Gifts: Actual Med-Chem Books
Brain Cells: Different From Each Other, But Similar to Something Else?
A New Book on Chemical Patents
Data Handling in Collaborations
Book Review: The Quest for the Cure
Garage Biotech: The Book
Drug Discovery History
Serendipity in Medicine
Friday Book Recommendation
Friday Book Recommendation
A Friday Book Recommendation
Physics, for Dogs and Others
Recommended Books For Medicinal Chemists, Part One
Business Books: The Enantiomers
A Med-Chem Book Recommendation
Inspirational Reading?

Business and Markets
Peter Thiel's Uncomplimentary Views of Big Pharma
Prison Sentences in the GSK China Scandal
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
Thiola, Retrophin, Martin Shkrell, Reddit, and More
The Most Unconscionable Drug Price Hike I Have Yet Seen
Clinical Trial Fraud
Google's Calico Moves Into Reality
A VC Firm Touts Its Successes - And Its Failures
InterMune Bought
Did Pfizer Cut Back Some of Its Best Compounds?
Med-Chem and Trucking, Together At Last
Amgen Cuts Hard
Targacept Comes Up Empty, Yet Again
The Antibiotic Gap: It's All of the Above
Neratinib Comes Through For Puma
How Many Biopharma Employees Would Rather Be Working Somewhere Else?
The Hep C Field Gets Nastier By the Minute
Allergan Twists and Turns
The Prospects of an Academic Job
Employment Among New Chemistry PhDs
Biopharma Stock Events for the Rest of the Year
AbbVie and Shire, Quietly
The GSK-China Situation Gets Even Weirder
Alzheimer's Bonds
Zafgen's Epoxide Pays Its Way
Go Home, Gaijin
Rearrangements Inside Bristol-Myers Squibb
Valeant's Misleading Case
Nutley Demolished
Valuing Biotech Startups
Sanofi's Feeling Just Wonderful
Pharmalot Returns
How to Buy, Buy, Buy
AstraZeneca Survives
Two Looks At Drug Industry Productivity
The Biggest Chemistry Employers - Guess
Pfizer/AstraZeneca: The Arm-Wrestling Phase
Perhaps Not Quite Technically Legal, Come to Think of It
AstraZeneca Says No Again
China Raises the Stakes in the GSK Scandal
Pfizer's Shareholders and AstraZeneca's
Pfizer-AZ: Politics and Press Releases
The Lessons of Intercept and NASH
AstraZeneca: Don't Buy Us
Fast Money, But What Direction Is It Going?
Pfizer/AstraZeneca: Asymmetric Cuts Look Likely
Some People at Pfizer Whose Fault This Isn't
Allergan: "Golf-Course Deprived"
AstraZeneca Tell Pfizer to Buzz Off
Can Anything Stop Pfizer-AstraZeneca From Going Through?
Concert's First Drug: Not So Great
Pfizer and AstraZeneca: What the Hell.
Ycombinator Gets Into Biotech
Shuffling the Departments
Pfizer Walks Again By Night
Novartis Gets Out of RNAi
AstraZeneca's Cambridge Move
Biotech Boom, Biotech Bust?
Outsourcing Everything
GSK Dismisses Employees in Bribery Scandal. Apparently.
Reality-Based Biotech Investing
Where The Hot Drugs Come From: Somewhere Else
A Look Back at Big Pharma Stocks
Another Whack at the Stem Shortage Myth
Always Insist on Error Bars
Startups vs. Big Pharma
Biggest US Cities for Biopharma Funding, Versus Whole Continents.
Novartis's Stealthy Headcount Reductions
A Bit More Realism in Consulting
The Instructive Case of Galena Biopharma
InterMune Comes Through
Big Drug Mergers: So They're OK, Right?
Jobs, He Says
Drug Discovery in India
How the New BioPharma IPOs Have Been Doing
Crowdfunding Independent Research
AstraZeneca Cutting Back - Some More
Overqualified For the Job
Novartis Does A Big, Quiet Reshuffle
How Not to Invest in Biopharma
AstraZeneca Closes a Lab - In India This Time
What STEM Shortage? Where? How?
Novartis Continues Closing and Rearranging
Abandoning the Chinese Drug Market
"We Had to Clear Out Some Chemists"
A Short Guide to the JP Morgan Conference
Alnylam Makes It (As Does RNAi?)
The 2013 Drug Approvals: Not So Great?
Grading the Drug Companies
Bristol-Myers Squibb Exits Diabetes
A Look Under the VC Hood For 2013
GlaxoSmithKline's New Sales Practices
A Year-End Review at Xconomy
Eye of the Beholder Stuff
Worst Biotech CEO Time
Drug Companies In Great Britain: Ease Up, Won't You?
Eisai Cuts Back
The Freshness Index
Cuts at Shire
Layoffs and Personal Finance
No More Stack Ranking at Microsoft
The Other Shoe Drops at Ariad
Exiting Two Therapeutic Areas
Now Novartis-Emeryville?
BMS Reshuffling
Novartis Closing Horsham
Bayer's Here to Tell You That There's a STEM Shortage
Merck's Aftermath
Totaling Up a Job Search
Decision Time at Merck
Ariad in Limbo
Size Doesn't Matter. Does Anything?
Cognitive Dissonance at Lilly
The Big Boston Biotech Boom
Good News in Hiring, Maybe?
Where Are the Biopharma Clusters, Really?
Did the Biotech IPO Window Just Close?
Forecasting Drug Sales: Har, Har.
Astex Gets Bought - At a Higher Price?
Man, That's A Lot of New Public Companies
Merck Cuts Back. Way Back.
A Phase III Failure at Eli Lilly. Yes, Again.
Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
When Does a Biotech Press Release Constitute Fraud?
Prosensa: One Duchenne Therapy Down
The Arguing Over PTC124 and Duchenne Muscular Dystrophy
Surveying BioPharma Job Ads
Value For the Money
Merck Does Something. Or Not. Maybe Something Else Instead.
Astex Gets Bought
Stack Ranking in Pharma: Bad Idea
The Myth of the STEM Shortage, In Detail
Promise That Didn't Pan Out
Amgen Buys Onyx
Options And Suchlike
What's a CEO Worth?
A Call For Merck to Cut R&D
Too Many Biotech IPOs?
Now It's Novartis's Turn in China
Sanofi in China
Merck Cuts Coming? Or Not?
Apparently, Ads Make Antihistamines Work Better
Pfizer Rearranges
Those Fortunate Onyx Option Traders
Update on the Bribery Scandal
Salary Freeze at Lilly
Good Advice: Get Lost!
BMS Moving Jobs to Florida
The GSK Jackpot
The Red Queen's Race For Funding
Aveo: The Rubble Continues to Bounce Around
More From Warp Drive Bio (And Less From Aileron?)
Good Fortune Smiles On Someone's Onyx Option Trades
The Ax At Aveo
AstraZeneca, As Expected, Pulls the Plug
Valeant Versus Genentech: Two Different Worlds
Another Look At Marketing Vs. R&D In Pharma
Promoting STEM Education, Foolishly
But Don't Drug Companies Spend More on Marketing?
How Much Do Drug Companies Spend on R&D, Anyway?
Crowdfunding Research
Astellas Closing the OSI and Perseid Sites?
Ken Frazier at Merck: An Assessment
A Startup's Post-Mortem
Pursuing Other Interests, As They Say
Regeneron Expands
Bristol-Myers Squibb Closes Down the Amylin Site
Pfizer Tears It All Down
The Wyeth/Elan Insider Trading Case Resolves
AstraZeneca Makes a Deal With Moderna. Wait, Who?
Affymax In Trouble
AstraZeneca Site Closings - And Openings
GlaxoSmithKline's CEO on the Price of New Drugs
Is GSK Up to Something Else, Too?
Sirtis Gets Shut Down in Cambridge
Biopharma Startups in India and China - Do They Exist?
Peter Kim Retires From Merck
TauRx's Funding Is Odd
What Really Makes a Biopharma Hub?
Pfizer's Covx Closing?
How Can There Be a Shortage of Scientists And An Excess At The Same Time/
Pfizer Slowly Shrinks in Groton
Addex Cuts Back: An Old Story, Told Again
Trouble Hiring Whom, Exactly?
Not Working Out So Well at Merck?
AstraZeneca's Nasty Numbers
Time to Refill Your Prescription For Zxygjfb
The Chemistry Jobs Market
Too Many Scientists: A "Pyramid Scheme"
Daniel Vasella Steps Down at Novartis
AstraZeneca Shakeup
A Big Change at Pfizer? Or Just a Rumor?
Deal of the Year?
The Happiest Darn Drug Company in America
Lilly's Two-Drugs-a-Year Prediction
Whitesides on Discovery and Development
The Worst Biotech CEO?
Off-Label Promotion Is Legal, You Say?
Marcia Angell's Interview: I Just Can't
Fluorous Technologies Is No More
When Drug Launches Go Bad
And Since We're Talking About Insider Trading
Easy Money, Right?
Small Molecules Slipping Off the List
The Novartis Pipeline
That's Where The Money Is
Your Press Release Has Already Been Written
Budgets and Revenues
Nassim Taleb on Scientific Discovery
The Supply of PhDs
Biotech Takeover Targets
C&E News: No Smiley Face This Time
"Basically, They're A Bunch of Lemmings"
Layoffs at Human Genome Sciences
Targacept Cuts Way Back
Crowdfunding A CNS Project
AstraZeneca Stops Buying Its Own Stock
A Totally New Way to Finance Drug Discovery
Pfizer's New Leaf
Elan's Discovery Efforts - What's Going On?
Pharmville: Good Grief, This Looks Awful
Sanofi Cuts Back in France
Roche: Manhattan Instead of Cambridge
Various Links Of Stuff
Boehringer Ingelheim Closing Laval Site
Merck (Germany) Cuts Back
How Did the Big Deals of 2007 Work Out?
Pharma: Geniuses or Con Men?
More on Pharma Stock Buybacks
Getting Drug Research Really, Really Wrong
Cuts at Bristol-Myers Squibb
Does Anyone Want to Invest in Pharma?
Quick Links
AstraZeneca Admits It Spent Too Much Money
Scientist Shortage? The Media Starts to Catch On.
The GlaxoSmithKline Settlement
Starting a Chemical Business
Effects of the Health Care Law on Pharma
Roche Closes Nutley, Once Its US R&D Home
The Next Five Years in the Drug Industry
Merck's Madagascar Marketing Mess
BS Your Way Partway to The Top
Organic Synthesis: A Dead End For Graduate Students?
China's Compulsory Licensing
Sunovion Layoffs?
Merck Finds Its Phase II Candidates For Sale on the Internet
By Any Other Name
AstraZeneca "Braced For Change"
Please Fund Them So They Can Fund Us
GSK and Immune Response: Not Quite An Amicable Divorce
The Counting of Beans
A Molecular Craigslist?
GSK Goes Hostile
PhDs On Food Stamps?
Benlysta's Adventures In the Real World
GSK with AstraZeneca?
The Biotech Class of the Early 90s
AstraZeneca Shuffles the Top Cards
Merck Serono Cuts Back
AstraZeneca Buys Ardea. And Who Else?
More on the Federation of Independent Scientists: Journal Access
AstraZeneca Cuts Again
A Federation of Independent Researchers?
"Taking the Ax to the Scientists Is Probably a Mistake"
Amylin on the Block
Pfizer: Making the Case for a Breakup
Virtual Biotech, Like It or Not
Lilly Tries to Make It Up in China
Merck's CALIBR Venture
Verastem's Chances
Coaching For Success. Sure.
Bad Day at AstraZeneca
Are the Numbers Improving?
Eroom's Law
A Response From Sanofi
What Sanofi Thinks About You
Inside A Chinese Pharmaceuticals Maker
Pfizer Layoff This Past Weekend?
The Terrifying Cost of a New Drug
Buying Back Shares: An Admission of Defeat
AstraZeneca in Waltham
AstraZeneca Layoffs and Closings
AstraZeneca Cutting Even More?
Roche Goes Hostile for Illumina
Alnylam Cuts Back Hard
Takeda Announces Cuts
Warp Drive Bio: Best Name or Worst?
Newhouse Research
Sanofi's Bridgewater Site - Closing This Week?
Welcome To the Jungle! Here's Your Panther.
The JP Morgan Myths
SciFinder Access For the Unemployed
Osiris And Their Stem Cells
2012 In Startups
That's Sir Andrew to You
More From Hua - A Change of Business Plans?
Merry Christmas, Fred
AstraZeneca's Problems
Deals of the Year in Biopharma (Bonus: Names That Can't Happen)
More on Chinese Pharma Espionage
Chinese Pharma Espionage?
Pharma Overview
The Loss of the Middle (Drugs and the People Who Find Them)
Merck in China
Novartis: No More Neuroscience
More on Alex Denner
Acronym-Fest: GSK and Its DPUs
Worst Biotech CEO of 2011?
So What Did Lipitor Do for Pfizer? Or Its Shareholders?
Of Drug Research and Moneyball
Business Note: Random Promotion, Anyone?
Ray Firestone's Take On Pharma's Plight
Virtual Pharma, Revisited
Managing For Motivation, The Simple Way
Exit Icahn, Enter Denner?
Geron, Stem-Cell Pioneers, Drop Stem Cells
In-Sourcing Chemistry: Lilly and AMRI
Verastem Goes Public: Why Not?
Sanofi Announces Layoffs
Exelixis Fights City Hall, and City Hall Looks Like Winning
A Note About Identity Spoofing
Merck, And What Used to Be Schering-Plough
Novartis Announces Cutbacks
NCPharma: Changing the Drug Industry How, Exactly?
The Layoff Project
Abbott Cuts the Drug Business Loose
Reorg at Merck? (And a Complaint about Wall Street)
Amgen: Brace Yourselves
So, How Come You're So Darn Lucky, Eh?
What Layoffs Have Done
GSK and McLaren: Two Different Worlds
China's Home-Grown Insanity?
China's Pharma Ambitions: Hua Pharmaceuticals Responds
Chinese Pharma: No Shortage of Ambition, Anyway
The NIH Wonders About the Future of Biomedical Workers
Is Carl Icahn Going Away?
Lundbeck Cutting R&D
The Economics of the Drug Industry: Big Can't Be Big Enough?
Bernard Munos Rides Again
Dendreon: Watch the Cost Curve Being Bent
A Former Pfizer Executive Finally Trashes Pfizer's Strategy
Merck, RNAi, Alnylam, And So On
Merck Announces More Big Cutbacks
The Secret History of Pfizer
Innovation and Return (Europe vs. the US)
Pfizer Reverses Course in Sandwich - A Bit
Drug R&D Spending Now Down (But Look at the History)
Not Looking So Good At Eli Lilly (or AstraZeneca)
How's All That Cost-Cutting Working Out?
Block That Review
Another Two-Person Drug Company
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Pfizer's Layoff Dance
Get Yer Telomeres Measured, Step Right Up
Imperfect Pitch
Icahn's Biotech Adventure
A Look Inside the Compound Collections
Pfizer: Breaking Up Is Hard to Do
Merck: How to Spend the Money
Pfizer Layoffs Today
AstraZeneca Tears 'Em Down
Now They Tell Us
Nothing Personal
Merck and J&J Finally Come to Terms
Coming Up in the World With CROs
Total Pharma Job Cuts
R&D Is For Losers?
What's Really Killing Pharma
Westphal Leaves GSK
Insider Trading at the FDA
The Supreme Court Slams Big Pharma? Not Exactly.
The Small Drug Companies And the Big Ones
Brave New Office
More Bad News in the UK: Novartis Horsham
Pfizer Moves Antibacterials to Shanghai
Pfizer: Bigger, Um, Isn't Better?
What A Fool Believes
The Pfizer Air Force
The Costs of Drug Research: Beginning a Rebuttal
A Postdoc's Lament
MannKind: It's Not Looking Good
The Pfizer Sandwich Closure
Is Big Pharma Killing Startup Companies?
Want to Live Where Merck Used to Work?
Cutting The Cuts to Save Money on the Money-Saving
The Key Player in the Sanofi-Genzyme Deal Speaks Out
Merck, J&J, and Remicade: Waiting Nervously
The Top 200 Drugs
Fanapt: Not Paying Out
Too Much Outsourcing: Has the Line Been Crossed?
Whistleblowers: Paid Too Much?
Not Letting Pfizer's UK Site Go to Waste?
Merck's Strategy vs. Pfizer's
Pfizer's CEO Speaks
Pfizer Part Two: Cuts at Groton
Bad News: Pfizer Closes Site in Sandwich
Abbott's Cutting Jobs
Merck's Thrombin Antagonist In Trouble
Sanofi's Slow-Motion Takeover of Genzyme
Ahem: "Sell Gobs of Dope"?
The PhD Problem
How to Fund a Nonprofit Drug Company - And Others?
Jobs Roundtable Recap
Science Jobs Roundtable - Day Four
Chemistry Jobs Roundtable: What About Tenure?
Too Many PhDs, Revisited
Big Pharma's Lost Stock Market Decade
Chemistry Jobs, Present and Future
Have Pfizer's Investors Had Enough?
Exit Kindler
Novartis, Meet Novartis (Job Cuts or Not?)
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
Roche Has Problems - But RNA Interference Has More
Comment of the Day: Outsourcing and Architecture
An Outsourcing Blast
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Merck vs. J&J: Wait For It
Exelixis Grabs A Life Preserver
The Layoff Picture
Spamming For Site Shutdowns. Sheesh.
Sanofi Goes Hostile
Sanofi-Aventis: It's $69/Share, And That's Where It Stays
Merck vs. J&J: It's Come to This, Eh?
Outsource to China, Then Move There?
China Outsourcing: Getting More Expensive, Fast?
Roche: Layoffs, or Rumors?
How About The Same Price You Turned Down Before? Hmm?
Sanofi-Aventis and Genzyme: Walking Away?
Going Hollywood
Reporting on Alternative Careers
Is Genzyme a Buyable Company At All?
MannKind and Seaside 88?
If You're Not A Chemist - What Next?
All Quiet on the Genzyme Front?
Know How to Make Praziquantel? Tell The World.
Charles River Gives Up
Let's Just Spread This Deal Out All Over the Paper, Why Don't We?
New from OSI / Astellas
Genzyme: On the Other Hand. . .
How Sleazy It Can Get
Genzyme Telling Sanofi-Aventis to Buzz Off?
Biosimilars: Not Easy, But Not Impossible, Either
Aventis: Is It Genzyme?
Hmmm: The Gates Foundation Bails
Lechleiter's Prescription for Science
Why Close One Research Site Over Another?
Merck Site Announcements - Closures and Otherwise
Drug Prices in the US: Not So High After All?
Sanofi-Aventis Acquires. . .Somebody?
GSK's Biotechy World
That Schering-Plough Lawsuit Isn't Going Away
Andrew Witty's Advice
Chemistry Employment in New England?
The Economic Impact of the Genomic Revolution's Failure
Checking the Business Ratios
Merck Layoffs - Underway?
Paying People to Take Their Medications
Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
Albany Molecular Cuts - In the US, Anyway
"Better Educated" in China?
India's Research Culture
Astellas and OSI: Nothing like MLNM/Takeda?
Manning the Phones
Astellas Buys Out OSI
Layoff at Takeda
China's Future
Perverse Incentives In Clinical Trials
Intermune: Right Back Down Again
Merck Rumors?
The Collapse of Complexity
Treatment INDs - For Any Generex Fans Out There
Sirtris's Compounds: Everyone Agrees?
Merck Closes a Site
Charles River Buys WuXi
Two Bad Ideas
Generex: Who Buys This Stuff, Anyway?
A Re-Org at Novartis
A Tiny Little Presentation Tip
Colchicine's Price Goes Through the Roof
Novartis, Roche Threaten To Leave the UK
Too Many Consulting Jobs Work This Way
Prediction Markets, Idea Sharing, and So On
The Crowd Goes Wild
Pfizer's Golden Age
Generex and Their Insulin Spray: Just Hype?
Let's Hope They're Right
Exelixis: Hmmmm.
If You Need Some Lab Equipment. . .
BioTime's Cellular Aging Results
Lilly Layoffs Today?
Intermune's Rise
Hope Darn Well Springs Eternal
Bad News at Exelixis
Merck/Schering-Plough People?
Twelve and One Half Per Cent
AstraZeneca Makes Its Move
Layoffs Coming at Eli Lilly?
Layoff News
Knocking on Doors
Merck Announces Cuts
Drug Patents in India
Picking Up Industrial Hires
Sanofi-Aventis Cuts Back
Where Would You Start a Company?
More On Pharma's Ugly Finances
Sheer Economics: How We Got in This Fix
BMS Freezes Salaries
GSK Day
And on the Carl Icahn Front. . .
GSK: More Cuts Coming
Merck and Sirna
Your First Pharma Bloodletting of 2010: AstraZeneca
Sequenom: Strike Up the Music, Bring On the Cream Pies
Honesty, Of A Sort
The Sirtris Compounds: Worthless? Really?
Carl Icahn Going For Genzyme?
Always Read the Fine Print
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Drug Companies Since 1950
Pfizer's Pearl River Layoffs
Merck, Shopping in the UK?
Go Spread It On the Rosebushes
Against Panic
Telling the Layoff Story
Pfizer's Chemistry Head Count - Really?
Pfizer's Site Closures - An Analysis
Pfizer's New Layout
Selling It, And Selling It Hard
Thoughts on What Used to Be Schering-Plough
J&J Raises the Ax
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fifty Years of Scientific History For You
The Best Ones Aren't Over Here Any More?
You Mean You Don't Have to Buy Them?
Red Flags in Biotech
Pfizer's People
O Brave New World! That Has Such Companies In't!
What Pfizer Will Look Like in a Year
Short Topics From All Over
"Day One" at Pfizer
Which Pfizer / Wyeth Sites Will Close?
The Drug Business: A Turbulent Future?
Lilly Shrinks
Pharma Whistleblowing: How It Works
Sepracor: A Desirable Property?
A 2.3 Billion Dollar Attention-Getter
Lexapro, Forest Labs, and the Hard Sell
Drug Companies Are Polar Bears? Maybe Not.
Pharma's Return on Investment: Yikes
Ghostwriting
Savient Feels The Pains of Gout
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
Drug Approvals, Natural And Unnatural
Incompetence, Avoided?
Too Many Scientists?
How Much Does the Drug Industry Spend on Marketing?
Vanda Comes Back From the Dead
Voluntary, You Say?
Meanwhile, Over At Sanofi-Aventis. . .
GSK's Getting Better. Just Ask the CEO.
One. . .Billion. . .Dollars!
Perpetual Patents: A Nasty Thought Occurs
CafePharma Will Now Approach The Bench
Will The Gentleman With the Pitchfork Please Speak Up?
A Deuterium Deal
Akt and Mek, But Not PDQ
Arena, Lorcaserin, and the FDA
J&J Lowers the Boom
Arena / Lorcaserin Update
San Francisco Biotech: Holding Up, or Not?
Goldman Sachs: Out Of the Drug Funding Business Already?
Kumbaya
Merck, Elsevier, and Fakery
Genentech: Let's Hope He's Right
Dendreon's Stock: What the Hey?
Dendreon's Revenge?
Pfizer's New Structure: Good Luck To All
Biogen Idec: What's Going On?
Layoffs At Merck
And That Is That
Roche / Genentech: The Chase Is Over
Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
The Merck Deal and the SEC: Not a Joke
Merck Actually Does It
Single, Simple Numbers: Use At Your Own Risk
Genentech's Culture: At Risk or Not?
Business Books: The Enantiomers
Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
Roche / Genentech: So There is a Deadline
How Long Is Roche Prepared to Wait?
Short Business Notes: AstraZeneca, Biogen, Vertex
Short Business Note: GSK's At Least Not Going to Merge
Sir James Black Vents, Therapeutically
Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
Roche Goes Hostile - Or Does It?
Opportunity Costs
Pfizer and the Credit Crunch
Pfizer / Wyeth: Different This Time?
Pfizer / Wyeth: They're Going to Take Us All Down With Them
Nitromed: Someone Wants Them
With A Straight Face, Yet
Lilly Pays the Price
More on Pfizer's Layoffs
Why Pfizer?
Layoffs. More Layoffs.
Insider Trading in Drug Stocks? Not Unknown. . .
The Worst Biotech CEO?
Pfizer's Restructuring Grinds Along
Goldman Sachs: A New Drug Research Model?
Roche Stalls For Time
Two Drugs in One? Maybe Not.
The Back Door to the Stock Market
Pfizer: Strategy, Layoffs, and Money
Lilly And Imclone: Not Expensive Enough!
Cutbacks - But Not As Bad This Time
Merck Cuts Back (Again)
Imclone Really Does Get Bought
Eli Lilly and Imclone: Sensible? Real?
Hard Times: A Manifesto
Various Drug Industry News, None of It All That Good
Imclone's Secret Admirer
Pfizer: As We Speak?
Ranbaxy: Cutting Corners, or Falsely Accused?
BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
US and UK Biotech: Growth and Form
Pfizer / Bayer?
Direct To Consumer Ads: Wasted Money?
RNAi: Bubble or Not?
Genentech and Roche, Act Two
Roche Palo Alto: What's Going On?
Job Seekers: Genentech, GSK, and Elsewhere
GSK Layoffs: Yes, Again
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Should Genentech Be a Part of Roche?
Vytorin: Another Round of Nasty Results
Sharing the Enlightenment
More on Outsourcing
Pfizer's Prospects: Just Ducky
Alli: "Underwhelming"
Suits vs. Lab Coats?
More On the GSK Layoffs
GSK: Money-Green Outside, Pink-Slip Inside
A Breath of Fresh Air from Fuji
Nullius in Verba
Awash in Yen
Cordaptive Q and A
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Free Sushi in the Cafeteria!
A Solution, Courtesy of the MIT Faculty
Hits, Misses, and Some More Misses
How Many PPIs Does the World Need?
Drugs and Money
Laissez-Faire?
Cheap Happiness
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Top of the Heap
Hearing Footsteps
Biogen's Not For Buying. For Now.
Med-Chem Layoffs, On the Front Page
More Belts Tighten
How You Doin'? How's Everybody Doin'?
Lights, Camera, Pharma!
Come On. Improve, Already.
Surveying the Exubera Crater
Biogen on the Block?
More Layoffs, And What They Might Mean
Hey, Graduates! Negotiate Hard, You Hear, Now?
Good News From the HR Department!
Have We Got A Deal For You!
Guess That Market
Oh, Come On
Ah, Rumors
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
European Drugs, American Drugs
Knowing What You Know. . .
Alas, Dendreon
Outsourcing Blues?
Put Your Money Down
Layoffs - Again
Amgen: The Pythian Oracle Laughs Again
Buy! Sell! Shout! Moan!
Vaccines Everywhere
Vectibix Lurches A Bit
Schering-Plough Goes Shopping
Biotech's Net Loss?
A Good Day's Work
Good Sense Breaks Out, Film at Eleven?
BMY-SNY?
The Big Picture
Pfizer's Pfinances
Novo Nordisk Axes Med-Chem
ICOS In Pieces?
Pfizer's Sizing
Sell! (It's Not Just Me)
Help Wanted - I Hope
Chinese Med-Chem - In China, For Once
Hope, Springing Eternal And All That
You Can't Make Money If You Don't Get Paid
Blow The Trumpets
Up Periscope And Fire All Bow Tubes
Imclone, Drama Queen of Biotech
Tough Targets
Walking the Plank at Bristol-Myers Squibb
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer's Man at the Top
Pfizer Recalculates
The Sun Shines at Pfizer
Getting and Spending
J&J Shrinks Their Labs Again
Neurocrine's Choice
The Fur Continues to Fly
What's German For "Food Fight"?
Leadership Secrets of the Data Fudgers
Full Disclosure
Golden Parachute, Still Packed and Ready
Rioting for Unemployment
Can You Say "Uebernahmeangebot"?
Nitromed's Slow Decline
More on Outsourcing
J&J Shakes Things Up
Forecast: Rain, Eventually
Imclone Revisited
The Tar Pit Beckons
James Cramer, Biocryst, and You
Human Genome Science Hits the Wall
Where Do the Good Ones Go?
The Check Shows Up in the Mail. Really.
Pfizer Opens Their Wallet - Again
You Figure It Out
Public Utility, You Say?
Punching the Clock at Merck
What Ails the Germans?
The Globalization of Med-Chem
Drug versus Stock
Waiting for the FDA
Glaxo v. Pfizer: Sales Force Stand-Down?
Pfizer's Prospects
Maybe They Should Fire Them All?
Optioning the Drug Portfolio
Don't Ask; Just Trade
Let's See What the Sharks Think of These Steaks!
Could I Have a Side Order of Risk With That?
Public Utility, You Say?
How Bad Are the Cox-2 Inhibitors, Anyway?
A Day With All the Bark Left On It
Rank and Yank?
Measure for Mismeasure
Around and About
Another Shot Across the Bow
Vox Populi
As Goes ASCO. . .
A Capacious Rat-Hole Indeed
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
Bulking Up
Thou Hast It Now. . .
Play It Again
Tasty New Recipes for the Root of All Evil
Quis custodiet ipsos custodes?
Pravachol vs. Lipitor Update
Mismatched Socks
Ignorance Was Bliss
I will do such things - What they are yet I know not. . .
Allons Pharmas de la Patrie!
. . .Your Huddled Pharmas Yearning to Breath Free
Ah, Marketing
Mismeasure for Mismeasure
Measure for Measure
What Sort of Number Did You Have in Mind?
O Brave New Market, That Has Such Medicines In It
Bad News at a Bad Hour of the Night
Caveat Lector
Muddying the Water For Fun and Profit
Back For Some More
Marketing Ueber Alles
By Any Other Name
The Apatosaurus. The Spruce Goose. The Pyramids
The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
A Less-Than-Subtle Plan

Cancer
Exelixis Against the Wall
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
Did Pfizer Cut Back Some of Its Best Compounds?
Incomprehensible Drug Prices? Think Again.
Is The Current Patent System Distorting Cancer Research?
Phenotypic Assays in Cancer Drug Discovery
Neratinib Comes Through For Puma
Thalidomide, Bound to Its Target
Would You Have Advanced BBI608?
A Horrible, Expensive, and Completely Avoidable Drug Development Mixup
Merrimack Wins One
Is Palbociclib Promising? Or Not?
Cancer Immunotherapy's Growing Pains
Dichloroacetic Acid, In a New Form
Years Worth of the Stuff
Repurposing for Cervical Cancer
More Good PD-1 News in Cancer
For Immediate Rewording. Uh, Release.
On Vitamin C, And On Linus Pauling
The Evidence Piles Up: Antioxidant Supplements Are Bad For You
Dacomitinib Doesn't Come Through
Trouble With Stapled Peptides? A Strong Rebuttal.
Adoptive T-Cell Therapy for Cancer: The Short Version
Lab Mice Are Being Kept Too Cold, Apparently
David Cameron, The Press, Alzheimer's, and Hope
Cancer Cell Line Assays: You Won't Like Hearing This
The Other Shoe Drops at Ariad
Just Build The Thing
Ariad (And Its Drug) In Trouble
The Reproducibility Initiative is Open
Merck Does Something. Or Not. Maybe Something Else Instead.
How Goes the War?
Amgen Buys Onyx
Aileron Reports Some Stapled Peptide Results
Another T-Cell Advance Against Cancer
Cancer and Autism: Slow Down
Kevan Shokat At The Challenges in Chemical Biology Conference
Stuart Schreiber at the Challenges in Chemical Biology Conference
More Details on T-Cell Leukemia Therapy
A Specific Crowdfunding Example
The Medical Periodic Table
Aveo Gets Bad News on Tivozanib
Costing Just Too Much
Watching PARP1 Inhibitors Fail To Work, Cell By Cell
Cancer: Back to N-of-One
Super-Enhancers in Cell Biology: ENCODE's Revenge?
Stealing A Compound, To Set Up in China
Novartis Loses the Glivec Patent Fight in India
A Therapy Named After You?
James Watson Likes Us, Anyway
Good News in Oncology: More Immune Therapy for Leukemia
Good News in Oncology: Oncolytic Virus Therapy
ABT-199 Clinical Trial Suspended (Updated)
Time to Refill Your Prescription For Zxygjfb
More on Metformin and Cancer (and Alzheimer's)
Reactive Oxygen Species Are Your Friends!
Overselling p53 Drugs
Stapled Peptides Take a Torpedo
More on Penn's T-Cell Therapy
A Good Example of Phenotypic Screening
JQ1: Giving Up a Fortune?
The Onion on Oncology Research
Texas And Its Cancer Funding
IGFR Therapies Wipe Out. And They're Not Alone.
A Lovely Petite Compound
CNN's Cure for Cancer
Geron, And The Risk of Cancer Therapies
Making Tumor Cells More Vigorous Through. . .Chemotherapy?
Getting Drug Research Really, Really Wrong
Does Aveo's Tivozanib Work, or Not?
Novartis Bankrolls T-Cell Cancer Therapies
Finding Fast Fruit Fly Feasibility
Cancer Drugs: Value for the Money?
Bert Vogelstein on Cancer Drugs and Cancer Screening
Antipsychotic Drugs Against Cancer?
Effects of the Health Care Law on Pharma
A Kinase Inhibitor Learns Something New
Live By The Bricks, Die By The Bricks
The Genetic Diversity of Cancer Cells
Cytotoxic? You Bet!
Sloppy Science
Personalized Medicine for Cancer? Try Every Cell.
Verastem's Chances
Remember When We Were Going to Eliminate Deaths from Cancer?
Academia and Industry, Suing Each Other
(Un)stoppable Pixantrone
Zelboraf: Treat One Cancer, Speed Up Another?
Fun With Epigenetics
AstraZeneca's Problems
Burzynski Revisited
Podcast on Avastin
The Burzynski Cancer Treatment
The Mouse Trap
Avastin Coverage, Amended
Avastin's Metastatic Breast Cancer Approval Revoked
Brain Cells: Different From Each Other, But Similar to Something Else?
Geron, Stem-Cell Pioneers, Drop Stem Cells
Verastem Goes Public: Why Not?
Medivation Comes Through With MDV3100
Exelixis Fights City Hall, and City Hall Looks Like Winning
Avastin: False Hope for Metastatic Breast Cancer
Too Many Cancer Drugs? Too Few? About Right?
So, How Come You're So Darn Lucky, Eh?
Terra Slightly Less Incognita
A Startlingly Good Leukemia Trial
More On Cancer Drug Shortages
Dendreon: Watch the Cost Curve Being Bent
The Duke Cancer Scandal and Personalized Medicine
Avastin and Medicare
Avastin At the FDA Today: Passion Should Lose
The Evolution of Resistance: Are We Doing It Wrong?
A Shortage of Cancer Drugs?
The Ethics of Avastin
Off the Beaten Track. Way, Way, Off.
More Zeroing In On Breast Cancer Cells
So, You Thought Breast Cancer Was Complicated?
Oncology Follow-Up Trials
New Cures! Faster! Faster!
Sanofi's PARP1 Inhibitor Misses
Not Enough Progress Against Cancer?
Detecting Single Cancer Cells
The Avastin Decision: A Reality Check
Resveratrol (SRT501): Development Halted
Halaven: Holder of the Record
Is Cancer A Disease of the Modern World?
Princeton's New Chemistry Building
PLX4032: The Good News and the Bad News
Metformin Against Cancer?
Avastin For Metastatic Breast Cancer: The Whole Story
Avastin: Taking It Back
Cancer Cells: Too Unstable For Fine Targeting?
Exelixis Gets a Compound Back
Mylotarg and the FDA
Angiotensin Receptor Blockers and Cancer: For Real?
Ipilimumab (And Progress Against Cancer)
Again, What's It Worth to You?
Eribulin Gets Reviewed, Finally
The Power of Photons, You Say?
DCA And Cancer: More Results
Malcolm Gladwell on Synta and Oncology
Environmental Cancer?
Perverse Incentives In Clinical Trials
SRT501 - A Trial Suspended
Masses of Data, In Every Sample
GeneVec's Pancreatic Cancer Therapy Crashes
Antisoma's Phase III Disaster
Diminishing Returns
The Problem With Research on Aging
Nanoparticles and RNA: Now In Humans
The PSA Test for Prostate Cancer: Useless
HER2 Confusion
The Front Lines of Cancer Treatment
MAGL: A New Cancer Target
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
A Nobel for Telomerase
Antioxidants and Cancer: Backwards?
Thalidomide for Myeloma: Whose Idea Was It?
Wasted Money, Wasted Time?
Avastin's Numbers
Akt and Mek, But Not PDQ
But You Can't Make Them Take It?
Angiogenesis Inhibitors: Helping or Hurting?
Into the Clinic. And Right Back Out.
Dendreon's Stock: What the Hey?
Dendreon's Revenge?
The Motions of a Protein
Kinases: Hot or Not?
Curse Of the Lost Compounds
Sunesis: No Substitutions Allowed?
BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
The Complicated Causes of Cancer
GSK Layoffs: Yes, Again
Vytorin: Another Round of Nasty Results
Auroral Activity
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Judah Folkman
Plants For Cancer?
Bacterial Infection: Better Or Worse Than Cancer?
Arsenic, Patents, and the World
The Current Cancer Long-Jump Record
Phase Zero?
Let A Thousand Flowers Bloom
Amgen: The Pythian Oracle Laughs Again
Awful, No Doubt. But Not As Awful as Before?
Vaccines Everywhere
Failure: Not Your Friend, But Definitely Your Companion
Vectibix Lurches A Bit
A Good Day's Work
Good Mistakes?
An Innocent Question
Reality, Here In This Little Dish
Sell! (It's Not Just Me)
Blow The Trumpets
Here and There
Imclone, Drama Queen of Biotech
Tell 'Em You Work On Something Else
Resistance Isn't Quite Futile
That Fount of Information We Call ASCO
Jungle Rot
New Frontiers in Self-Deception
Price Gouging or Not?
Gold and Lasers
What's It Worth to You?
Mice, Humans, and Cancer
Another Shot at Cancer
The Hard News on Cancer
Hype or Hope?
No Such Disease
Selectivity: One of Those Flexible Concepts
A Tale of Two Trials
Cancer Delusions
When the Alternative is Nothing
Biotech At Last, Eh?
That Has to Be Good, Right?
ASCO Fever
'Tis the Season
The Price of Desperation
Targretin's Troubles
Drug versus Stock
Still Not All That Easy
Springtime for Oncology
What We Are Pleased to Call State of the Art
Black Friday: One Damn Thing After Another
The Coming Oncology
Check, Please
Tarceva Targets
Clay Lies Still, But Blood's A Rover
Costs and Benefits, Risks and Rewards
Another Shot Across the Bow
Bungee Jumping with PPAR Drugs
It'll Cost You
Vox Populi
As Goes ASCO. . .
All the Myriad Ways
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
A New Cancer Target - Maybe
Back on the Air
Pneumonia, of All Things
O Brave New Market, That Has Such Medicines In It
Not Even Funny
Genetic Optimism
The Wall Street Journal versus the FDA
Consequences of Aneuploidy
Aneuploidy, or What're A Few Chromosomes, More or Less?
HER-1 And HER-2, Too
Save Your Tears
A Few Words
Did He Say What They Thought He Said?
Now Is the Peptide of Our Discontent
Hype and Glory
More Imclone, More Food for Thought
A Certain Tension in the Air
Imclone in Progress

Cardiovascular Disease
A VC Firm Touts Its Successes - And Its Failures
Novartis Impresses Where Others Have Failed
Ezetimibe In the Marketplace
The Nasty Side of HDL
Merck Pulls One Out
Nasty Odor as a Drug Side Effect
Dietary Fat and Heart Disease
The First PCSK9 Phase III
Clinical Trial Fraud Uncovered
An Anticoagulant Antidote
Merck's Liptruzet: A Cause For Shame?
Regeneron Expands
Affymax In Trouble
Merck Finally Settles Over Vytorin
CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
Merck's Tredaptive Comes to a Halt
Mipomersen In Trouble
Eli Lilly's Drumbeat of Bad News
Niacin: How Does It Work, Anyway?
Caloric Restriction Flops?
The CETP Rogues Gallery
500,000 Excess Deaths From Vioxx? Where?
Strangely Good Results in Diabetes and Cardiovascular Disease
Is HDL Always "Good Cholesterol"?
The CETP Saga Continues (And It's Not Getting More Entertaining)
Statin Safety
Lipitor Expiration Day
Regeneron Finally Makes It to the Market
Pushing Onwards with CETP: The Big Money and the Big Risks
Geron, Stem-Cell Pioneers, Drop Stem Cells
Anticoagulants, One After Another
A Few More Victories Like This, And We Will Be Undone
Cardiac Hope and Cardiac Hype
Niacin's Unexpected Flop
Fenofibrate: Good For Much?
Phase II Failures
Merck's Vorapaxar: Bleeding, Indeed
Merck's Thrombin Antagonist In Trouble
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
Apotex's Plavix Adventure: Four Years Later
Avandia: Was the Evidence Buried?
That Schering-Plough Lawsuit Isn't Going Away
Lilly's Statin - Yes, It Is 2010
Angiotensin Receptor Blockers and Cancer: For Real?
Raising Your HDL - Through the Brain?
Pfizer Halts a Trial Early - On Good News
Steve Nissen vs. GlaxoSmithKline
Animal Studies: Are Too Many Never Published At All?
Diminishing Returns
Tricor's Troubles
Steve Nissen's Meeting with GSK
Remember Apo-A1 Milano? Pfizer Does.
Plavix vs. Effient
Zetia Takes Another Torpedo
Placebos Can Work the Other Way, Too
Statin Safety?
Rolofylline Hits the Skids
CafePharma Will Now Approach The Bench
Mipomersen - It Still Works
Exercise and Vitamins: Now, Wait A Minute. . .
Farewell to ACAT, and to Lots of Time and Money, Too
Niacin, No Longer Red-Faced?
The Polypill Rides Again
Takeda Gets A Surprise
Torcetrapib: What Was the Problem? And Does It Matter?
Crestor: Would It Save Any Lives?
Crestor: Risks Up, Risks Down
Prasugrel Today?
Vytorin: Another Round of Nasty Results
Prasugrel: Come Back This Fall
Merck, Vioxx: Seventeen and Three
In Which I Hate A Wonder Drug
Cordaptive Q and A
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
Vytorin Numbers
Vytorin: It's A Pity
Pfizer vs. the NEJM: A Legal Showdown
Off Target? Which Target Did You Mean?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Renin, Wherefore Art Thou, Renin?
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
The HDL Compost Pile
AGI-1067: Dead or Alive?
Torcetrapib: The Foil-Lined Hat Perspective
Bigger And Greasier
Too Near the Sun?
The Torcetrapib Catastrophe
Pfizer's Sizing
Ah, the Heck With the Error Bars
Elsewhere
It Should Work. It Just Doesn't.
Plavix Plot Twists
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer Recalculates
More Statin Skirmishing
Vioxx: 18 Months to Trouble?
As Merck Caroms Off Another Tree
Merck and the Numbers
Merck's Latest Underwhelming Data
The New England Journal And Its PR Flacks
Merck, So Far
Nitromed's Slow Decline
The Big Statin Pillow Fight
NEJM vs. Its Contributors, Round Two
Merck versus the New England Journal
Does Celebrex Have A Future At All?
An Expensive Way Back for Celebrex
The New England Journal of Legal Immunity?
Selectivity: One of Those Flexible Concepts
Merck on Trial
Where's the Combo?
A Drug's Target, Finally
COX-2 Aftermath
Waiting for the FDA
Boarding Up the Windows
The FDA Weighs In
Let's See What the Sharks Think of These Steaks!
Cox-2 Confusion
How Bad Are the Cox-2 Inhibitors, Anyway?
More on Merck
A Day With All the Bark Left On It
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Pravachol vs. Lipitor Update
Ignorance Was Bliss
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
Sic Transit Gloria Mundi
Trials of Trials
Cholesterol Lowering, One Way or Another

Chem/Bio Warfare
Chemical Warfare in Syria?
The Litvinenko Case: More On Polonium and Alpha Particles
Evil Thoughts of Evil Things
A Fire, And Its Flames
Osmium Tetroxide, Of All Things
Ricin Redux
More Ricin
Ricin
And While We're On the Subject - Mercury?
A Mystery Gas?
Chemical Warfare, Part Five: The Real World
Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
Chemical Warfare, Part Three: How Nerve Agents Work
Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
Chemical Warfare, Part One: Introduction

Chemical Biology
Reactive Groups: Still Not So Reactive
Proteins Grazing Against Proteins
Put Them in Cells and Find Out
An Easy Way to Make Cyclic Peptides
Modifying Red Blood Cells As Carriers
Single-Cell Compound Measurements - Now In A Real Animal
Covalent Fragments
The Science Chemogenomics Paper is Revised
More on the Science Chemogenomic Signatures Paper
Biology Maybe Right, Chemistry Ridiculously Wrong
Encoded Libraries Versus a Protein-Protein Interaction
Binding Assays, Inside the Actual Cells
Small Molecule Chemistry's "Limited Utility"?
Years Worth of the Stuff
Another DNA-Barcoded Program From GSK
Another Round of Stapled Peptide Wrangling
Ces3 (Ces1) Inhibition As a Drug Target
Clicked-DNA Works In Human Cells
Trouble With Stapled Peptides? A Strong Rebuttal.
A Tool Compound's New Personality
Erythropoetin From Scratch
Cancer Cell Line Assays: You Won't Like Hearing This
Just Build The Thing
Making the Bacteria Make Your Fluorinated Compounds
Chemistry On The End of DNA
Evolving Enzymes: Let 'Em Rip
Ben Cravatt At The Challenges In Chemical Biology Conference
Kurt Deshayes At The Challenges in Chemical Biology Conference
DNA Can Be Messed With More Than You'd Think
Kevan Shokat At The Challenges in Chemical Biology Conference
Udo Opperman At The Challenges in Chemical Biology Conference
Stuart Schreiber at the Challenges in Chemical Biology Conference
Forcing Fungi to Make Stranger Compounds
Chemical Biology Highlights
A Short Peptide And A Small Molecule
Chemical Probes Versus Drugs
The DNA-Encoded Library Platform Yields A Hit
Using DNA to Make Your Polymers. No Enzymes Needed.
Selective Inhibitor, The Catalog Says
So How Does One Grow Beta-Cells?
Halogen Bonds
More on the Parabon NSF Press Release
Parabon's DNA Structures: What The Hey?
Stapled Peptides Take a Torpedo
An Engineered Rhodium-Enzyme Catalyst
A Good Example of Phenotypic Screening
Picosecond Protein Watching
JQ1: Giving Up a Fortune?
Zafgen's Epoxide Adventure
EMBL Chemical Biology: Progress in Oncology
EMBL Chemical Biology: The ChEMBL Database
EMBL Chemical Biology: George Whitesides on Ligand Binding
EMBL Chemical Biology: Greasy Labels
EMBL Chemical Biology: How Receptors Really Work
EMBL Chemical Biology: Unnatural Amino Acid Labels
EMBL Chemical Biology: Discovering Catalysts
EMBL Chemical Biology: Labeling Proteins
EMBL Chemical BIology: Natural Product Multiheterocycles
EMBL Chemical Biology: Covalent Probes
EMBL Chemical Biology: Weird Aggregating Compounds
EMBL Chemical Biology: Natural Product Leads
Four Billion Compounds At a Time
Screening Quickly Through the Mutants
A First Step Toward A New Form of Life
Chemical Biology: Engineering Enzymes
Chemical Biology: Plastic Antibodies?

Chemical News
Weirdly, Tramadol Is Not a Natural Product After All
Reactive Groups: Still Not So Reactive
The Smallest Drugs
Sulfates, And What They Can Make
Decorating Heterocycles Via Sulfinates
Rule of Ten?
Sulfur Fluoride Exchange
The Synthesis Machine
Thalidomide, Bound to Its Target
An Easy Way to Make Cyclic Peptides
Catalyst Voodoo, Yielding to Spectroscopy?
Corrosion Using Selectfluor?
Where's the Widest Variety of Chemical Matter?
Stephanie Kwolek, 1923-2014
More On Automated Medicinal Chemistry
Med-Chem, Automated?
Whack-A-Mole
The Robustness Test: Why Don't We Just Require It?
Get the Science Out of Your Yogurt
Alex Shulgin, 1925-2014
Covalent Fragments
The Science Chemogenomics Paper is Revised
Mix-and-Match Natural Products
I'll have the Cesium Cole Slaw and the Francium Fries, Too
Photochemical Reaction Discovery
Google Honors Dorothy Hodgkin and Percy Julian
Fluorination, The Old-Fashioned Way
A Ligand Efficiency Reply
For A Science Center, This Is a Disgrace
Photoredox Marches On
Watching A Palladium Reaction, In A Crystalline Flask
Back Ordered, I'll Bet
Is That Food or Not?
Funding Undergraduate Summer Research
Molecular Printing of Drug Molecules. Say What?
Gitcher SF5 Groups Right Here
The Latest Protein-Protein Compounds
Total Synthesis in Flow
More on the Science Chemogenomic Signatures Paper
Biology Maybe Right, Chemistry Ridiculously Wrong
Yeah, That Must Be It
A New Fluorination
Nitrogen Heterocycles Ahoy
Another Use for Xenon
Small Molecule Chemistry's "Limited Utility"?
More Things Synthetic Chemists Hate
What If Total Syntheses Had Only 25 Steps to Work In?
Some New Reviews
A Structure From the Molecular Sponge
Making Arenes React, Via Rhodium
Alan Katritzky 1928-2014
The Bread Rolls of Synthesis
Today We Have Naming of Parts
Thermodynamics of Life
On Vitamin C, And On Linus Pauling
The West Virginia Formaldehyde Claim Is Nonsense
A Long Fight Over Allegations of Fraud
A New Olefin Coupling
Easy Aziridines
A Table of Smells, Stinks, And Aromas
A Mystery Chemistry Glassware Kit
Erythropoetin From Scratch
Free Chemical Patent Searching
Tiny Details, Not So Tiny
Best Chem-Blog Posts of 2013
Low Energy Records
The Old Days in Organic Chemistry
Cesium, Uh, Trifluoride?
Fred Sanger, 1918-2013
In Praise of Organic Chemistry
More Magic Methyls, Please
Getting van der Waals Forces Right
Diazomethane Without Tears. Or Explosions.
Microwave Synthesis
Unpacking a JACS Total Synthesis Paper
The 2013 Nobel Prize in Chemistry
36 Basic Types of Reactions?
Element Shortages, Really Light and Really Heavy
Ligands From Nothing
A New Version of ChemDraw Mobile
Bring Me More Cute Ring Systems
Making the Bacteria Make Your Fluorinated Compounds
Chemistry On The End of DNA
The 3D Fragment Consortium
Ingenol: A Walk In The Park
A Microwave Argument
The Norbornyl Cation Structure (Really)
How Robust Is That New Reaction, Anyway?
Product Inhibition, Or Grinding To A Halt
Influential Chemists, Anyone?
The Overselling of Ionic Liquids
Getting Your Hands on All Those Three-Dimensional Structures
Quaternary Chiral Centers Made to Order
ChemDraw on the iPad
The Flip Side: Organic Chemistry That Should Be More Famous
The Current Kudzu of Chemistry?
A Total Synthesis Archive
Check Out These Molecules
Making the Non-Flat, Non-Aromatic Compounds
A New Way to Determine Chirality
Alkynes and Nitriles
GSK's Published Kinase Inhibitor Set
Pyrrolidines, Not the Usual Way
Total Synthesis in Print
The Portable Chemist's Consultant
What's Translational Synthesis, Anyway?
How To Deal With the Ridiculously Huge Universe of Compounds
PPAR Delta For Cycling? I Think Not.
New Sirtuin Inhibitors
Chlorine Trifluoride: Some Empirical Findings
More Reaction Discovery
ChemBark Closing Down (Update: Not Really!)
The DNA-Encoded Library Platform Yields A Hit
Automated Med-Chem, At Last?
The Baran Group Blog (And Some Others?)
The IBX Answer
Putting the (Hard) Chemistry Back in Med Chem
The Industrial Diels Alder, Revisited in Detail
Not What It Says On the Label, Though
Natural Product Fragments: Get Rid of the Ugly Ones Now
Phil Baran at Blog Syn
More From Blog Syn
What Would Go Into the Chemistry Museum Displays, Anyway?
Anyone Still Swimming in the Chiral Pool?
Vibrational Scent Wins A Round?
The Hydrophobic Effect: I Don't Understand It, Either
Halogen Bonds
Blog Syn: An Idea Whose Time Has Come?
Bright, Glowing Industrial Chemistry
Oxidizing Alcohols - With Water
Know How to Make 3,4 Difluorothiophene?
Don't Let the Art Director Draw Your Molecules
Natural Products Continue to Weird Me Out
Why Did Pfizer Have All That Gold Dust, Anyway?
Fluorous Technologies Is No More
Stanford's Free Electron Laser Blasts Away
Every Tiny Detail
Think Your Drug Is Strange-Looking? Beat This.
Science Gifts: Chemistry Sets
Chemistry Software Questions Here
An Engineered Rhodium-Enzyme Catalyst
The Galaxy Is Full of Gunk
ChemDraw Magic
Sulfolane
Hexacyclinol Round-Up
Hexacyclinol Retracted. It Only Took Six Years.
Unknown Heterocyles: Destined to Remain That Way?
Picosecond Protein Watching
Sudden Onset of Promiscuity
Hype, Malpractice, and Scientific Misconduct in Organic Synthesis
March of the Ugly Tool Compounds
Another Controversial Scaffold?
You Should Take Chemistry: A Response
"Why Are You Forcing My Son to Take Chemistry?"
A New Diels-Alder
There Will Be No More Woodwards
The 2012 Nobel In Chemistry. Yes, Chemistry.
November Conference on Drug Discovery in Boston
A Lovely Petite Compound
We Were Ahead of the Crowd
The American Chemical Society's Lawsuit Problem
Rearrange Those Chemists
Another One of Those Startling Molecular Images
Chemistry in the Quantum Vacuum. No, Really.
K. C. Nicolau, Rice University, Six Million Dollars, And Malevolent Aliens
Nicolaou Moving? Others?
Nobel Season Begins!
Absolutely The Worst Ad For a Rota-Vap You Will See Today
A Synthetic Retraction
Chemistry's Mute Black Swans
The Good Ol' Diels-Alder
More Boronic Esters, Please
Four Billion Compounds At a Time
Enzymes, Nanotech, and Picky, Picky Details
Just How Do Enzymes Work?
Shootmenowicene
Public Domain Databases in Medicinal Chemistry
Synthetic Chemistry: The Rise of the Algorithms
A Diazirine That Will Knock You Out
Mix 'Em All Together
Science Fiction Gets the Upper Hand
Quick Links
Bungled Structure, And How
The Good Ol' Friedel-Crafts
A New Reaction Discovery Platform
The World of Metal-Catalyzed Couplings
More Reaction Discovery (Now With Antibody Detection)
Cytotoxic? You Bet!
Build Your Own Reactive Reactors
Virtual Biotech, Like It or Not
A Quick Note to Eli Lilly
One Does Not Simply Walk Into Fluorine Chemistry
Inside A Chinese Pharmaceuticals Maker
Pseudephedrine Made Easy. Kind of.
An Actual Motivational Poster
The Worst Compound You've Ever Drawn?
Imidazole-1-Sulfonyl Azide HCl: Look Out
A Real Periodic Table - With Real Elements
Synthetic Electrochemistry: Who's Done Any?
Glass Structure, Atom by Atom
Potassium Hydride Is Not Your Friend
Lead-Oriented Synthesis - What Might That Be?
The UCLA Lab Fatality: Criminal Charges Filed
Chemistry, The Movie!
Trifluoromethylation, The Easy Way?
An NMR Poster
Now That's A Catalyst
Nothing Says "Chemistry" Like Nonsense!
Finding Even More New Reactions By Looking For them
Georgia Tech Forgets How to Draw Structures
Brow-Furrowing Chemical Ads
A Quasicrystal Nobel Prize
Pulling Molecules Apart, For Fun
Finding New Reactions By Looking For Them
Terra Slightly Less Incognita
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
Get Yer Rhodanines Here
Crazy Shape-Shifting Bullvalenes
New Ways to Fluorinate
Bait And Switch For Type B GPCRs
Precious Metal Time
The Public Perception of Chemistry
Will Macrocycles Get It Done?
Getting Rid of Pesky Chirality
Like Charges, Er, Attract?
Quis Custodiet Ipso Custodes?
Process Chemistry Makes the Headlines
In Memoriam, Two Chemists
What Medicinal Chemists Really Make
In Which I Do Not Lose It, For Once
Smell The Vibrations? Fruit Flies Might Be Able To. . .
The Solid Phase
Not On My Street - I Hope
Going to Let Someone Else Do This One
Halaven: Holder of the Record
Finally, An Alternative to Palladium. About Time.
ACS Survey - Or Something Else?
Graphene Oxide as a Reagent
Princeton's New Chemistry Building
Back to Philadelphia
Meeting Time
A Nobel For Palladium Couplings, At Last
Chemical Biology: Engineering Enzymes
Chemical Biology: Plastic Antibodies?
Wisterone: A Structure I Can't Believe
Nobel Season 2010
Delightful, But It Apparently Works
Chemical Biology - The Future?
Synthetic Chemistry: All Mined Out?
Want To Make an Amide? Have I Got Good News For You!
Sodium Hydride As Oxidant, Again?
Ancient Chemistry Comes Back to Life?
Organic Chemistry: A Lack of Challenges?
Metal-Free Coupling Reactions: Now Wait A Minute. . .
Running Your Fingers Over A Single Molecule
Know How to Make Praziquantel? Tell The World.
Another Zero-Palladium Delusion?
The Ideal Synthesis
Maitotoxin: It's On, All Right
Sparteine and Other Fine Chemical Shortages
Max Gergel's Memoirs
What's the Condensation Record?
Pyridines and Dichloromethane
You Don't See Many Names Starting with "Tellura-"
Maitotoxin Revisited
Report from C&E News
Nonsense About LSD
Flowing, Not So Gently
Together At Last
Sure About That?
More Binding Site Weirdness
K. C. Nicolaou, Call Your Office
Hoist, Petard, Etc.
Retire These Reactions!
Microwaves Aren't Magic
Nobel Season 2009
Chew On This, Enzyme
More on T2, and Degrees
175 Times. And Then the Catastrophe.
"Scratch and Sniff" Turns Into "Zap and React"
Another Iron Reaction Hits The Mat
Rings of the Future!
Everything In Its Place
The Further In You Go, The Bigger It Gets
Devils, Metals, and Details
TMS Diazomethane: Update On a Fatality
Writing With Triazoles
The Motions of a Protein
Grabbing Onto A Protein's Surface
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Hexacyclinol - Another Request
Hexacyclinol: A Forensic Case
The Original Nanotechnology
A Long Tail Indeed
The Real Hazards of the Lab
The Great Acetonitrile Shortage
Diversity-Oriented Synthesis: Oriented The Right Way?
Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
An Impressive Nanolist of Nanocitations
Copper: A Gentleman's Disagreement
New Tricks With Glassware
DNA Forklifts, DNA Pliers
Le Dernier Cri
One For the Brave
Ertl Wins: Down With Witchcraft
All Sorts of Holes
Steve Ley, Azadirachtin, and Me (Very Much in That Order)
ACS Meetings
Calcium: A Backwater
Smell the Vibrations
Six Chem-Geek Questions
Hexacyclinol Rides Again
Hexacyclinol? Or Not?
Chem-Geek Alternate History
A New Route to Tamiflu?
More on Woodward
Archaeologists Announce Dirty Laundry Discovery
Why Total Synthesis?
Climbing Mountains

Clinical Trials
Messed-Up Clinical Studies: A First-Hand Report
Update on Alnylam (And the Direction of Things to Come)
Clinical Trial Fraud
Novartis Impresses Where Others Have Failed
Exelixis Against the Wall
Drug Repurposing
Amicus Fights Its Way Through in Fabry's
Incomprehensible Drug Prices? Think Again.
Is The Current Patent System Distorting Cancer Research?
Targacept Comes Up Empty, Yet Again
Neratinib Comes Through For Puma
Targacept Fumbles the Bad News on Alzheimer's
A Drug Candidate from NCATS
Studies Show? Not So Fast.
Alzheimer's Bonds
Taking Risks - You Have To, So Do It Right
Whooo-eee
The Virtual Clinical Trial: Not Quite Around the Corner
Stem Cells: The Center of "Right to Try"
A "Right to Try" Debate
Right To Try: Here We Go
Good News! Our Alzheimer's Drug Didn't Work!
Would You Have Advanced BBI608?
AstraZeneca Looks At Its Own History, And Cringes
The Real Numbers on Tamiflu
Merrimack Wins One
Concert's First Drug: Not So Great
Cancer Immunotherapy's Growing Pains
Google's Big Data Flu Flop
Always Insist on Error Bars
Repurposing for Cervical Cancer
More Good PD-1 News in Cancer
A Call To Rein In Phase III Trials
InterMune Comes Through
Dacomitinib Doesn't Come Through
PTC's Latest Ataluren Woes
Alzheimer's Therapies: A Reasonably Gloomy Update
Should Drug Industry Research All Get Rejected For Publication?
A New Look At Clinical Attrition
Outcomes, Expensive Outcomes
Merck's Drug Development in The New Yorker
Zafgen's Epoxide Clears A Hurdle
Nasty Odor as a Drug Side Effect
Sarepta's Approval Woes
Darapladib Misses Its Endpoint
Another Pain Drug Wipes Out
Compassionate Access: No Good Answer
The FDA: Too Loose, Or Appropriately Brave?
The First PCSK9 Phase III
Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
Prosensa: One Duchenne Therapy Down
Mannkind's Latest Data
Apparently, Ads Make Antihistamines Work Better
More Behind-the-Scenes Maneuvering. How Wonderful.
More Details on T-Cell Leukemia Therapy
One GSK China Scandal Blends Into Another
The NIH's Drug Repurposing Program Gets Going
More on the NIH and Its Indian Clinical Trials
Does That Answer Your Question? Not Quite, No.
Lilly Goes All In on Solanezumab
Clinical Trial Fraud Uncovered
The Last PPAR Compound?
A Beta-Secretase Inhibitor Hits the Skids in Alzheimer's
AstraZeneca, As Expected, Pulls the Plug
And The Award For Clinical Futility Goes To. . .
Aveo Gets Bad News on Tivozanib
Cancer: Back to N-of-One
A Therapy Named After You?
The Wyeth/Elan Insider Trading Case Resolves
Good News in Oncology: More Immune Therapy for Leukemia
Good News in Oncology: Oncolytic Virus Therapy
NeuroSearch's Decline
von Eschenbach Takes Another Whack at Phase III Trials
ABT-199 Clinical Trial Suspended (Updated)
DUCTS: Down with Useless Clinical Trial acronymS
Not Working Out So Well at Merck?
Mipomersen Approved (Bonus Antisense Roundup Included)
CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
That Many Compounds in Development? Really?
A Short Rise Out of Depression
Overselling p53 Drugs
Merck's Tredaptive Comes to a Halt
CNS Drug Development Claims Another Victim
Asking the Tough Questions: Doomsday in the Clinic
Rheumatoid Arthritis Wins A Couple of Rounds
Eli Lilly's Brave Alzheimer's Talk
Merck Presses Ahead on Alzheimer's:
TauRx Goes Into Phase III For Alzheimer's
And Since We're Talking About Insider Trading
Oh Yeah, Now That You Mention It, They're Dead
The Coming Battle Over Alzheimer's Disease
"Basically, They're A Bunch of Lemmings"
The Generic Wellbutrin Problem: Whose Fault Is It?
Another Prospective Alzheimer's Trial
GSK Opens Up Its Trial Data
Lilly's Solanezumab: Did It Actually Work?
Transcelerate: What Is It, Exactly?
Geron, And The Risk of Cancer Therapies
Eli Lilly's Drumbeat of Bad News
Lilly's Solanezumab: A Miss or a Win?
Is Ampyra Any Good?
Does Aveo's Tivozanib Work, or Not?
Bapineuzumab Still Does Not Work Against Alzheimer's
When Is A Company Shading the Truth About Its Clinical Trials?
Bapineuzumab Does Not Work Against Alzheimer's
AstraZeneca Admits It Spent Too Much Money
The CETP Rogues Gallery
A Preventative Trial for Alzheimer's: The Right Experiment
The CETP Saga Continues (And It's Not Getting More Entertaining)
Making Their Own ALS Drug
Biomarker Caution
Stem Cells in Texas: Quite the Business
Bias in Industry-Funded Trials in Rheumatoid Arthritis?
Eschenbach Says Market, Then Test
Reaction to Andy Grove's Clinical Trial Proposals
Rexahn Rides Again
Targacept's Antidepressant Fails, And How
Medivation Comes Through With MDV3100
Exelixis Fights City Hall, and City Hall Looks Like Winning
Too Many Cancer Drugs? Too Few? About Right?
Andy Grove's Idea For Opening Up Clinical Trials
Bernard Munos Rides Again
Laquinimod Fails For Multiple Sclerosis
The Duke Cancer Scandal and Personalized Medicine
An Unethical Clinical Trial
Making the Numbers Confess
Niacin's Unexpected Flop
The Ethics of Avastin
Fenofibrate: Good For Much?
Phase II Failures
Lucentis and Avastin: Results
Update on Avastin and Lucentis
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Use Avastin! Don't Use Avastin!
Down In Phase III. Again.
Oncology Follow-Up Trials
Sanofi's PARP1 Inhibitor Misses
Not Enough Progress Against Cancer?
Merck's Vorapaxar: Bleeding, Indeed
Reboxetine Doesn't Work. But That's Not the Real Problem.
Merck's Thrombin Antagonist In Trouble
Detecting Single Cancer Cells
Resveratrol (SRT501): Development Halted
Of Deck Chairs, Six Sigma, And What Really Ails Us
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
Trusting the Medical Literature?
Avastin: Taking It Back
Cancer Cells: Too Unstable For Fine Targeting?
Alzheimer's Markers and Collaboration
Resveratrol (SRT501): Buy Now - Why Wait?
Alzheimer's and Amyloid, Again
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Avandia: Was the Evidence Buried?
Alzheimer's: Extracting Data From Failed Trials
Pfizer Halts a Trial Early - On Good News
DCA And Cancer: More Results
Perverse Incentives In Clinical Trials
Steve Nissen vs. GlaxoSmithKline
SRT501 - A Trial Suspended
A Landmark In Clinical Trial Data Interpretation
Ardea's Gout Drug Progresses
Animal Studies: Are Too Many Never Published At All?
GeneVec's Pancreatic Cancer Therapy Crashes
Antisoma's Phase III Disaster
Diminishing Returns
Nanoparticles and RNA: Now In Humans
Benford's Law, Revisited
Tricor's Troubles
Intermune's Rise
Hope Darn Well Springs Eternal
Dimebon, Grasping at Straws
Dimebon Comes Crashing to Earth
HER2 Confusion
Steve Nissen's Meeting with GSK
The Front Lines of Cancer Treatment
Dimebon for Alzheimer's: A Black Box Indeed
A Database of Side Effects
Correlations, Lovely Correlations
Sirtuin Scenarios
Lilly's R&D Outsourcing
An Alzheimer's Compound Runs Into Big Trouble
All Of You Industrial Scientists: Out Of the Room
Plavix vs. Effient
Zetia Takes Another Torpedo
Massaging the Data for Neurontin?
Placebos Can Work the Other Way, Too
Arzoxifene: Not the Road to Big Profits?
Wasted Money, Wasted Time?
Amyloid in Trouble
Medarex, Ipilimumab, Prostate Cancer, And Reality
Avastin's Numbers
Rolofylline Hits the Skids
CafePharma Will Now Approach The Bench
Akt and Mek, But Not PDQ
Arena, Lorcaserin, and the FDA
Surrogate Markers Are Awful, But They're Ours
Goldman Sachs: Out Of the Drug Funding Business Already?
Into the Clinic. And Right Back Out.
Farewell to ACAT, and to Lots of Time and Money, Too
Another Obesity Drug? Not Likely.
Lilly's Latest Loses (This Time)
And While We're Talking About Industry-Sponsored Studies. . .
What Results Did You Have In Mind?
Drug Industry Research: Reliable or Not?
Want A Hard Disease Target? Try Lupus
Maribavir, Ouch
New Year - I Hope!
Goldman Sachs: A New Drug Research Model?
Torcetrapib: What Was the Problem? And Does It Matter?
Avandia: Trouble, Run Head to Head
Two Drugs in One? Maybe Not.
Crestor: Would It Save Any Lives?
Crestor: Risks Up, Risks Down
Down The Chute in Phase III
Rember for Alzheimer's: Methylene Blue's Comeback
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Vytorin: Another Round of Nasty Results
Glaxo Asks the Eurocrats
Another Alzheimer's Compound Goes Down
Fun With Bacteria
And You Thought Exubera Was A Disaster Before
Another Cholesterol Medication Goes Down (Or Does It)?
Vytorin: It's A Pity
You Get What You Pay For?
Taranabant in Trouble?
Hits, Misses, and Some More Misses
Antidepressants: Depressing News or Not?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Come On. Improve, Already.
Deactivation, After All
Rimonabant: Down to Earth
Rimonabant, Out In the Light
Phase Zero?
Pecunia Non Olet?
The Avandia Wars Continue
Knowing What You Know. . .
Avandia: Trouble or Not?
Deep Breaths
Vectibix Lurches A Bit
FDA Advisory Panels: Pay, No Play
AGI-1067: Dead or Alive?
Vertex, Hepatitis, and Gripping the Arms of Your Chair
Upside Down Activity
Torcetrapib: The Foil-Lined Hat Perspective
Too Near the Sun?
The Torcetrapib Catastrophe
It Should Work. It Just Doesn't.
A Spray-Painted Crystal Ball
Tough Targets
Tegenero, In Detail
Vioxx: 18 Months to Trouble?
Formally Undecideable
A Question For the Crowd
Access to Phase I Drugs: A Constitutional Right?
A Word to the Wise About TGN1412
TNG1412: Was There a Warning?
Update on TGN1412
No Immunity From Immunity
But His Name Lives On. . .
The FDA Loosens Its Tie
An Expensive Way Back for Celebrex
Rigel's Puzzling Failure
This Had Better Be Good
By a Nose in a Head to Head
No Clear Winners
Muraglitazar's Turn
Gritting Our Teeth
Where's the Combo?
Still Not All That Easy
The NIH in the Clinic
One More On Basic Research and the Clinic
How It Really Works
Unburied
Me Too, Part Two
Clinical Trials And What to Do With Them
Fast, Cheap, and Sometimes Even Good
Primum Non Nocere, Eh?
The Journals Fight Back
Your One-Stop Clinical Data Superstore?
Cue the Music
Pravachol vs. Lipitor Update
Ignorance Was Bliss
More From the Me-Too Front
Putting A Price on Proving It
Here and There
Trials of Trials
Statins and Multiple Sclerosis
Muddying the Water For Fun and Profit
Save Your Tears

Closing Time
Med-Chem Layoffs, On the Front Page
Massachusetts Moving
A Post I've Been Looking Forward to For Months
Layoffs - Again
More Help Wanted?
Have We Got a Job For You!
A Break, Whether I Felt Like It Or Not
Open For Business
Ghost Town
Out With the Old
Cleans Down to What Should Be the Shine
Hi, My Name Is [...]
The Paper Mountain
Vial Thirty-Three: Warp Drive
Where Do All The Chemicals Go?
The Race Is On

Current Events
Another Whack at the Stem Shortage Myth
Jailhouse Secrets They Don't Want You to Know About!
The West Virginia Formaldehyde Claim Is Nonsense
China's GlaxoSmithKline Crackdown
Eight Toxic Foods: A Little Chemical Education
The Drug Industry and the Obama Administration
Making Changes Inside Merck's R&D
One. . .Million. . .Pounds (For a New Antibiotic?)
Promoting STEM Education, Foolishly
Just Work on the Winners
A Dumb Proposal for the NSF
A Bombing
Pick Your Stench
Anti-GMO. Until This Week.
C&E News Covers the Apocalypse
Chemical Warfare in Syria?
There Go the Lights
Budgets and Revenues
Time For An Election Post
Lab Animals Wiped Out in Hurricane Sandy
Way Too Much Hydrofluoric Acid
A Russian Chemist in Jail
PhRMA Waits For The Supreme Court
Information Density
Science, A Zero-Sum World, and the State of the Union
More on Chinese Pharma Espionage
The Force of Cluelessness
A Brief Note on Current Events
A Radiation Chart to Clip and Save
Potassium Iodide Pills
Quick Japan Update
Bias And How to Deal With It
Japan
Science and Revolution
Health Care Reform and the Drug Industry: How Goes It?
And a Quick Political Note
Lethal Injection: A Case For the FDA?
Martin Gardner, RIP
Floyd Landis: The Isotopes Weren't Lying, After All
Report from C&E News
Bits And Pieces
Sir James Black, 1924-2010
The Health Care Bill: A Therapeutic Rant
Theft at Eli Lilly
Pharma and the Health Care Bill: Value For the Money?
Sanofi-Aventis Cuts Back
Here's a Business Plan For You
GSK Day
A Scorched-Earth Policy at Wyeth's Princeton Site?
GE Healthcare's Idiotic Libel Suit
Once You Have Paid Him the Danegeld. . .
Climategate and Scientific Conduct
Warren DeLano
Prof. Keith Fagnou
Against Panic
A Nobel for Ribosome Structure
A Nobel for Telomerase
The Details of the Baucus Bill
Pay Them Now, Or Pay For It Later
Norman Borlaug
The PhRMA Deal
PhRMA's Negotiating Game
Health Care Reform - Really?
Iran: Politics and Technology Update
Proxy Server Update
Proxies and Politics Again
Politics: Proxy Servers Revisited
Proxies for Iran (More Politics - Mixed With Technology)
And Now Some Politics
Will The Gentleman With the Pitchfork Please Speak Up?
But You Can't Make Them Take It?
Kumbaya
Faking It on Facebook
Don't Hit The Bunkers Just Yet
Biogen Idec: What's Going On?
Sponsor A Gene?
Layoffs At Merck
Greedy Biotechs?
Wyeth v. Levine: Pre-emption Goes Away
Ranbaxy in Trouble
Single, Simple Numbers: Use At Your Own Risk
Autism and Vaccines: Boiling Over Yet Again
Their Crime? Collaborating With Other Scientists. . .
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
Well, Hose Me Down. . .
Layoffs. More Layoffs.
Pfizer's Restructuring Grinds Along
We Interrupt This Science. . .For Some Politics
BlackLight Power Responds
Blacklight Power: What on Earth?
A Green Fluorescent Nobel Prize
Nobel Season 2008
Pfizer: As We Speak?
More Pfizer Layoffs?
Nullius in Verba
Judah Folkman
Ah, Politics
Unnatural, And Proud Of It
Ertl Wins: Down With Witchcraft
Nobel Chemistry Odds
Nobel Season
The Choir Hears It Again
Pour Encourager Les Autres
Access To Science
Time To Conduct Some Business
Layoffs - Again
Hedgehogs in Stockholm
F. A. Cotton, 1930-2007
CMPI Conference: Critical Path
CMPI Conference: Lunch With the FDA
CMPI Conference: Panel on the Politics of Drug Evaluation
CMPI Conference: Panel on Media Coverage
That Smell
And The Winner Is. . .
Injustice
The Litvinenko Case: More On Polonium and Alpha Particles
Polonium Poisoning
Help Wanted - I Hope
Here and There
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Airplanes and Chemicals
Testosterone, Carbon Isotopes, and Floyd Landis
Explosion News
Poor Put-Upon Intelligent Design
The Dover Decision Comes Down
Merck Update
Merck, Finally
Intelligent Design, Molecule By Molecule
The Dover Decision
Merck Off the Mat
Metathesis Nobel!
A Piece of the Action
Okay, One More Merck Point
No More Merck For A Couple of Days
Judgement Day
Welcome to the World, I Hope
Strangers on a Train
Special Off-Topic Weekend Irrelevancy
Actually, It's Everything Else That's Off-Topic
Happy Fourth of July
Osmium Tetroxide, Of All Things
And Another Thing. . .

Diabetes and Obesity
Reversal of Type II Diabetes May Be Possible
Zafgen's Epoxide Pays Its Way
Speaking of Polyphenols. . .
Ces3 (Ces1) Inhibition As a Drug Target
Irisin and Metabolism - A New Target Emerges
Boost Your NAD And Fix It All?
Bristol-Myers Squibb Exits Diabetes
Zafgen's Epoxide Clears A Hurdle
Exiting Two Therapeutic Areas
Mannkind's Latest Data
The Last PPAR Compound?
Today's Avandia Hearing at the FDA
Trouble for a Whole Class of Diabetes Drugs?
A New Old Diabetes and Obesity Drug Candidate
So How Does One Grow Beta-Cells?
More on Metformin and Cancer (and Alzheimer's)
Is Obesity An Infectious Disease?
Huge But Effective
Zafgen's Epoxide Adventure
The Return of CB1
Caloric Restriction Flops?
An Oral Insulin Pill?
Strangely Good Results in Diabetes and Cardiovascular Disease
Arena and Lorcaserin, Back at the FDA
Dapagliflozin Goes Down (For the Last Time?)
More From Hua - A Change of Business Plans?
Regeneron Finally Makes It to the Market
SRT1720: Good (And Confusing) News for Obese Mice
mINDY Mice - No Obesity, No Diabetes?
GSK and Alli. Not Quite Working Out
MannKind: It's Not Looking Good
Lorcaserin's Complete Response
Avandia Goes Down: A Research Rant
Live-Blogging Arena's FDA Committee Hearing
Lorcaserin in Trouble
MannKind and Seaside 88?
PPAR: A Veil Is Lifted, At Last
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Avandia: Was the Evidence Buried?
Insulin Degrading Enzyme's Turn in the Spotlight
Steve Nissen vs. GlaxoSmithKline
Treatment INDs - For Any Generex Fans Out There
Generex: Who Buys This Stuff, Anyway?
The Crowd Goes Wild
ACC2: Great Metabolic Target, Or Total Bust?
Generex and Their Insulin Spray: Just Hype?
Rats and High-Fructose Corn Syrup
Tricor's Troubles
Your Own Personal Bacteria
Steve Nissen's Meeting with GSK
Avandia: Off the Market or Not?
Sirtuin Scenarios
Gaining and Losing and Discovering and Selling
MAGL: A New Cancer Target
Obesity: Hope Springs Eternal (Summer 2009 Version)
Obesity Shows Up in the Death Rate? Right?
Arena, Lorcaserin, and the FDA
Arena / Lorcaserin Update
Exercise and Vitamins: Now, Wait A Minute. . .
A DPP-IV Compound Makes It Through
Another Obesity Drug? Not Likely.
Takeda Gets A Surprise
Does Glucophage Make Alzheimer's Worse?
Avandia: Trouble, Run Head to Head
CB-1 Obesity Drugs: Farewell to the Whole Lot
Fructose In The Brain?
Taranabant Is No More
Metabolic Hope Springs Eternal
All The Fat Cells You'll Ever Have - Sort Of
Alli: "Underwhelming"
Merck Bails on Natural Products
Why Buy, Anyway?
Exubera, Safety, and No Guarantees
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Taranabant in Trouble?
Off Target? Which Target Did You Mean?
More On Merck and Taranabant
What You Become Known For
Eat It, Breath It, Soak in It?
Avandia: Going Under for the Third Time?
Bad Luck For Novartis - And For Diabetics
Depressing Figures for Acomplia
Surveying the Exubera Crater
More Things Than Are Dreamt Of
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
Deactivation, After All
Visfatin: Real Or Not?
Right Down the Alli
Rimonabant: Down to Earth
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
Exubera: This Time With Feeling
Rimonabant, Slowly
You Can't Make Money If You Don't Get Paid
Up Periscope And Fire All Bow Tubes
The Inscrutable French
Neuropeptide Y Dies, But It Never Surrenders
Tell 'Em You Work On Something Else
Rimonabant Arrives
What's French for "Trust Us"?
Rimonabant Bangs Into. . .Something
Pfizer Takes a Deep Breath
Ghrelin and Obestatin
Pargluva Goes Down?
This Had Better Be Good
Waiting for Pargluva
Muraglitazar's Turn
Gritting Our Teeth
Symlin, At Last
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
Why Own the Car, When You Can Own the Road?
Ah, Marketing
Of All Sad Words. . .
Fighting City Hall
A Treadmill Pill?
Enzymes, Right and Wrong

Drug Assays
Reactive Groups: Still Not So Reactive
A VC Firm Touts Its Successes - And Its Failures
Are Your Compounds Ugly? Do You Know?
A New Look at Phenotypic Screening
Fragonomics, Eh?
Don't Optimize Your Plasma Protein Binding
Phenotypic Assays in Cancer Drug Discovery
Put Them in Cells and Find Out
Outsourced Assays, Now a Cause For Wonder?
Where's the Widest Variety of Chemical Matter?
Dark Biology And Small Molecules
Med-Chem, Automated?
Hosed-Up X-Ray Structures: A Big Problem
Predicting New Targets - Another Approach
Covalent Fragments
DMSO Will Ruin Your Platinum Drugs. Take Heed.
Encoded Libraries Versus a Protein-Protein Interaction
Binding Assays, Inside the Actual Cells
Another Target Validation Effort
A New Way to Study Hepatotoxicity
Years Worth of the Stuff
Another DNA-Barcoded Program From GSK
Another Round of Stapled Peptide Wrangling
Ligand Efficiency: A Response to Shultz
Cancer Cell Line Assays: You Won't Like Hearing This
Phenotypic Screening Everywhere
Unraveling An Off-Rate
The Arguing Over PTC124 and Duchenne Muscular Dystrophy
Ligands From Nothing
More Thoughts on Compound Metrics
Chemistry On The End of DNA
Too Many Metrics
GPCRs As Drug Targets: Nowhere Near Played Out
High Throughput Screening Services
The 3D Fragment Consortium
More Whitesides on Ligand Binding
Protein-Protein Compounds - The Flip Side
Aggravating Aggregators
Making Peroxides, Quietly And Unhelpfully
GSK's Published Kinase Inhibitor Set
Why Not Share More Bioactivity Data?
Drug Assay Numbers, All Over the Place
What's Translational Synthesis, Anyway?
Fragments For Receptors: It Can Be Done
Pharmacology Versus Biology
Mass Spec Continues Its Conquests
The Basics of Phenotypic Screening
Good Ways To Mess Up Your Screening
The DNA-Encoded Library Platform Yields A Hit
Automated Med-Chem, At Last?
Getting Down to Protein-Protein Compounds
Putting the (Hard) Chemistry Back in Med Chem
Not What It Says On the Label, Though
Selective Inhibitor, The Catalog Says
Natural Product Fragments: Get Rid of the Ugly Ones Now
The Hard Targets: How Far Along Are We?
Mouse Models of Inflammation Are Basically Worthless. Now We Know.
The European Lead Factory
All Those Drug-Likeness Papers: A Bit Too Neat to be True?
So How Does One Grow Beta-Cells?
Eating A Whole Bunch of Random Compounds
The Theology of Ligand Efficiency
Automated Ligand Design?
Metal Impurities Will Waste Your Time
How Many Good Screening Compounds Are There?
Four Million Compounds to Screen
A Broadside Against The Way We Do Things Now
Roche Repurposes
Advice For Those Trying High-Throughput Screening
Think Your Drug Is Strange-Looking? Beat This.
How Do Chemist (Think That They) Judge Compounds?
What's A Phenotypic Screen, And What Isn't?
A Good Example of Phenotypic Screening
Sudden Onset of Promiscuity
Controversial Scaffold Is Right
Free the Labels
Watch that Little Letter "c"
Four Billion Compounds At a Time
Finding Fast Fruit Fly Feasibility
Public Domain Databases in Medicinal Chemistry
Antipsychotic Drugs Against Cancer?
Science Fiction Gets the Upper Hand
A Kinase Inhibitor Learns Something New
Watch Your Cell Assays
Return of the Rhodanome
Another Vote Against Rhodanines
The NIH's Drug Repurposing Initiative: Will It Be a Waste?
A New Way to Kill Amoebas, From An Old Drug
Antidepressant Drugs and Cell Membranes
How Do Drugs Get Into Cells? A Vicious Debate.
DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)
Phenotypic Screening's Comeback
Europe Wants Some of That Molecular Library Action
The Artificial Intelligence Economy?
Sloppy Science
Dealing with the Data
The Blackian Demon of Drug Discovery
Drug Discovery for Physicists
More on the NIH's Molecular Libraries Program
The Infinitely Active Impurity
Fluorine NMR: Why Not?
Do We Believe These Things, Or Not?
Lead-Oriented Synthesis - What Might That Be?
Riding to the Rescue of Rhodanines
Rating A Massive Pile of Compounds
Francis Collins Speaks
Does Anyone Want the NIH's Drug Screening Program?
Different Drug Companies Make Rather Different Compounds
Lilly's Open Screening Program: An Update
Get Yer Rhodanines Here
How Many New Drug Targets Aren't Even Real?
Kibdelomycin, A New Antibiotic. In A Way.
Is Anyone Doing the Pfizer Screening Deal?
Bait And Switch For Type B GPCRs
Phenotypic Screening For the Win
In Which I Do Not Lose It, For Once
A Look Inside the Compound Collections
Fragments Versus DOS: A Showdown
The NIH's New Drug Discovery Center: Heading Into the Swamp?
And One Was Just Right?
Enthalpy and Entropy Again
Laser Nematode Surgery!
A Cautionary Tale
Chemical Biology: Plastic Antibodies?
GSK's Response to the Sirtuin Critics
Natural Products: Not the Best Fit for Drugs?
Masses of Data, In Every Sample
Charles River Buys WuXi
Take These?
Animal Studies: Are Too Many Never Published At All?
Compounds and Proteins
Privileged Scaffolds? How About Unprivileged Ones?
Privileged Scaffolds
Drugs And Their Starting Points
We Don't Know Beans About Biotin
Tricor's Troubles
Garage Biotech
Why You Don't Want to Make Death-Star-Sized Drugs
Calorimetry: What Say You?
Two For One Sale
Polluting the Literature with PAINs
Merck and Sirna
The Infinitely Active Impurity
GSK and Sirtris: A Bit More
The Sirtris Compounds: Worthless? Really?
Run It Past the Chemists
Selective Scaffolds
Why Don't We Have More Protein-Protein Drug Molecules?
More Binding Site Weirdness
Side Effects, Predicted?
Lumpy Assay Results
What Exactly Does Resveratrol Do?
To What End?
Dealing With Hedgehog Screening Results
Drug Approvals, Natural And Unnatural
Why Does Screening Work At All? (Free Business Proposal Included!)
Eli Lilly Gives It Away
More Hot Air From Me on Screening
Want To Screen Pfizer's Compounds? Sign Here.
No MAGIC Involved
Drugs For Bacteria: Really That Hard, Or Not?
Tie Me Molecule Down, Sport
Structure-Activity: Lather, Rinse, and Repeat
The Hideous Numbers of Compounds
Diversity-Oriented Synthesis: Oriented The Right Way?
Sticking It to Proteins
Wash Your Tubes; Mess Up Your Data
Animal Models: How High to Set the Bar?
X-Ray Structures: Handle With Care
Receptors: Can't Live With 'Em, Can't Understand 'Em
Sharing the Enlightenment
Oops
The Miracle Solvent
Whose Guess Is Better?
Start Small, Start Right
Getting Real With Real Cells
The Animal Testing Hierarchy
These Fragments I Have Shored Against My Ruins
A Bad Assay: Better Than None?
Let Us Now Turn To the Example of Yo' Mama
The Current Cancer Long-Jump Record
Travels In Numerica Deserta
Less Than Zero
No Shortcuts
Good Mistakes?
Upside Down Activity
Reality, Here In This Little Dish
The Unattractive Truth
Those Darn Invisible Creatures
Waste O' Time Awards
More on Voodoo
And 0.04 Molar in Eye of Newt. . .
Everything's Under Control, Right?
Seven Questions
What Makes A Target, Anyway?
Compounds for the Sake of Compounds
Oh, Dear
Too Interesting For Us
Model Systems, From Inside and Out
What Ails Us
The Vapor Trail I Referred To
Our Cheerful Buddy, The Cell Membrane
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
How Drugs Die
A Request From Biology
Ratio Rationalizations
That Voodoo That We Do

Drug Development
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
A Question: Monoclonal Antibodies in the Clinic
Drug Repurposing
A New Look at Phenotypic Screening
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
Why Not Bromine?
Did Pfizer Cut Back Some of Its Best Compounds?
Don't Optimize Your Plasma Protein Binding
The Antibiotic Gap: It's All of the Above
Phenotypic Assays in Cancer Drug Discovery
K. C. Nicolaou on Drug Discovery
How to Run a Drug Project: Are There Any Rules at All?
A Drug Candidate from NCATS
Alzheimer's Bonds
Zafgen's Epoxide Pays Its Way
Taking Risks - You Have To, So Do It Right
A "Right to Try" Debate
Right To Try: Here We Go
Two Looks At Drug Industry Productivity
Where the Talent Comes From
AstraZeneca Looks At Its Own History, And Cringes
The Daily Show on Finding New Antibiotics
The Lessons of Intercept and NASH
Telling the Truth
Outsourcing Everything
A New Way to Study Hepatotoxicity
Small Molecule Chemistry's "Limited Utility"?
Predicting What Group to Put On Next
Compassionate Use: An Especially Tough Case
Ligand Efficiency: A Response to Shultz
Drug Discovery in India
More Ligand Efficiency
A New Book on Scaffold Hopping
Alnylam Makes It (As Does RNAi?)
A New Look At Clinical Attrition
Three Options With Five Billion to Spend
Positive Rules and Negative Ones
Merck's Drug Development in The New Yorker
Lipinski's Anchor
Leaving Antibiotics: An Interview
The Past Twenty Years of Drug Development, Via the Literature
Exiting Two Therapeutic Areas
Merck's Aftermath
More Magic Methyls, Please
Size Doesn't Matter. Does Anything?
Forecasting Drug Sales: Har, Har.
Prosensa: One Duchenne Therapy Down
The Arguing Over PTC124 and Duchenne Muscular Dystrophy
Merck Does Something. Or Not. Maybe Something Else Instead.
A Drug Delivery Method You Haven't Thought Of
Promise That Didn't Pan Out
Too Many Metrics
Is The FDA the Problem?
A Regeneron Profile
Druggability: A Philosophical Investigation
How Much to Develop a Drug? An Update.
An Interview With A GSK Shanghai Scientist
The NIH's Drug Repurposing Program Gets Going
Salary Freeze at Lilly
Good Advice: Get Lost!
The GSK Jackpot
The Last PPAR Compound?
The Drug Industry and the Obama Administration
Bernard Munos on The Last Twelve Years of Pharma
The Atlantic on Drug R&D
Tecfidera's Price
Sirtuins Live On at GSK
A Therapy Named After You?
The DNA-Encoded Library Platform Yields A Hit
The NIH, Pfizer, and Senator Wyden
Automated Med-Chem, At Last?
AstraZeneca Makes a Deal With Moderna. Wait, Who?
Affymax In Trouble
GlaxoSmithKline's CEO on the Price of New Drugs
Does Baldness Get More Funding Than Malaria?
Who to Manufacture an API?
Getting Down to Protein-Protein Compounds
All Those Drug-Likeness Papers: A Bit Too Neat to be True?
Addex Cuts Back: An Old Story, Told Again
CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
Daniel Vasella Steps Down at Novartis
Eating A Whole Bunch of Random Compounds
The Theology of Ligand Efficiency
That Many Compounds in Development? Really?
Drug Discovery With the Most Common Words
Lilly's Two-Drugs-a-Year Prediction
Marcia Angell's Interview: I Just Can't
A Broadside Against The Way We Do Things Now
When Drug Launches Go Bad
Roche Repurposes
Every Tiny Detail
The Novartis Pipeline
Nassim Taleb on Scientific Discovery
JQ1: Giving Up a Fortune?
Zafgen's Epoxide Adventure
IGFR Therapies Wipe Out. And They're Not Alone.
The One-Stop CRO
Transcelerate: What Is It, Exactly?
Going After the Big Cyclic Ones
Geron, And The Risk of Cancer Therapies
Accelerated Approval And Its Discontents
A New Malaria Compound
Eli Lilly's Drumbeat of Bad News
How Did the Big Deals of 2007 Work Out?
Pharma: Geniuses or Con Men?
Genentech's Big Worry: Roche?
Good Forum for a Response on Drug Innovation?
A Quick Tour Through Drug Development Reality
Donald Light Responds on Drug Innovation and Costs
Getting Drug Research Really, Really Wrong
AstraZeneca Admits It Spent Too Much Money
The Next Five Years in the Drug Industry
Live By The Bricks, Die By The Bricks
Predicting Toxicology
Merck Finds Its Phase II Candidates For Sale on the Internet
Scaling Up Arteminisin
An Oral Insulin Pill?
Another Vote Against Rhodanines
The NIH's Drug Repurposing Initiative: Will It Be a Waste?
A New Way to Kill Amoebas, From An Old Drug
A Molecular Craigslist?
A Preventative Trial for Alzheimer's: The Right Experiment
Competitive Intelligence: Too Much or Too Little?
A Long-Delayed COX2 Issue Gets Settled - For $450 Million?
India's First Drug Isn't India's First Drug
A Federation of Independent Researchers?
The Artificial Intelligence Economy?
Winning Ugly and Failing Gracefully
Virtual Biotech, Like It or Not
What's the Ugliest Drug? Or The Ugliest Drug Candidate?
Dealing with the Data
Merck's CALIBR Venture
Not Quite So Accelerated, Says PhRMA
The Blackian Demon of Drug Discovery
The Brute Force Bias
Drug Discovery for Physicists
Scaling Up a Strange Dinitro Compound (And Others)
The Terrifying Cost of a New Drug
Putting a Number on Chemical Beauty
Fun With Epigenetics
Biogen: A "Decimated" Pipeline?
Welcome To the Jungle! Here's Your Panther.
Do We Believe These Things, Or Not?
Lead-Oriented Synthesis - What Might That Be?
More From Hua - A Change of Business Plans?
The Sirtuin Saga
Drugs, Airplanes, and Radios
Riding to the Rescue of Rhodanines
Pushing Onwards with CETP: The Big Money and the Big Risks
"You Guys Don’t Do Innovation. The iPad. That’s Innovative"
Francis Collins Speaks
A Note to Andy Grove
Harvard to the Rescue
Too Many Cancer Drugs? Too Few? About Right?
Different Drug Companies Make Rather Different Compounds
How Many New Drug Targets Aren't Even Real?
GlaxoSmithKline Reviews the Troops
Chinese Pharma: No Shortage of Ambition, Anyway
Bernard Munos Rides Again
2011 Drug Approvals Are Up: We Rule, Right?
Will Macrocycles Get It Done?
Phenotypic Screening For the Win
Innovation and Return (Europe vs. the US)
Drug R&D Spending Now Down (But Look at the History)
What Translational Research Should Academia Do?
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Maybe It Really Is That Hard?
Imperfect Pitch
Process Chemistry Makes the Headlines
What Medicinal Chemists Really Make
Translation Needed
Off the Beaten Track. Way, Way, Off.
R&D Is For Losers?
Your Comments on the NIH's CNS Drug Program?
The NIH Goes For the Gusto
Value in Structure?
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Down In Phase III. Again.
Gonna Focus on Re-Engineering the Tools for the Process
New Cures! Faster! Faster!
Drug Problems: A Diagnosis
Fragments Versus DOS: A Showdown
The NIH's New Drug Discovery Center: Heading Into the Swamp?
What's the Most Worthwhile New Drug Since 1990?
Oh, And While You're At It. . .
Merck's Vorapaxar: Bleeding, Indeed
Merck's Thrombin Antagonist In Trouble
Gassing Your Crystals
How to Fund a Nonprofit Drug Company - And Others?
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
And One Was Just Right?
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Trusting the Medical Literature?
Chemical Biology: Engineering Enzymes
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
GSK's Response to the Sirtuin Critics
Going Hollywood
Cancer Cells: Too Unstable For Fine Targeting?
Open-Source Pharmaceutical Babble
Fungal Structures to the Rescue
Exelixis Gets a Compound Back
Flibanserin: Not a "Female Viagra" At All
The Economic Impact of the Genomic Revolution's Failure
The Atlantic Monthly on Drug Pipelines
Another Set of Eyes
Biosimilars: Not So Dang Easy
Malcolm Gladwell on Synta and Oncology
Perverse Incentives In Clinical Trials
The Collapse of Complexity
Rosetta@Home
Pfizer's Future: Biotech Followups
Charles River Buys WuXi
A Landmark In Clinical Trial Data Interpretation
Pfizer's Golden Age
Drugs And Their Starting Points
Merck and Sirna
Sirtuin Scenarios
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Selective Scaffolds
All Of You Industrial Scientists: Out Of the Room
Recommended Books For Medicinal Chemists, Part One
Ozonides As Drugs: What Will They Think of Next?
O Brave New World! That Has Such Companies In't!
The Drug Business: A Turbulent Future?
Industrial Research: More Grounded in Reality, or Not?
To What End?
Thalidomide for Myeloma: Whose Idea Was It?
Polymorphs and Salts: India Raises an Eyebrow
Arzoxifene: Not the Road to Big Profits?
Spray-Painted For Success
Pharma's Return on Investment: Yikes
Drug Approvals, Natural And Unnatural
How Much Does the Drug Industry Spend on Marketing?
Eli Lilly Gives It Away
Medarex, Ipilimumab, Prostate Cancer, And Reality
One. . .Billion. . .Dollars!
Funky Carbocycles
Genzyme's Virus Problems
More Hot Air From Me on Screening
The View From Pfizer's Corner Offices
Ugliness Defined
A Deuterium Deal
Akt and Mek, But Not PDQ
Deuterated Drugs: The PTO Says OK, So Far
The NIH Takes the Plunge
Goldman Sachs: Out Of the Drug Funding Business Already?
Farewell to ACAT, and to Lots of Time and Money, Too
An HIV Drug. Or A Gout Drug? Or Both. . .
The Mechanical Chemist?
Two! Two! Two Drugs in One!
Gene Expression: You Haven't Been Thinking Big Enough?
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Single, Simple Numbers: Use At Your Own Risk
Heavy Atoms, Heavy Profits?
A Med-Chem Book Recommendation
Kinases: Hot or Not?
Open Pharma?
Opportunity Costs
New Year - I Hope!
Goldman Sachs: A New Drug Research Model?
Curse Of the Lost Compounds
Prodrugs: How the Pros Do It?
Noisy Numbers
CB-1 Obesity Drugs: Farewell to the Whole Lot
Down The Chute in Phase III
Animal Models: How High to Set the Bar?
Where Are the Drugs?
Taranabant Is No More
The Complicated Causes of Cancer
Samurai! Unleash Your Drug Candidates!
Sticky Containers, Vanishing Drugs
Replacing What's Being Lost
Confident
Sharing the Enlightenment
Glaxo Asks the Eurocrats
Lurching Around For Fun and Profit
In Which I Hate A Wonder Drug
"Not Useful" Means "Not Approvable", Right?
Cordaptive Q and A
Exubera, Safety, and No Guarantees
Pre-emption For Real?
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
RNA Interference: Even Trickier Than You Thought
Getting To Lyrica
That's Never Gonna Work
Now Your Liver Doesn't Have to Make It For You
A Solution, Courtesy of the MIT Faculty
Dissolve Your Troubles Away
Off Target? Which Target Did You Mean?
What You Become Known For
Getting Real With Real Cells
A Look Under the Hood
The Animal Testing Hierarchy
Eat It, Breath It, Soak in It?
The EU Suspects No One, And Suspects Everyone
Rainbows and Fishing Expeditions
Plants For Cancer?
A Bad Assay: Better Than None?
Bad Luck For Novartis - And For Diabetics
Then I Felt Like Some Watcher of the Skies. . .
You Do The Easy Stuff; I'll Do the Easier
Quiz Time!
Here Be Chiral Dragons, With Fluorinated Fangs
Reasons to Be Different
Lights, Camera, Pharma!
Andy Grove: Rich, Famous, Smart and Wrong
Nerve, Lots and Lots of Nerve
Resistant Little Creatures
Bacterial Infection: Better Or Worse Than Cancer?
Come On. Improve, Already.
Ugly, But Useful
Arsenic, Patents, and the World
Don't Step Over It, Even If It's Right in Front of You
Drugs From Where?
Guess That Market
Renin, Wherefore Art Thou, Renin?
Elbow Room
Like Clockwork
Winning, By Tying Losers Together
Here, Fix This, Would You?
Run! Anthropologists!
You Discover It, We Sell It. Deal?
From the Sequencer to the Drugstore?
Deactivation, After All
A Farewell to Tin
Bigger, Tougher, Longer? Or Not?
Less Than Zero
Awful, No Doubt. But Not As Awful as Before?
Failure: Not Your Friend, But Definitely Your Companion
The HDL Compost Pile
Naked Synthesis
FDA Advisory Panels: Pay, No Play
AGI-1067: Dead or Alive?
No Shortcuts
Quietly Disappearing From the Skies
There's Toxicity and There's Toxicity
Going Hollywood, For Our Own Good?
What Can Academia Do?
The Big Picture
Upside Down Activity
Reality, Here In This Little Dish
Bigger And Greasier
Hope, Springing Eternal And All That
Experimental Compound Codes
The Unattractive Truth
Peptides as Texts
More Handedness
A Spray-Painted Crystal Ball
Ray Kurzweil's Future
The Sun Shines at Pfizer
Fuzeon's Fallout
Disapproval of Approvability
A Natural Wonder Drug - Now What?
Have The Rules Changed?
All Natural
Heart-Warming Stories of Success
Kinase Inhibitors: Doomed From the Start?
If It's Not One Thing. . .
What Makes an Ugly Molecule?
Five Questions
Out the Door and Over the Edge
Selectivity: One of Those Flexible Concepts
Another Thing You'd Think Would Be Simple
Seven Questions
Morphine in the Brain: Go For It, or Not?
How Much Success?
Modeling the Modelers
Tailfins and All
Knocking Opportunity Costs
The Globalization of Med-Chem
Bigger and Greasier
How'd We End Up Here, Anyway?
Hope in a Drum
The Novartis Way
Model Systems, From Inside and Out
Finishing, And Starting
Proteins to the Rescue?
DNA to Drug?
More on Merck
Drug Development: The Current Odds
The NIH in the Clinic
One More On Basic Research and the Clinic
How Much Basic Research?
How It Really Works
Me Too, Part Two
Down in the Salt Mine
How Long Can This Go On?
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
The Two Ends of the Stick
Down the Hatch
What Ails Us
Odd Elements in Drugs: Silicon
The Vapor Trail I Referred To
Stuart Schreiber on Stuart Schreiber
The March of Folly Leader Board
How Drugs Die
Sic Transit Gloria Mundi
New! Improved! Now With Stickier Lumps!
What Sort of Number Did You Have in Mind?
Structure-Inactivity Relationship Would Be More Like It
You Don't Hear "Eureka" That Often
They All Get Real at Some Point
Our Buddies at the FDA
What to Do When the Rats Die on You
A Twisty Road
Another Shot
It's Not Pretty, But It Works
What's a Project Manager to Do?

Drug Industry History
The Early FDA
Drug Repurposing
The Smallest Drugs
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
Did Pfizer Cut Back Some of Its Best Compounds?
Abandoned Pharma
The Antibiotic Gap: It's All of the Above
K. C. Nicolaou on Drug Discovery
How to Run a Drug Project: Are There Any Rules at All?
Two Looks At Drug Industry Productivity
Where the Talent Comes From
AstraZeneca Looks At Its Own History, And Cringes
The Daily Show on Finding New Antibiotics
One and Done
Ancient Modeling
Where The Hot Drugs Come From: Somewhere Else
Small Molecule Chemistry's "Limited Utility"?
Startups vs. Big Pharma
Big Drug Mergers: So They're OK, Right?
Drug Discovery in India
A New Look At Clinical Attrition
The Old AstraZeneca Charnwood Site
Merck's Drug Development in The New Yorker
Lipinski's Anchor
Phenotypic Screening Everywhere
Leaving Antibiotics: An Interview
The Past Twenty Years of Drug Development, Via the Literature
Merck's Aftermath
Size Doesn't Matter. Does Anything?
Is The FDA the Problem?
Big Pharma And Its Research Publications
A Regeneron Profile
Druggability: A Philosophical Investigation
How Much to Develop a Drug? An Update.
Reworking Big Pharma
Good Advice: Get Lost!
Bernard Munos on The Last Twelve Years of Pharma
One. . .Million. . .Pounds (For a New Antibiotic?)
Valeant Versus Genentech: Two Different Worlds
But Don't Drug Companies Spend More on Marketing?
How Much Do Drug Companies Spend on R&D, Anyway?
And The Award For Clinical Futility Goes To. . .
IBM And The Limits of Transferable Tech Expertise
AstraZeneca's Move To Hot, Happening Cambridge
Affymax In Trouble
Does Baldness Get More Funding Than Malaria?
Putting the (Hard) Chemistry Back in Med Chem
The Hard Targets: How Far Along Are We?
CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
Daniel Vasella Steps Down at Novartis
Marcia Angell's Interview: I Just Can't
A Broadside Against The Way We Do Things Now
When Drug Launches Go Bad
Roche Repurposes
Nassim Taleb on Scientific Discovery
IGFR Therapies Wipe Out. And They're Not Alone.
Pfizer's New Leaf
Eli Lilly's Drumbeat of Bad News
How Did the Big Deals of 2007 Work Out?
Chemistry's Mute Black Swans
Four Billion Compounds At a Time
Getting Drug Research Really, Really Wrong
By Any Other Name
The NIH's Drug Repurposing Initiative: Will It Be a Waste?
The Counting of Beans
The Biotech Class of the Early 90s
A Long-Delayed COX2 Issue Gets Settled - For $450 Million?
Drug Company Culture: It's Not Helping
Phenotypic Screening's Comeback
The Artificial Intelligence Economy?
"Taking the Ax to the Scientists Is Probably a Mistake"
Virtual Biotech, Like It or Not
What's the Ugliest Drug? Or The Ugliest Drug Candidate?
The Blackian Demon of Drug Discovery
The Brute Force Bias
Coaching For Success. Sure.
Eroom's Law
The Terrifying Cost of a New Drug
Putting a Number on Chemical Beauty
Nowhere to Go But Up?
The Sirtuin Saga
Pharma Overview
Drugs, Airplanes, and Radios
The Loss of the Middle (Drugs and the People Who Find Them)
Naming Your Company After Yourself
Lipitor Expiration Day
So What Did Lipitor Do for Pfizer? Or Its Shareholders?
Regeneron Finally Makes It to the Market
Of Drug Research and Moneyball
Two From Glaxo's Old Days
Ray Firestone's Take On Pharma's Plight
Virtual Pharma, Revisited
Merck, And What Used to Be Schering-Plough
Too Many Cancer Drugs? Too Few? About Right?
Different Drug Companies Make Rather Different Compounds
Ah, Remember Those Days? How Will We Remember These?
What Layoffs Have Done
Targets to Avoid (Or That We Wish We Had)
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
A Dish Best Served Cold
GlaxoSmithKline Reviews the Troops
Chinese Pharma: No Shortage of Ambition, Anyway
The Economics of the Drug Industry: Big Can't Be Big Enough?
Read the Comments
Bernard Munos Rides Again
A Former Pfizer Executive Finally Trashes Pfizer's Strategy
Merck Moving Research From Rahway?
2011 Drug Approvals Are Up: We Rule, Right?
The Secret History of Pfizer
Phenotypic Screening For the Win
Innovation and Return (Europe vs. the US)
The Histamine Code, You Say?
Drug R&D Spending Now Down (But Look at the History)
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Maybe It Really Is That Hard?
Ups and Downs
A Look Inside the Compound Collections
Pfizer: Breaking Up Is Hard to Do
R&D Is For Losers?
What's Really Killing Pharma
Value in Structure?
The Small Drug Companies And the Big Ones
Pfizer: Bigger, Um, Isn't Better?
The Costs of Drug Research: Beginning a Rebuttal
Drug Problems: A Diagnosis
The Top 200 Drugs
Too Much Outsourcing: Has the Line Been Crossed?
Merck's Strategy vs. Pfizer's
The NIH's New Drug Discovery Center: Heading Into the Swamp?
What's the Most Worthwhile New Drug Since 1990?
How to Fund a Nonprofit Drug Company - And Others?
And So, 2011
Big Pharma's Lost Stock Market Decade
Have Pfizer's Investors Had Enough?
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
Halaven: Holder of the Record
Comment of the Day: Outsourcing and Architecture
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Well, Okay: The Ugliest Biopharma Sites?
Most Picturesque Biopharma Location?
Drug Discovery History
Princeton's New Chemistry Building
Serendipity in Medicine
Avandia Goes Down: A Research Rant
Columns Outside The Doors
Going Hollywood
Not The End. Not At All
Open-Source Pharmaceutical Babble
Natural Products: Not the Best Fit for Drugs?
GSK's Biotechy World
The Economic Impact of the Genomic Revolution's Failure
Looking Back at the Genome
Alzheimer's: Extracting Data From Failed Trials
The Atlantic Monthly on Drug Pipelines
Insulin Degrading Enzyme's Turn in the Spotlight
Malcolm Gladwell on Synta and Oncology
The Collapse of Complexity
Two Bad Ideas
Colchicine's Price Goes Through the Roof
Too Many Consulting Jobs Work This Way
Diminishing Returns
Privileged Scaffolds? How About Unprivileged Ones?
Privileged Scaffolds
Where Would You Start a Company?
More On Pharma's Ugly Finances
Polluting the Literature with PAINs
Sheer Economics: How We Got in This Fix
Remember Apo-A1 Milano? Pfizer Does.
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Drug Companies Since 1950
Why Don't We Have More Protein-Protein Drug Molecules?
Against Panic
Thoughts on What Used to Be Schering-Plough
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fifty Years of Scientific History For You
You Mean You Don't Have to Buy Them?
O Brave New World! That Has Such Companies In't!
Fall From Grace
The Drug Business: A Turbulent Future?
Sepracor: A Desirable Property?
Rings of the Future!
Thalidomide for Myeloma: Whose Idea Was It?
Drug Companies Are Polar Bears? Maybe Not.
Spray-Painted For Success
Pharma's Return on Investment: Yikes
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
Amyloid in Trouble
Drug Approvals, Natural And Unnatural
Why Does Screening Work At All? (Free Business Proposal Included!)
How Much Does the Drug Industry Spend on Marketing?
Jargon Will Save Us All
GSK's Getting Better. Just Ask the CEO.
The View From Pfizer's Corner Offices
CafePharma Will Now Approach The Bench
Akt and Mek, But Not PDQ
The NIH Takes the Plunge
San Francisco Biotech: Holding Up, or Not?
Book Review Department
Farewell to ACAT, and to Lots of Time and Money, Too
Genes to Diseases: Hard Work, You Say?
Who They?
Scientists Running Your Drug Company?
The Mechanical Chemist?
The Equipment Graveyard
Drugs For Bacteria: Really That Hard, Or Not?
Roche / Genentech: The Chase Is Over
Merck Actually Does It
Does Glucophage Make Alzheimer's Worse?
Kinases: Hot or Not?
Sir James Black Vents, Therapeutically
A Long Tail Indeed
Ten Years After: The Genomics Frenzy
Why Pfizer?
New Year - I Hope!
When Placebos Were All There Were
Curse Of the Lost Compounds
Novartis and Reality
Down The Chute in Phase III
Where Are the Drugs?
Sunesis: No Substitutions Allowed?
Replacing What's Being Lost
Confident
Pfizer's Prospects: Just Ducky
A Breath of Fresh Air from Fuji
Awash in Yen
Lurching Around For Fun and Profit
Merck Bails on Natural Products
O Pioneers!
Why Buy, Anyway?
That's Never Gonna Work
Pen and Paper
Hits, Misses, and Some More Misses
Smaller, Wetter, Harder to Work With
What You Become Known For
Judah Folkman
Plants For Cancer?
Top of the Heap
Hearing Footsteps
Med-Chem Layoffs, On the Front Page
Then I Felt Like Some Watcher of the Skies. . .
One Year
Reasons to Be Different
Lights, Camera, Pharma!
Andy Grove: Rich, Famous, Smart and Wrong
Surveying the Exubera Crater
More Layoffs, And What They Might Mean
Good News From the HR Department!
The Good Old CombiChem Days
Guess That Market
Renin, Wherefore Art Thou, Renin?
You Discover It, We Sell It. Deal?
From the Sequencer to the Drugstore?
Godzilla vs. Mothra? Relman vs. Epstein!
First Impressions
Bigger, Tougher, Longer? Or Not?
Awful, No Doubt. But Not As Awful as Before?
Biotech's Net Loss?
Going Hollywood, For Our Own Good?
The Big Picture
Way Out Here
Novo Nordisk Axes Med-Chem
Good Stuff and Bad Stuff
The Paper Mountain
Help Wanted - I Hope
Naming of Names
Experimental Compound Codes
Peter Kim, So Far
Chem-Geek Alternate History
All Natural
Why All the Gloom?
Procter and Gamble Throws in the Towel
But At My Back I Always Hear. . .
Serono's Suitors
The Old Stuff
The Painful History of Substance P
Room At the Top?
Biotech At Last, Eh?
Days of Silicon and Roses
Some Perspective
Merck's State of Mind
Different or Not? You Tell Me.
Pharma Flock Begins Migration
Circular Mistakes
How Much Basic Research?
The State of the State of the Art
Loose Lips
Dumpster Diving for Data?
What Ails Us
The Last Word on Taste
The March of Folly Leader Board
The March of Folly
Reality's Revenge
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
The Old Days, Some Older Than Others
Here and There
Thalidomide in the Mirror
Overpatenting?
Where Credit's Due
And I Still Have Some of Those Shirts
Fun While It Lasted
Nothing Like It in the World
Separation Anxiety

Drug Prices
Thiola, Retrophin, Martin Shkrell, Reddit, and More
The Most Unconscionable Drug Price Hike I Have Yet Seen
BioCentury on the Coming Drug Pricing Crisis
Incomprehensible Drug Prices? Think Again.
The Price of Sovaldi
Another Whack at the Cost of Drugs Issue
Prices Rising - Every Year, Every Drug?
Outcomes, Expensive Outcomes
Catalyst Pharmaceuticals And Their Business Plan
Value For the Money
The Atlantic on Drug R&D
Costing Just Too Much
Tecfidera's Price
The NIH, Pfizer, and Senator Wyden
GlaxoSmithKline's CEO on the Price of New Drugs
Pharmaceutical Shortages in Greece
Marcia Angell's Interview: I Just Can't
When Drug Launches Go Bad
The Coming Battle Over Alzheimer's Disease
Good Forum for a Response on Drug Innovation?
A Quick Tour Through Drug Development Reality
Donald Light Responds on Drug Innovation and Costs
Getting Drug Research Really, Really Wrong
Cancer Drugs: Value for the Money?
Nexavar Licensed by Force in India
Eroom's Law
The Terrifying Cost of a New Drug
Makena's Market. Or Lack of One.
More On Cancer Drug Shortages
Does Anyone Want Axanum?
Dendreon: Watch the Cost Curve Being Bent
Drugs for Multiple Sclerosis: Worth the Price, Or Not?
Avastin and Medicare
Process Chemistry Makes the Headlines
Lucentis and Avastin: Results
Update on Avastin and Lucentis
KV Pharmaceuticals and Makena: The FDA's Move
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Use Avastin! Don't Use Avastin!
Avastin For Metastatic Breast Cancer: The Whole Story
Going Hollywood
Drug Prices in the US: Not So High After All?
Ipilimumab (And Progress Against Cancer)
Again, What's It Worth to You?
Pfizer's Future: Biotech Followups
Colchicine's Price Goes Through the Roof
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fall From Grace
Lexapro, Forest Labs, and the Hard Sell
The PhRMA Deal
PhRMA's Negotiating Game
Just Give It to NIH
Health Care Reform - Really?
Book Review Department
Kumbaya
Direct To Consumer Ads: Wasted Money?
A Solution, Courtesy of the MIT Faculty
Drugs and Money
Laissez-Faire?
The EU Suspects No One, And Suspects Everyone
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Guess That Market
Godzilla vs. Mothra? Relman vs. Epstein!
European Drugs, American Drugs
Brazil Raises The Pirate Flag
Fuzeon's Fallout
Price Gouging or Not?
What's It Worth to You?
Pfizer Takes a Deep Breath
Ugly, But Effective
The Undefeated Brazilian Team
Brazil Pulls Out the Pin
Check, Please
Cui Bono?
Preach It, Brother
Prices and Innovation
Peter Rost, Oddity
Kicking the Dinosaur's Tail - Again
Me Too, Part Two
I'll Have the Price They're Having
John Kerry on Drug Prices
Costs and Benefits, Risks and Rewards
So What's Wrong With A Little Money Changing Hands?
It'll Cost You
You'd Think It Was An Election Year or Something
Price Hydraulics
Getting the Word Out, For Once
Welding the Steering Wheel
More From the Me-Too Front
Putting A Price on Proving It
One Of Us Is Hallucinating
Reimportation's Just the Beginning
Drug Prices and Costs - From the Mail
More on Prices, High and Otherwise
The Contact Sport of Cost Accounting
Darn Those R&D Costs, Anyway
From Each According To Their Creativity, To Each According To Their Difficulty?
The Pricing Weapon
Good Sense Wins a Round
More on Drug Prices
The Dismal Science of Drug Prices

General Scientific News
Peter Thiel's Uncomplimentary Views of Big Pharma
The Broad Gets $650 Million For Psychiatric Research
Chemistry Class For the "Food Babe"?
No Scripps/USC
All Natural And Chemical Free
Don't Learn to Science?
Scripps Update
Scripps Merging With USC?
Freeman Dyson on the PhD Degree
Sydney Brenner on the State of Science
Down With P Values
Crowdfunding Independent Research
Humble Enzyme Dodges Spotlight
The 2013 Medicine/Physiology Nobel: Traffic
A War On Expertise?
Nobel Speculation Time
MacArthur Awards in Chemistry
The Hydrogen Wave Function, Imaged
A Specific Crowdfunding Example
Crowdfunding Research
More Single-Cell Magnetic Imaging
Scientific Snobbery
A Nobel Follow-Up
Overly Honest Experimental Methods
Anti-GMO. Until This Week.
Chem Coach Carnival: A Few Questions
Reproducing Scientific Results - On Purpose
GSK's Anti-Doping Ad
A Brief Word From Mars
More "More Scientists" Debate
Another Critical Shortage
How Not to Do Science Education
Worst And/Or Craziest Misconceptions
PhDs On Food Stamps?
A Federation of Independent Researchers?
Running Out of Helium?
Nobel Prizes in Chemistry For People Who Aren't Chemists
Let's Start Off the Meeting With An Ad, OK?
Strangest Presentation You've Seen?
Worst Lecture of All, Or Greatest?
What's the Hardest Thing?
Very Likely Not Real, But Still. . .(The E-Cat)
Liquid Handling
The Singularity, Postponed
Podcast Interview on Drug Discovery
Yep, That's A Nobel Prize, Right There
Chemistry Nobel Time
The NIH Wonders About the Future of Biomedical Workers
Gilenya's Price
Return of the Arsenic Bacterium
A Google Oddity
Ups and Downs
Writing About Science, and Liking It
Politics in the Lab
NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
Arsenic Bacteria: Does The Evidence Hold Up?
Kitchen Chemistry Gear
Is Cancer A Disease of the Modern World?
So, How Well Does Winning a Nobel Set You Up?
Nobel Season 2010
Chemical Biology - The Future?
Know How to Make Praziquantel? Tell The World.
Lechleiter's Prescription for Science
Let's Sequence These Guys
Try It At Home
Garage Biotech
A Friday Book Recommendation
Maybe You Need Some More Testosterone Over There
Find That Pattern
Pass the Popcorn
Copyright 1671: I Like the Sound of That
Climategate and Scientific Conduct
Real Electrons
Real Molecules
Jargon Will Save Us All
Altermune - Real Stuff or Not?
The Mechanical Chemist?
Fan Mail
Tie Me Molecule Down, Sport
Science and Its Values
Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
Awkward Conversations
Enhancing the Brain: Here We Go
Protein Folding: Complexity to Make More Complexity?
The Gates Foundation: Dissatisfied With Results?
Nullius in Verba
An Eye For the Numbers
Science By Country
Getting Smarter Already?
DNA Forklifts, DNA Pliers
Room At The Bottom, For Sure
And Speaking of Discovering Things. . .
Dumber in English?
Enzyme Humility
Unnatural, And Proud Of It
Winning, By Tying Losers Together
Hype In Spaaaace!
The Chamber of DNA Secrets
The Big Time
Naked Synthesis
Inspirational Reading?
Forty NMR Magnets and 3000 Proteins Later. . .
Cheer Up, You Chemists
Another Chemistry Prize for Biology
RNA Interference: Film at Eleven
Nobel Update: RNAi Wins
Nobel Fever Is Upon Us
By Any Other Name
If You Want Your Explanations Overnight, It'll Cost You
Explain This, Hot Shot!
Ray Kurzweil's Future
Peptide Craziness
Pounding Sand
Aluminum: Friend or Foe?
Outside Reading
Attack of the Angry Viruses
Play by Play in the Lab
Start Your Engines
The Tiniest Doors Begin to Open
Outside Reading
For Further Enlightenment
An Off-Topic Ramble
Why Carbon Matters
Exobiochemistry
How Often Do We Land on Another World?
More Fun With DNA
Tadpoles to the Rescue?
Memorial
The Dull Edge of Nanotech
A Birthday Worth Noting
Nuclear Fusion, Wordsworth, German Cooking. The Usual.
A Request From Biology
Looking Back, Looking Forward
Place Your Bets
Unequivocal Good News
A New Form of Hype, uh, Life?
What I, um, Meant to, um, Say
Left and Right, Revisited
Y'all Are Going to Think I'm Nuts, But. . .
The Good Old Days of Really Bad Teeth, Revisited
Et in Arcadia Ego
Faces In the Clouds
Cloning's Growing Pains
Nobelity and Lesser Nobelity
Another Stuffed Shirt
Nobel Time!
The Bigger They Are
Our Friend the Phosphate Group, Redux
Our Friend the Phosphate Group
A Strange Compound, In Strange Places

Graduate School
The Worst Seminar
ChemDraw Days
Changing A Broken Science System
Suing Your Grad School, And Your Professor
Too Many Scientists: A "Pyramid Scheme"
More on Grad School Pressures
Grad School in Chemistry - The Mental Health Aspects
The Supply of PhDs
Accident Report, or One Damn Thing After Another
Chem Coach Carnival: A Few Questions
More on Getting a Science PhD
Organic Synthesis: A Dead End For Graduate Students?
PhDs On Food Stamps?
Grad School Opportunity Costs? Not to Worry!
Dealing With Dishonesty
The UCLA Lab Fatality: Criminal Charges Filed
The NIH Wonders About the Future of Biomedical Workers
Sezen / Sames: What Does it Say About Grad School?
The Fox's Lament
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
The PhD Problem
The Hours You Put In
Posters and Pickiness
How Long Would It Take - If Everything Worked?
How Much is the PI To Blame?
Gegen die Dummheit . . .Well, Guess Who Wins, Again
Reasons Not to Go to Grad School?
I'll Get Right On That For You, Professor
Random Questions, Answered Randomly
The Real Hazards of the Lab
Out the Door and Down the Stairs
More Than This
How Not To Do It: Water Aspirators
Scrape Off Some Attitude
And It Goes Like This!
Looking Backwards
Understanding Dawns
Cheer Up
". . . Jobs That Don't Exist"
Pilferage
The Doctorate and Its Discontents
Doctorate or Not?
Fish Nor Fowl?
Decisions, Decisions
Depraved and Deprived
Levoglucosan
German, Anyone?
Tenderbutton Calls It Quits
Spectroscopic Days
If You Want Your Explanations Overnight, It'll Cost You
Hobson's Choice
Academia in Summertime
Grad School, Blogged
Arcadia's Furnishings
Never Came In Handy. Not Once.
. . .It's a Wonder I Can Think At All
Industry vs. Academia: The Mental Aspect
Differences Between Industry and Academia, Pt. 1
Sweet Maybe, But Trouble, Too
A Couple of Days Off

How Not to Do It
How Not to Do It: Chromium Trioxide
Accident Report, or One Damn Thing After Another
Ten Tons of Sodium And Just One Lake
Ten Tons of Sodium And Just One Lake
When Reagents Attack!
Storage of Industrial Chemicals, Gone Rather Wrong
How Not To Do It: Hydrogen Gas Mixtures
Max Gergel's Memoirs
How Not to Do It: Acetylene Cylinders
Phthalate: A Natural Product? Sure 'Bout That?
How Not to Do It: Liquid Oxygen Cylinders
Mental Health Break: The Alkali Metals Show Their Personalities
Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
How Not To Do It: The Secret Patent Decoder Ring
How Not To Do It: Water Aspirators
How Not To Do It: Diazomethane
How Not To Do It: Column Chromatography
How Not to Do It: Hydrogen Bromide
How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
How Not to Do It: Tertiary Butyllithium
How Not To Do It: Ruining Stuff
How Not to Do It: Sophomore Organic Edition
How Not to Do It: Distilling HMPA
How Not to Do It: Liquid Nitrogen Tanks
How Not to Do It: Ether Peroxides
How Not to Do It: Bromine
How Not to Do It: Vacuum Pumps
How Not to Do It: Distilling Benzene
Speak for Themselves, They Do
Ping! Ping! Ping!
How Not to Do It: Sulfenyl Chlorides
How Not to Do It: Sodium
How Not to Do It - Hydrogen Balloons
Our Friend, the Carbon-Aluminum Bond
How Not to Do It: Solvent Stills
Not Like Law School

How To Get a Pharma Job
Where the Talent Comes From
A Question for Recruiters
Those Drag-Over-the-Coals Interviews
Lessons For a New Medicinal Chemist
Imperfect Pitch
Walk Around Some
Making the Adjustment to Smallness
If Not This, What?
Hey, Graduates! Negotiate Hard, You Hear, Now?
". . . Jobs That Don't Exist"
More on Interview Seminars
Starting Up Again
Fish Nor Fowl?
Decisions, Decisions
Have We Got a Job For You!
Are You Experienced?
The Other Side of the Table
Bad Interviews
Man Hands on Misery to Man
Here's A Shovel. Could You Dig Yourself In Some More?
Name Reactions for One Thousand, Alex
Hire the Thoroughbreds?
What Sort of Training?
Dinner the Night Before
Getting Hired as a PhD
How To Get Hired: Associate Positions
Sneaking Out for an Interview
Getting A Job

In Silico
The Virtual Clinical Trial: Not Quite Around the Corner
Hosed-Up X-Ray Structures: A Big Problem
Predicting New Targets - Another Approach
Ancient Modeling
Predicting What Group to Put On Next
Computational Nirvana
Ligand Efficiency: A Response to Shultz
"It Is Not Hard to Peddle Incoherent Math to Biologists"
A New Metabolism Predictor
Picking Diverse Compounds
Standards of Proof
Low Energy Records
When the "c" in cLogP Stands For "Crazy" (Update: Fixed!)
Models and Reality
Unraveling An Off-Rate
Molecular Dynamics, Pro and Con
Allosteric Binding Illuminated?
More Thoughts on Compound Metrics
Too Many Metrics
An HIV Structure Breakthrough? Or "Complete Rubbish"?
Druggability: A Philosophical Investigation
The 3D Fragment Consortium
Evolving Enzymes: Let 'Em Rip
More Whitesides on Ligand Binding
MedChemica: When One Compound Collection Isn't Enough
GPCRs Are As Crazy As You Thought
How Many Binding Pockets Are There?
IBM's Watson Does Drug Discovery?
All Those Drug-Likeness Papers: A Bit Too Neat to be True?
Farewell to Bioinformatics
The Hydrophobic Effect: I Don't Understand It, Either
Halogen Bonds
Virtual Screening, The Good Parts and the Bad Ones
Automated Ligand Design?
Did Kaggle Predict Drug Candidate Activities? Or Not?
Chemistry Software Questions Here
Watch that Little Letter "c"
Predicting Toxicology
The Artificial Intelligence Economy?
Rational Drug Design. Hmm.
Putting a Number on Chemical Beauty
A Look Into the Future?
Where's the Best Place to Apply Modeling to Drug Discovery?
Foldit Notches a Protein Structure Success (And Some Failures)
Design a Molecule, Win an IPad (Which is More Than You Usually Get)
Modeling and Structure
Value in Structure?
Maybe We Should Make It More of a Game
Free Software
What Has Bioinformatics Ever Done For Us?
Modeling in Drug Discovery: Questions?
Unlovely Polyphenols
Bill Gates Put Some Money On Schrödinger
Another Proposal For the Scientific Literature
Compounds and Proteins
We Don't Know Beans About Biotin
Benford's Law, Revisited
Selective Scaffolds
Why Don't We Have More Protein-Protein Drug Molecules?
Side Effects, Predicted?
Warren DeLano
The Further In You Go, The Bigger It Gets
Why Does Screening Work At All? (Free Business Proposal Included!)
What's So Special About Ribose?
Another Thing We Don't Know
Jargon Will Save Us All
Mexican Lemons To the Rescue
The Motions of a Protein
Structure-Activity: Lather, Rinse, and Repeat
Floppiness Is Not Your Friend: Who Knew?
Protein Folding: Complexity to Make More Complexity?
X-Ray Structures: Handle With Care
Up Close and Personal
O Pioneers!
Start Small, Start Right
Smaller, Wetter, Harder to Work With
Melting Keys and Squishy Locks
No Shortcuts
Wrong, But Still Convincing
Love and Anger
Enzymes Do Whatever They Want To
Crystals of Doubt
Molecular Modeling Cage Match
The Hazards of Molecular Modeling
Clamping Down, or Loosening Up?
Crossing Your Fingers, Authoritatively
Kinases and Their Komplications
FullCell 1.0?
The March of Folly
Reality's Revenge

Infectious Diseases
Pharma and Ebola
The Antibiotic Gap: It's All of the Above
The Hep C Field Gets Nastier By the Minute
The Price of Sovaldi
The Real Numbers on Tamiflu
The Daily Show on Finding New Antibiotics
Google's Big Data Flu Flop
Another DNA-Barcoded Program From GSK
Repurposing for Cervical Cancer
Antivirals: "I Love the Deviousness of It All"
Tiny Details, Not So Tiny
More Vaccine Fearmongering
Leaving Antibiotics: An Interview
Holding Back Experimental Details, With Reason
An HIV Structure Breakthrough? Or "Complete Rubbish"?
Stuart Schreiber at the Challenges in Chemical Biology Conference
One. . .Million. . .Pounds (For a New Antibiotic?)
Sulfa Side Effects, Decades Later
A Little Ranbaxy Example
Another Germ Theory Victory - Back Pain?
Does Baldness Get More Funding Than Malaria?
IBM's Watson Does Drug Discovery?
Mouse Models of Inflammation Are Basically Worthless. Now We Know.
Three Rings in a Row
Is Obesity An Infectious Disease?
Nasty Drug Molecules: Amphotericin B
A New Malaria Compound
A New Way to Kill Amoebas, From An Old Drug
A Molecular Craigslist?
India's First Drug Isn't India's First Drug
DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)
How Do These Things Get Published?
Trouble With a Boron-Containing Drug Candidate
Hepatitis C: Reality Intrudes
The XMRV Story Is Not Getting Any Saner
Cyclodextrin's Day in the Sun
XMRV - Work Went On
XMRV: This Is Not Good
XMRV: Over With and Done?
Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
Kibdelomycin, A New Antibiotic. In A Way.
DRACOs: New Antivirals Against Pretty Much Everything?
The Evolution of Resistance: Are We Doing It Wrong?
Murine Viruses and Chronic Fatigue: Does the Story Continue
XMRV and Chronic Fatigue: Down For More Than the Third Time
Process Chemistry Makes the Headlines
Selenium In a Drug Structure: Why Not?
Pfizer Moves Antibacterials to Shanghai
XMRV: It's Ugly, But That's Science
Chiral What? Chiral How?
HIV Therapies: A Thank-You
TRIM21: A Cure For the Common Cold? Maybe Not. . .
XMRV? Or Umpteen Other Viruses? Or What?
Know How to Make Praziquantel? Tell The World.
XMRV and Chronic Fatigue: You Thought You Were Confused Before
Unlovely Polyphenols
Rosetta@Home
A Landmark In Clinical Trial Data Interpretation
Dundee's NMT Inhibitors for Sleeping Sickness: An Update
Good News Versus Sleeping Sickness
Your Own Personal Bacteria
A Friday Book Recommendation
XMRV and Chronic Fatigue Syndrome: More Negative Data
A Pile of Malaria Leads For the Taking
Two Doses of Crazy
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
Ozonides As Drugs: What Will They Think of Next?
Chronic Fatigue - Retroviruses to Blame, or Not?
A Nobel for Ribosome Structure
A Deuterium Deal
Altermune - Real Stuff or Not?
Don't Hit The Bunkers Just Yet
An HIV Drug. Or A Gout Drug? Or Both. . .
Two! Two! Two Drugs in One!
Drugs For Bacteria: Really That Hard, Or Not?
A Quick Quiz (Re: Antibacterials)
Bacteria: Respect Must Be Paid
A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
Maribavir, Ouch
Fun With Bacteria
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
Smaller, Wetter, Harder to Work With
Resistant Little Creatures
Bacterial Infection: Better Or Worse Than Cancer?
Now With Ethyl Mesylate!
Evolution In Action
Brazil Raises The Pirate Flag
A New HIV Therapy. Yawn?
Deep Breaths
Vertex, Hepatitis, and Gripping the Arms of Your Chair
Peptides as Texts
Enzymes Do Whatever They Want To
Fuzeon's Fallout
A New Route to Tamiflu?
Tamiflu: Good For Anything, Or Not?
One Darn Miracle After Another
Cash For Vaccines
The Flu Plan, Part Two: Antiviral Drugs
The Flu Plan, Part One: Vaccines
Buy! It's More Expensive Than Usual!
Well Deserved
Antivirals "Gathering Dust"?
The Check Shows Up in the Mail. Really.
And It Goes Like This
More on Brazil and Kaletra
Brazil Pulls Out the Pin
Where's the Combo?
Fan Mail
Pfizer Opens Their Wallet - Again
Fungal Problems
Dr. Rath Does What He Can
Vertex Turns Over a Winner
Do It Again
An Antiviral Example
Can Med-Chem Help With Bird Flu?
Empty Shelves
Resistance to Resistance
It's a Bacterial Planet, You Know
They Will Do Such Things. . .
A Last-Ditch Effort - Or Is It?
Better Them Than Me
A Twisty Road
New! Viruses So Potent, You'd Swear They Were Homemade!
If It Were Easy. . .
New Drugs for HIV

Inorganic Chemistry
Surfin' On The Surface
Neil Bartlett, 1932-2008
Copper: A Gentleman's Disagreement
A Salute

Intelligent Design
Unintelligent Design
Brief Political Interlude
Ban Intelligent Design?
Poor Put-Upon Intelligent Design
The Dover Decision Comes Down
Intelligent Design, Molecule By Molecule
The Dover Decision
An Off-Topic Ramble
Intelligent Chemical Design

Job Postings
Chemistry Job Postings: Worth a Try

Life As We (Don't) Know It
Artificial Base Pairs in Living Cells
Thermodynamics of Life
Hybrid Biomolecules, Edible And Not
How Many Binding Pockets Are There?
The Galaxy Is Full of Gunk
Arsenic Life No More
The Redfield Paper Is Out (And So Are Arsenic Bacteria, It Seems)
Arsenic Bacteria Ride Again. (Or Don't).
A First Step Toward A New Form of Life
Arsenic in DNA: The Kinetic Argument.
Life With Arsenic: Who'd Have Thought?
Chemical Biology - The Future?
Let's Sequence These Guys
Friday Book Recommendation
What's So Special About Ribose?
Mass Spec on Mars
Intelligent Chemical Design
Exobiochemistry
Our Friend the Phosphate Group
Mirror Stars

Life in the Drug Labs
Grinding Up Your Reactions
One of Those Days
What Structures Have Turned on You?
How to Run a Drug Project: Are There Any Rules at All?
Absence Makes the Ideas Flow?
That's Just Too Colorful
This All Too Open Office
How Many Elements Have You Used, As Elements?
Gitcher SF5 Groups Right Here
The Bread Rolls of Synthesis
"The Time Had Now Come to Attempt the First Large-Scale Reaction. . ."
Beelzebub Pharma, Inc.
Throwing Out the Files
Evidence Against Open Offices
Positive Rules and Negative Ones
What Reagents Will You Never Forget?
Merck's Aftermath
A Decent Smell, For Once
Bring Me More Cute Ring Systems
Stack Ranking in Pharma: Bad Idea
Instrument Nostalgia
Biogen Idec Goes Open-Office
Sealed Up And Ready to Go
Product Inhibition, Or Grinding To A Halt
Making the Non-Flat, Non-Aromatic Compounds
Underappreciated Analytical Techniques
Real Reactions, From Real Lab Notebooks
Old Friends, And Those Other Guys
I'll Just Take a Tour of Your Lab Drawers Here
The Finest Green in the Lab?
The Finest Blue in the Lab
Asking the Hard Questions
Down With the Ullmann
An Article That Shows What Med-Chem Is Like?
How Do Chemist (Think That They) Judge Compounds?
Sulfolane
Caring About Yields?
Chem Coach Carnival: A Few Questions
Careers, And Those Words "Stuck" and "Advance"
The Good Ol' Diels-Alder
Watch that Little Letter "c"
Amines and the Landscape of Chemical Stink
Come Back Thiophene; All Is Forgiven
The Best Rings to Put in Your Molecules?
They Don't Make These Things to Have Dichloromethane Poured on 'Em
Odd Functionality in Drugs: A Bis-N-Oxide
Dead Reagents, Dead Reactions
Desperation In the Lab
Chemists and Biologists, In Detail
Drug Company Culture: It's Not Helping
What Makes a Beautiful Molecule?
Winning Ugly and Failing Gracefully
Dealing with the Data
Double-Bond-S
A Response From Sanofi
What Sanofi Thinks About You
Scaling Up a Strange Dinitro Compound (And Others)
When Reagents Attack!
Potassium Hydride Is Not Your Friend
The Future of Pharma? Yikes.
Putting a Number on Chemical Beauty
Open Office Plans - A Question or Two
This All Too Open Office
The Research World Staggers Back to Work
Uranium, Eh?
Rating A Massive Pile of Compounds
Fish Nor Fowl
Tossing Out the 1920s Hydrogenators: Can It Be Done?
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
From the RSC/SCI Symposium: A Med-Chem Anomaly
Disappearing Information, Courtesy of Aldrich Chemical
Drug Research Areas You Wish You'd Never Heard Of
High Pressure - The Good Kind
Chem-Geekery: Name Reactions You've Never Run
Underused Lab Solvents
Pfizer's Brave New Med-Chem World
What Would You Get Rid Of?
A Complete Diversion: Purple Compounds
What Medicinal Chemists Really Make
Return of the Magic Methyl Group
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
Surely You Have Something Else to Do
A 200-Proof Shot of Medicinal Chemistry
Brave New Office
It's Worth It to Know That There Are Others
Dogs and Ponys
Fluorination Without Tears. Or Panicked Shouts.
A Quick Glassware Question
Novartis and the Labs of the Future
Comment of the Day: Outsourcing and Architecture
Good Old Medicinal Chemistry: What Can You Get Away With?
Shine A Light
Enthalpy and Entropy Again
Settle A Bet
If You're Not Excited, Sit Down
Keeping Track Of All Those Chemicals
Palladium Couplings: You Can't Run Them All
Conference Thoughts
Workhorse Reactions
Put In Another Methyl Group: A Villanelle
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
Intermediates
How Much Compound?
Nanopowders?
Sparteine and Other Fine Chemical Shortages
A Quick And Nerdy Question
Curse of the Plastic Tubes
Compounds and Proteins
Privileged Scaffolds? How About Unprivileged Ones?
The Chemical Suppliers: Customer Reviews
Good Suppliers - And The Other Guys
Science Buildings: Good, Bad, and Weird
Not Gonna Make That One
Flowing, Not So Gently
Cranking Away
Chemical Supplier Question
The Infinitely Active Impurity
In Hoc Signo Non Vinces
What Should Non-Chemists Know About Medicinal Chemistry, Anyway?
Oxford's New Building, One Year Later
Data, Raw and Otherwise
Recommended Books For Medicinal Chemists, Part One
Fear Of Academic Chemistry?
But These Reagents, Where Are They?
What Are the Best Med-Chem Books?
Lumpy Assay Results
Lab Equipment: Any H-Cube Troubleshooters Out There?
Four Med-Chem Questions
Reduce Your Number of Reductions, Why Don't You?
Elements I Have Yet to Use
Consultants
Hoist, Petard, Etc.
Retire These Reactions!
Colorful Junk
Sulfoxides: A Sneaking Affection
How A Real Drug Industry Project Meeting Goes
Everything In Its Place
RUR
Funky Carbocycles
Ugliness Defined
Don't Make Them in the First Place?
Random Questions, Answered Randomly
Instant Med-Chem Wisdom
Ever Have One of Those Days?
Wait For It. . .Wait For It. . .
Surfin' On The Surface
The Mechanical Chemist?
The Equipment Graveyard
Your Temperamental Diva Reactions
How Good (or Bad?) Are Patent Procedures, Anyway?
Hot Chemistry, Low Tech to High
Inspiration Is Where You Find It
Structure-Activity: Lather, Rinse, and Repeat
The Limits of Free Scientist Chow?
Supplies of Suppliers
Prep TLC: The Good Old Days Live On
Fancy Building, Fancy Science?
The Real Hazards of the Lab
Lack of Experience, You Know
Poor Equipment Revisited
The Perils of Poor Equipment
The Yield Monster - And Its Friend, The Model Monster
We Now Return to Our Regularly Scheduled Program
Out the Door and Down the Stairs
Fearful Symmetry?
Old School - Really Old
Why Don't You Just. . .
Sugars: Still Crazy After All These Years
How Not To Do It: Water Aspirators
Fighting Boredom, Profitably
Questions You Don't Necessarily Want the Answers To . . .
Backtracking, Necessary and Unnecessary
Lowe's Law of Diurnal Distribution
How's The New Boss Doing?
I Can Has Ugly Molecules?
Tote That Barge, Lift That Bale
Oops
Ah, Glassware
The Miracle Solvent
Copper: A Gentleman's Disagreement
Summer Student Time
Explaining It All
Naming of Names
Walk Around Some
A Meditation on Solvents
Another Pop Quiz!
The Lucky Bonus Pack
Putting Out the Inevitable Fires
One Time Only. Or Maybe Just a Few.
Write It Down, Write it Down
Dig the New Breed
A Few Questions For My Fellow Pharma Chemists
Extractions: A Way of Life
Cheap Happiness
Winterize Your Ideas
Scrape Off Some Attitude
Underperforming Triple Bonds
The Big and the Little
Still and All
You Do The Easy Stuff; I'll Do the Easier
Maybe Not Improved, But Definitely New
How You Doin'? How's Everybody Doin'?
Here Be Chiral Dragons, With Fluorinated Fangs
Looking Backwards
No Problem At All
Go With The Er, Flow?
Don't Step Over It, Even If It's Right in Front of You
Fresh Air, Or What Passes For It
Aromatherapy
Here It Goes
These You Shall Have Always With You
Run! Anthropologists!
A Farewell to Tin
Over There, Behind That Stack of Whatchamacallits
Starting Up Again
Sunbeams, Single Electrons, and You
Safer Every Day!
Forewarned is Forearmed
The Doctorate and Its Discontents
Doctorate or Not?
Sulfur, Your Pal. Mostly.
I Want A New Nitro
Lousy Reactions: Reader's Choice
Something From Nothing
Wake Up and Smell the Solvents
Problems and Solutions
Good Stuff and Bad Stuff
You'll Be Safe Under Here. Maybe.
Cleans Down to What Should Be the Shine
Old School? Same School!
Family Portraits
Five Things I Haven't Used in Years
Test Your Skills!
By Any Other Name
The Last Word on Eerie Glowing Labs
The Future is Unwritten
More Purple Radiance
Memo to the Public Relations Department
Best When Used By. . .
A Day at the Rota-Vap
Sulfurous Stenches: A Connisseur's Guide
The Process of Process
Cleaning Out the Hood: An Internal Monologue
Grad School, Blogged
First Slide, Please
Stream of Consciousness
The Good New Days
Gimme That Old Time Reaction
Sort Of Like A Wine Cellar
Home Sweet Home
. . .And That Settles It
Gooooaaaal!
The Latest in Pharmaceutical Technology
Tribes
A Sensitive Guy
Having the Hands
Differences Between Academia and Industry, Pt. 4
Let's Check This Blank Page, Here
Seven Questions
Hydrogenation Made Easy?
How Safe Is This Stuff?
The Voice of Experience
Cuprate Voodoo
Sneaking Out for an Interview
A Smelly Riddle
Lost Arts
Ten Questions
Ancient Metals
The Latest from the Fume Hood
Law and Disorder
Does Your Labmate Have the Hands?
Glassware Geek
Through the Looking Plastic
Our Friend the Nitrogen Atom
Lab of the Future!
Beg to Differ
Chemistry Geekery
Nine Things I'm Having Trouble Imagining
A Visit To Academia
Well, Sonny, That's Not How We Did It
It's All Local, All Right
A Spin of the Wheel
Ping! Ping! Ping!
A Day in the Life: Dichloromethane and Peanut Butter
Public Utility, You Say?
We Have Ways of Keeping You Safe
Measure for Mismeasure
Rational Drug Design
A Week in the Life
Solid Citizens
Lighting Out for the Frontier
Wipe Down
The Latest From the Fishing Hole
Catalyst Catfishing
Next on the Food Channel. . .
The Last Word on Taste
Beyond the Teeth, Beyond the Pale
By Any Other Name
At My Desk, Playing 500-Card Stud
Mutter, Mutter, Mutter
Obvious to One Skilled in the Art
Quis custodiet ipsos custodes?
A Quick One While He's Away
A Chemical Wish List
Multitasking
Idle Hands
And I Still Have Some of Those Shirts
Talk, Cheap and Otherwise
More Pfizer Explosion Details
Blowups Happen
Another Shot
A Clean Lab is A Happy Lab
Back to Whatever It Is I Do
Colors May Fade
More Colors and Smells

Lowe's Laws of the Lab
Prediction Markets, Idea Sharing, and So On
Cheese Dip and Hydrochloric Acid
A Law of the Lab: Yields and Variations
Yet Another Law
Another Law of the Lab
Think Twice
Law Number One

Metaphors, Good and Bad
Block That Metaphor!
Melting Keys and Squishy Locks

Natural Products
Weirdly, Tramadol Is Not a Natural Product After All
Speaking of Polyphenols. . .
How Polyphenols Work, Perhaps?
Mix-and-Match Natural Products
Hit the Polyamine Pedal, And Hold It
Tramadol Turns Out to Be a Natural Product
Making the Bacteria Make Your Fluorinated Compounds
More on Warp Drive Bio and Cryptic Natural Products
Ingenol: A Walk In The Park
More From Warp Drive Bio (And Less From Aileron?)
Protein-Protein Compounds - The Flip Side
Picking Out Incorrect Natural Products
Forcing Fungi to Make Stranger Compounds
A Total Synthesis Archive
Natural Product Fragments: Get Rid of the Ugly Ones Now
Anyone Still Swimming in the Chiral Pool?
Natural Products Continue to Weird Me Out
Sudden Onset of Promiscuity
Bungled Structure, And How
Organic Synthesis: A Dead End For Graduate Students?
Nevirapine: Not Chiral. Paper: Not Right. Editorial Staff: Not Doing Their Job
Kibdelomycin, A New Antibiotic. In A Way.
Chiral What? Chiral How?
And One Was Just Right?
Vinca Alkaloids, And Where They End Up

Odd Elements in Drugs
Why Not Bromine?
The Medical Periodic Table
Silicon In Drug Molecules: Not Quite There
Trouble With a Boron-Containing Drug Candidate
Selenium In a Drug Structure: Why Not?
You Don't See Many Names Starting with "Tellura-"
Ozonides As Drugs: What Will They Think of Next?
One For the Brave
Arsenic, Patents, and the World
My Shopping List
Odd Elements in Drugs: Silicon
Odd Elements in Drugs

Patents and IP
Is The Current Patent System Distorting Cancer Research?
The Hep C Field Gets Nastier By the Minute
What If Drug Patents Were Written Like Software Patents?
Oncoceutics' Odd Press Releases (Spam Never Sleeps)
A Horrible, Expensive, and Completely Avoidable Drug Development Mixup
Crap, With the Force of Law Behind It
CRISPR In the Courts
Eli Lilly vs. Canada
Can You Patent A Natural Product? Prepare For a Different Answer
A New Book on Scaffold Hopping
Free Chemical Patent Searching
The Past Twenty Years of Drug Development, Via the Literature
Suing Your Grad School, And Your Professor
Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World
The Supreme Court Rules on Myriad
Deuterated Drugs: An Obvious Idea?
Novartis Loses the Glivec Patent Fight in India
Standard of Care? Not So Fast, Not in the United Kingdom
Oops. We Didn't Mean to Publish That.
JQ1: Giving Up a Fortune?
The American Chemical Society's Lawsuit Problem
The Myriad Gene Patent Case: Trickier Than You Might Think
What Compound Are You Trying to Patent, Again?
China's Compulsory Licensing
Publishing Without Consent
A Long-Delayed COX2 Issue Gets Settled - For $450 Million?
The Supreme Court Makes Me Smile
Department of Lots of Nerve (Patent Applications Desk)
Independent Inventions
Academia and Industry, Suing Each Other
Don't Dose That Patient Until You Pay Up
Amgen's New Patent: Explanations, Anyone?
A New Book on Chemical Patents
Patent Trolling, Money and Fun
A Dish Best Served Cold
Chinese Research: Not Quite the Juggernaut?
Roche Prevails Over Stanford
Roche and Stanford: Academia v. Industry?
Freedom to Operate
Are Genes Patentable Or Not?
Apotex's Plavix Adventure: Four Years Later
You May Not Be Interested In It - But It's Interested In You
Running Out of Decent Molecules to Patent?
Patent Chart Update
Take These?
Only Three Patents? Really?
The Ariad Decision and Written Description
Myriad's BRCA Gene Case: Wait For It
Ariad Loses on Appeal
Drug Patents in India
Acorda and Ampyra
So, Do I Own This, Or What? Answer: What
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
How To Get Useful Data Out of a Drug Patent
Ignoring Patents?
Thalidomide for Myeloma: Whose Idea Was It?
Ariad's Patent Rises From the Grave to Smite the Living
Polymorphs and Salts: India Raises an Eyebrow
How Not To Do It: The Secret Patent Decoder Ring
Professors Patent Pathways and Possibly Profit? Please.
Perpetual Patents: A Nasty Thought Occurs
Perpetual Patent Motion Machine
Deuterated Drugs: The PTO Says OK, So Far
Ariad's Patent: Let Us Now Dance In Circles
How Good (or Bad?) Are Patent Procedures, Anyway?
Ariad's Patent: A Court Rules
Rember for Alzheimer's: Methylene Blue's Comeback
Confident
Patents Stopping an Alzheimer's Wonder Drug?
Unknown - But You Can Buy It
Hearing Footsteps
Fixing the Patent System?
Ugly, But Useful
Arsenic, Patents, and the World
Nonsense. On Stilts. Playing a Trumpet.
Brazil Raises The Pirate Flag
Obvious Ain't Obvious No More
Crichton, Patents, and Genes
The Paper Mountain
Show What You Know
Inherently Obvious - It's Obviously Inherent
Move On, Move On - Nothing To See Here. . .
Ariad's Patent Eviscerated
Plavix Plot Twists
Respect! Honor! Recognition! All For $149.95!
The Great Plavix Disaster
Getting and Spending
Ariad Wins a Round
Full Disclosure
A Shot Across the Bow
Ariad's Day in Court
Once More Into the Patent Breech
Down With Patents, Eh?
Ah, It's Fine. Just Send the Darn Thing Out Already.
The Examiner Finally Snaps
Arr, Me Hearties!
The Leash of the Law
Brazil Pulls Out the Pin
Vaccines and Human Folly
The Research Exemption Lives!
Merck and Integra Go the Distance
Between Friends. Sort of.
Back For More
Dysfunctional Disclosure
Elbow Room
Merck Takes Another One
Success Has A Thousand Fathers
Fixing the Drug Industry?
Keep It To Yourself
I'll Have the Lot
Alexander Would Have Understood
Hey, I Could Patent That. . .
Will the Uncommon Work for the Common Good?
Living by the IP Sword
Back for More
Lighting Out for the Frontier
Doublets, Triplets, Whateverlets
This Isn't the Kind of Office Action You're Thinking Of
All the Myriad Ways
Owning the Road
Why Own the Car, When You Can Own the Road?
Oblivious to One Skilled in the Art
Obvious to One Skilled in the Art
How to Be an Inventor
From Each According To Their Creativity, To Each According To Their Difficulty?
And Now for Something Completely Different
Don't Wait - Patent Today!
Generic Prilosec - the Sequel
It'll Be a While
The Latest Mudfight
Overpatenting?
Different Opinions About A Difference That Makes No Difference
More Fun With Patent Expirations
The Patent Expiration Fun Continues
A Last-Ditch Effort - Or Is It?
Great Moments in Legal Reasoning
Now, Where Was I?
A Race to the Bottom
Hands Off
Not As Bad As It Looks
Eliminate the Middleman

Pharma 101
Eating A Whole Bunch of Random Compounds
Improving Half-Life
Lessons For a New Medicinal Chemist
How Do Drugs Get Into Cells? A Vicious Debate.
Why You Don't Want to Make Death-Star-Sized Drugs
What Are the Best Med-Chem Books?
Animal Testing: A View From the Labs
Prep TLC: The Good Old Days Live On
Floppiness Is Not Your Friend: Who Knew?
Elbow Room
Like Clockwork
Proteomics 101

Pharmacokinetics
Why Not Bromine?
Don't Optimize Your Plasma Protein Binding
Modifying Red Blood Cells As Carriers
Single-Cell Compound Measurements - Now In A Real Animal
A New Way to Study Hepatotoxicity
Dosing by Body Surface Area
A New Book on Scaffold Hopping
A New Metabolism Predictor
Nasty Odor as a Drug Side Effect
Unraveling An Off-Rate
Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
Too Many Metrics
Deuterated Drugs: An Obvious Idea?
An Update on Deuterium Drugs
Watching PARP1 Inhibitors Fail To Work, Cell By Cell
Nano-Drugs: Peaked, Or Maybe Past
Getting Down to Protein-Protein Compounds
In Case You Were Wondering What We Thought About the Liver
Eating A Whole Bunch of Random Compounds
Stapled Peptides Take a Torpedo
Improving Half-Life
Going After the Big Cyclic Ones
Come Back Thiophene; All Is Forgiven
Live By The Bricks, Die By The Bricks
An Oral Insulin Pill?
Antidepressant Drugs and Cell Membranes
How Do Drugs Get Into Cells? A Vicious Debate.
The Artificial Intelligence Economy?
Unlovely Polyphenols
A Brief and Not At All Intemperate Evaluation of the Current Literature
What Do Nanoparticles Really Look Like?
Nanoparticles and RNA: Now In Humans
Make Your Compound Go Away
Why You Don't Want to Make Death-Star-Sized Drugs
Recommended Books For Medicinal Chemists, Part One
Ugliness Defined
Instant Med-Chem Wisdom
A Deuterium Deal
Heavy Atoms, Heavy Profits?
A Med-Chem Book Recommendation
Prodrugs: How the Pros Do It?
Down The Chute in Phase III
Sticky Containers, Vanishing Drugs
Getting To Lyrica
The Animal Testing Hierarchy
Eat It, Breath It, Soak in It?
Like Clockwork
Sulfur, Your Pal. Mostly.
Bigger And Greasier
Clay Lies Still, But Blood's A Rover
Down the Hatch
The March of Folly Leader Board
How Drugs Die

Press Coverage
Studies Show? Not So Fast.
Is Palbociclib Promising? Or Not?
For Immediate Rewording. Uh, Release.
The West Virginia Formaldehyde Claim Is Nonsense
A Long Fight Over Allegations of Fraud
More Worthless Press Releases
Worst Scientific Press Releases of 2013?
An Alzheimer's Cure? Not So Fast.
Overselling p53 Drugs
More on the Parabon NSF Press Release
Parabon's DNA Structures: What The Hey?
Pfizer's Gold Dust Makes it to the WSJ
Oh Yeah, Now That You Mention It, They're Dead
CNN's Cure for Cancer
Drug Discovery on Radio 4
Nobel Prizes in Chemistry For People Who Aren't Chemists
Avastin Coverage, Amended
Geron, Stem-Cell Pioneers, Drop Stem Cells
Freedom of the Press: Science Reporting Division
Foldit Notches a Protein Structure Success (And Some Failures)
2011 Drug Approvals Are Up: We Rule, Right?
The Public Perception of Chemistry
For Responsible Stem Cell Reporting. . .
Telling Everyone What It's Like
The Failure of Modern Medicine?
Cardiac Hope and Cardiac Hype
Even Worse Than Reality
What A Fool Believes
Noted, Through Massive Self-Restraint, With Almost No Comment Whatsoever
Engaging the Public?
Where Are the Cures?
Alzheimer's Markers and Collaboration
Lechleiter's Prescription for Science
The Atlantic Monthly on Drug Pipelines
Anyone from GSK Interested?
Malcolm Gladwell on Synta and Oncology
C&E News - A Few Questions
Generex and Their Insulin Spray: Just Hype?
Lilly's R&D Outsourcing
Lexapro, Forest Labs, and the Hard Sell
Jargon Will Save Us All
Medarex, Ipilimumab, Prostate Cancer, And Reality
Live-Blogging A Conference: Trouble?
And While We're Talking About Industry-Sponsored Studies. . .
Drug Industry Research: Reliable or Not?
Autism and Vaccines: Boiling Over Yet Again
An Alternative Prescription From Chopra, Roy, and Weil
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
Pharmalot Is No More
Samurai! Unleash Your Drug Candidates!
Nanotech Stem Cells, Order Now!
Pre-emption For Real?
Vytorin: It's A Pity
The EU Suspects No One, And Suspects Everyone
Vytorin, Holed Under the Waterline
The Avandia Wars Continue
More Avandia, And More on Marketing
FDA Advisory Panels: Pay, No Play
CMPI Conference: Critical Path
CMPI Conference: CATIE and ALLHAT
CMPI Conference: Lunch With the FDA
CMPI Conference: Panel on the Politics of Drug Evaluation
CMPI Conference: Panel on Media Coverage
Crichton, Patents, and Genes
That Can't Be Right - Try Again
Jungle Rot
Full Disclosure
Well-Rounded?
Okadaic Acid Makes Vanity Fair
Gene to Drug: You Bet
Say It Again!
". . .And to Furbish Falsehoods For a Magazine"
Okay, One More Merck Point
The Place to Be
At Your Newsstand Today
And It Goes Like This
A Day in the Life of Peter Rost
Biotech At Last, Eh?
Preach It, Brother
Angell's Book
The Old Days, Some Older Than Others
Sic Transit Gloria Mundi
Not Even Funny
The Wall Street Journal versus the FDA
Did He Say What They Thought He Said?
Hype and Glory

Regulatory Affairs
The Early FDA
Drug Repurposing
Incomprehensible Drug Prices? Think Again.
Allergan Twists and Turns
The Virtual Clinical Trial: Not Quite Around the Corner
Stem Cells: The Center of "Right to Try"
Right To Try: Here We Go
The Reasons for Failure at the FDA
The 2013 Crop of New Drugs
PTC's Latest Ataluren Woes
Merck Pulls One Out
The 2013 Drug Approvals: Not So Great?
Merry Christmas From the FDA
23 And Me And the FDA
Sarepta's Approval Woes
The Other Shoe Drops at Ariad
The FDA: Too Loose, Or Appropriately Brave?
Catalyst Pharmaceuticals And Their Business Plan
Ariad (And Its Drug) In Trouble
Ariad's Ponatinib Runs Into Big Trouble
Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
Value For the Money
Is The FDA the Problem?
More on the NIH and Its Indian Clinical Trials
On the Priority Breakthrough Accelerated Fast Track
The Drug Industry and the Obama Administration
Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World
Today's Avandia Hearing at the FDA
Aveo Gets Bad News on Tivozanib
The NIH, Pfizer, and Senator Wyden
The FDA's New Alzheimer's Guidance: Wonder or Blunder?
Suing A Generic Drug Maker: When And How?
von Eschenbach Takes Another Whack at Phase III Trials
2012's New Drugs
PhRMA And Why People Dislike the Drug Industry
DUCTS: Down with Useless Clinical Trial acronymS
Free To Promote Off-Label? Not So Fast. . .
Off-Label Promotion Is Legal, You Say?
Budgets and Revenues
The Coming Battle Over Alzheimer's Disease
"Basically, They're A Bunch of Lemmings"
The Generic Wellbutrin Problem: Whose Fault Is It?
Accelerated Approval And Its Discontents
Is Ampyra Any Good?
Bert Vogelstein on Cancer Drugs and Cancer Screening
A Diazirine That Will Knock You Out
A Total Mess At the FDA
Vivus and Qsymia: The Oddest Drug Approval
Qnexa Approved? Someone Seems To Know. . .
Employee Surveillance at the FDA
The GlaxoSmithKline Settlement
Effects of the Health Care Law on Pharma
Shire's Replagal Problems: An Inside Look?
Regulatory Hurdles
Side Effects - Lots of Side Effects
Not Quite So Accelerated, Says PhRMA
Nexavar Licensed by Force in India
Eight Billion Dollars Apparently Isn't Enough
Stem Cells in Texas: Quite the Business
Statin Safety
Guidance on Biosimilars
(Un)stoppable Pixantrone
Reaction to Andy Grove's Clinical Trial Proposals
Plan B and the FDA: Unprecedented
Not Just FDA-Bashing?
Podcast on Avastin
Regeneron Finally Makes It to the Market
Avastin Coverage, Amended
Avastin's Metastatic Breast Cancer Approval Revoked
Makena's Market. Or Lack of One.
KV Pharmaceutical's Latest Makena Move
President Obama Orders the FDA to. . .Do What, Exactly?
Avastin: False Hope for Metastatic Breast Cancer
Andy Grove's Idea For Opening Up Clinical Trials
2011 Drug Approvals Are Up: We Rule, Right?
Massive Piles of Faked Data - But Right On Time
The Duke Cancer Scandal and Personalized Medicine
Avastin and Medicare
Avastin At the FDA Today: Passion Should Lose
Generic Drug Warning Labels: The Supreme Court Speaks
Cladribine Is Gone
A Shortage of Cancer Drugs?
Block That Review
More Insider Trading at the FDA?
Fenofibrate: Good For Much?
When Lipitor Goes Generic
Let the Healing Begin
KV Pharmaceuticals and Makena: The FDA's Move
Insider Trading at the FDA
The Supreme Court Slams Big Pharma? Not Exactly.
More on KV and Makena's Pricing
Makena's Price: What to Do?
Oncology Follow-Up Trials
Health Care Reform and the Drug Industry: How Goes It?
Not Enough Progress Against Cancer?
Reboxetine Doesn't Work. But That's Not the Real Problem.
Ahem: "Sell Gobs of Dope"?
Drug Approvals 2010
The Avastin Decision: A Reality Check
A Whistleblowing Record
Lorcaserin's Complete Response
Avandia Goes Down: A Research Rant
Live-Blogging Arena's FDA Committee Hearing
Lorcaserin in Trouble
A New Way to Approve Drugs
Avastin For Metastatic Breast Cancer: The Whole Story
Not Your Usual FDA Hearing
Going Hollywood
Biosimilars: Not Easy, But Not Impossible, Either
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Mylotarg and the FDA
Flibanserin: Not a "Female Viagra" At All
Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
Eribulin Gets Reviewed, Finally
Regulatory Approvals in the US versus Europe
Environmental Cancer?
Intermune: Right Back Down Again
Treatment INDs - For Any Generex Fans Out There
Novartis, Roche Threaten To Leave the UK
Garage Biotech
Intermune's Rise
Vaccines in the Court
The Plasmid Committee Will See You Now
HER2 Confusion
Avandia: Off the Market or Not?
Pharma and the Health Care Bill: Value For the Money?
Plavix vs. Effient
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
The Details of the Baucus Bill
Pay Them Now, Or Pay For It Later
Statin Safety?
The Drug Business: A Turbulent Future?
A 2.3 Billion Dollar Attention-Getter
REACH for the Sky!
Obesity Shows Up in the Death Rate? Right?
The PhRMA Deal
PhRMA's Negotiating Game
Savient Feels The Pains of Gout
Health Care Reform - Really?
Vanda Comes Back From the Dead
Snort Yourself Some Zinc. Or Maybe Not.
Selling Zyprexa
Arena, Lorcaserin, and the FDA
Book Review Department
Dendreon's Revenge?
A DPP-IV Compound Makes It Through
And While We're Talking About Industry-Sponsored Studies. . .
Takeda Gets A Surprise
More on Wyeth v. Levine and Preemption
Wyeth v. Levine: Pre-emption Goes Away
We Won't Stay Off The Radar Screen For Long, Y'Know
Lilly Pays the Price
Liable For Generics? You Are Now!
Prasugrel Today?
Rember for Alzheimer's: Methylene Blue's Comeback
Glaxo Asks the Eurocrats

Safety Warnings
Safety Warning: Togni's Reagents
Accident Report, or One Damn Thing After Another
The Sangji/UCLA/Harran Case: Now Officially a Mess
Imidazole-1-Sulfonyl Azide HCl: Look Out
Potassium Hydride Is Not Your Friend
The UCLA Lab Fatality: Criminal Charges Filed
Charges in the TMS Diazomethane Case
How Much is the PI To Blame?
Gegen die Dummheit . . .Well, Guess Who Wins, Again
How Not To Do It: Hydrogen Gas Mixtures
More on T2, and Degrees
175 Times. And Then the Catastrophe.
On the Uselessness of the MSDS
Blowups Happen
TMS Reagents: Handle With Care!

Science Gifts
Science Gifts: Telescopes, Etc.
Science Gifts: Elements and More
Science Gifts: Running Experiments at Home
Science Gifts: Medicinal Chemistry Books
The Heirloom Chemistry Set
Science Gifts: Microscopes
Science Gifts: Telescopes
Science Gifts: Actual Med-Chem Books
Science Gifts: The Elements
Science Gifts: Experiments At Home
Science Gifts: Chemistry Sets

Snake Oil
All Natural And Chemical Free
Chemical-Free Products: The Complete List
Stem Cells: The Center of "Right to Try"
Whack-A-Mole
Sweet Reason Lands On Its Face
Getcher Nucleic Acids, Cheap
Jailhouse Secrets They Don't Want You to Know About!
More Vaccine Fearmongering
Kevin Trudeau Goes to Jail, At Long Last
The Herbal Supplement Industry Is Not A Very Funny Joke
On Conspiratorial Thinking
One Conspiracy After Another
Eight Toxic Foods: The Aftermath
Eight Toxic Foods: A Little Chemical Education
Nativis Returns
The Name of a Cure
Scamorama
Dr. Oz's Problem
Honking, Squawking Chemical Ignorance
Luc Montagnier Is Not Losing It. Luc Montagnier Has Lost It.
Nativis Update
Burzynski Revisited
The Burzynski Cancer Treatment
Translation Needed from Execulinga
Very Likely Not Real, But Still. . .(The E-Cat)
In Which We Learn Lots About Wine Swirling
Transcendental Meditation: Hold That Paper!
Senator Hatch And His Wonderful Industry
The Failure of Modern Medicine?
More Crankitude: All Natural This Time
Crankitude: A Quick Glossary
Weirdness: A Cold Fusion Demonstration?
Weirdness: Montagnier Again, Teleporting DNA
Has Luc Montagnier Lost It?
MMR Vaccine and Autism: Lies, All Lies
Guess the Author: Revealed
Amazing Stuff! Guess Where It's From. . .
The Horror Of Asking For Data
"Doctor's Data": Telling the Truth and Getting Sued For It
Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
Nativis: Waiting and Seeing
The Power of Photons, You Say?
The Problem With Research on Aging
Dietary Supplements, Charted
Department of Placebo Effects
Two Doses of Crazy
Argumentum ad Crumenam
Snort Yourself Some Zinc. Or Maybe Not.
Homeopathic Merchants Take Your Questions! Well, Sort Of.
But You Can't Make Them Take It?
Qi Gong and Placebo Effects
An Alternative Prescription From Chopra, Roy, and Weil
Extracting Money From Matthias Rath, For A Change
Torcetrapib: The Foil-Lined Hat Perspective
Kevin Trudeau Was Born in 1963
Give The People What They Want
Deception Begins at Home
Run, Do Not Walk, To The Nearest Exit
Matthias Rath, Pioneer
pHooey
Kevin Trudeau's Snake Oil Empire
Dr. Rath Does What He Can
Am I Blue?
Stupidity, But Not the Dangerous Kind
The Company You Keep
And All For a Little Money
And Another Thing
F. Scott Fitzgerald Had Something to Say About This
Get Your Miracle Elixir

The Central Nervous System
The Broad Gets $650 Million For Psychiatric Research
Alex Shulgin, 1925-2014
A Call For Better Mouse Studies
A Huntington's Breakthrough?
The Genetics of Bipolar Disorder: What A Tangle
Parkinson's From the Environment?
Merck's Drug Development in The New Yorker
Exiting Two Therapeutic Areas
Unraveling An Off-Rate
Allosteric Binding Illuminated?
Catalyst Pharmaceuticals And Their Business Plan
An Alzheimer's Cure? Not So Fast.
A New Pathway For Memory
Cancer and Autism: Slow Down
Ben Cravatt At The Challenges In Chemical Biology Conference
Your Brain Shifts Gears
Tecfidera's Price
NeuroSearch's Decline
A Short Rise Out of Depression
Automated Ligand Design?
CNS Drug Development Claims Another Victim
More on That Crowdsourced CNS Research
The Generic Wellbutrin Problem: Whose Fault Is It?
Targacept Cuts Way Back
Crowdfunding A CNS Project
Various Links Of Stuff
Eli Lilly's Drumbeat of Bad News
Is Ampyra Any Good?
Getting Drug Research Really, Really Wrong
Closure at the Neurosciences Institute?
Antipsychotic Drugs Against Cancer?
A Kinase Inhibitor Learns Something New
GSK and Immune Response: Not Quite An Amicable Divorce
Antidepressant Drugs and Cell Membranes
Making Their Own ALS Drug
Stem Cells in Texas: Quite the Business
The Infinitely Active Impurity
AstraZeneca's Problems
Novartis: No More Neuroscience
Rexahn Rides Again
Regeneron Finally Makes It to the Market
Brain Cells: Different From Each Other, But Similar to Something Else?
Targacept's Antidepressant Fails, And How
Tiny, Tiny Molecules for MS
Cyclodextrin's Day in the Sun
The Singularity, Postponed
Is Alzheimer's An Infectious Disease? The Spread of Protein Misfolding
Gilenya's Price
Laquinimod Fails For Multiple Sclerosis
Drugs for Multiple Sclerosis: Worth the Price, Or Not?
Cladribine Is Gone
Your Comments on the NIH's CNS Drug Program?
The NIH Goes For the Gusto
New Cures! Faster! Faster!
Fanapt: Not Paying Out
Reboxetine Doesn't Work. But That's Not the Real Problem.
Fishing Around for Biomarkers
More On Homemade Street Drugs
Drugs At Home
Laser Nematode Surgery!
Where Are the Cures?
Kurzweil Responds
Reverse-Engineering the Human Brain? Really?
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Flibanserin: Not a "Female Viagra" At All
Raising Your HDL - Through the Brain?
OCD Linked to the Immune System?
The Memory Goes Because. . .the Acetyl Groups Go?
Homemade Morphine?
A Landmark In Clinical Trial Data Interpretation
A Tiny Little Presentation Tip
Dimebon, Grasping at Straws
A Modest Literature Proposal
Dimebon for Alzheimer's: A Black Box Indeed
Acorda and Ampyra
Maybe You Need Some More Testosterone Over There
Correlations, Lovely Correlations
An Alzheimer's Compound Runs Into Big Trouble
Massaging the Data for Neurontin?
Chronic Fatigue - Retroviruses to Blame, or Not?
Placebos Can Work the Other Way, Too
To What End?
Lexapro, Forest Labs, and the Hard Sell
Amyloid in Trouble
Vanda Comes Back From the Dead
Selling Zyprexa
Lilly's Latest Loses (This Time)
And While We're Talking About Industry-Sponsored Studies. . .
Enhancing the Brain: Here We Go
Liable For Generics? You Are Now!
Fructose In The Brain?
Where Are the Drugs?
Taranabant Is No More
Antipsychotics: Do They Work For A Completely Different Reason?
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Whose Guess Is Better?
Getting To Lyrica
Now Your Liver Doesn't Have to Make It For You
You Get What You Pay For?
Taranabant in Trouble?
Antidepressants: Depressing News or Not?
Fast Plaques in a Slow Disease
Rainbows and Fishing Expeditions
Thimerosal. Again.
Rimonabant: Down to Earth
Rimonabant, Out In the Light
Failure: Not Your Friend, But Definitely Your Companion
Schering-Plough Goes Shopping
CMPI Conference: Critical Path
CMPI Conference: CATIE and ALLHAT
It Should Work. It Just Doesn't.
Touch Me Not
Neurocrine's Choice
Tied to the Mast
By a Nose in a Head to Head
No Clear Winners
The Painful History of Substance P
Morphine in the Brain: Go For It, or Not?
More Brain Surprises
Rewiring the Brain?
Neurotoxins
More Faces in Even More Clouds
All the Not-So-Myriad Ways
Cartesian Aging

The Dark Side
Prison Sentences in the GSK China Scandal
Messed-Up Clinical Studies: A First-Hand Report
Clinical Trial Fraud
Peer Review, Up Close and Personal
Citable Garbage
That Retracted Stressed Stem Cell Work
The GSK-China Situation Gets Even Weirder
Varieties of Scientific Deception
No More Acid Stem Cells
China Raises the Stakes in the GSK Scandal
J. Appl. Drivel or Gibberish Lett.? Choices, Choices.
Professor Fukuyama's Solvent Peaks
More on the UT-Austin Retraction Case
The Instructive Case of Galena Biopharma
"It Is Not Hard to Peddle Incoherent Math to Biologists"
Beelzebub Pharma, Inc.
A Long Fight Over Allegations of Fraud
It Just So Happens That I Have A Conference Right Here
Press Release Fraud - The Verdict Stands
Shop Up Some Gels For the Paper
What You Can Publish After a Shamectomy
Authorship For Sale. Papers For Sale. Everything For Sale.
A Place to Go For Scientific Whistleblowing
The Herbal Supplement Industry Is Not A Very Funny Joke
ACSNano on Problematic Papers
Holding Back Experimental Details, With Reason
A Leak at Lilly
An Open Access Trash Heap
They'll Fake the Journal if You'll Fake the Papers
An Unknown Author With Someone Else's Work. Why?
File Under "Nerve, Lots Of"
Exposing Faked Scientific Papers
Now It's Novartis's Turn in China
Sanofi in China
An Interview With A GSK Shanghai Scientist
Make Up the Elemental Analysis: An Update
Academic Kickbacks in China?
GSK Scandal Info
One GSK China Scandal Blends Into Another
China's GlaxoSmithKline Crackdown
Touching Up the Spectra
An Update on the Wisconsin Lab Theft Case
Clinical Trial Fraud Uncovered
Non-Reproducible Science: A Survey
19 Years to a Retraction. Bonus Midnight Camera Footage Included.
More on the GSK Shanghai Scandal
Mutato Nomine De Te Fabula Narratur
Research Fraud at GSK Shanghai?
A Little Ranbaxy Example
Ranbaxy: Looking Under the Rock
One Case of Plagiarism Down. Two Zillion to Go.
Research Fraud, From A Master Fraud Artist
Stealing A Compound, To Set Up in China
Fake Journals - But They'd Like Real Money
The Wyeth/Elan Insider Trading Case Resolves
Thallium Poisoning, Again
Anonymity, Fakery, et al.
The Wages of Copy-Pasting
How To Enhance Your Online Reputation. Sure.
Coincidence, No Doubt. Well, Some Doubt.
Dr. Das Sues U Conn. Good Luck With That.
Science Fraud and Legal Action
The Last Thing a Professor Wants to Hear
Dr. Gilman's Turn Toward the Inside
And Since We're Talking About Insider Trading
Easy Money, Right?
How Much Fraud, As Opposed to Plain Old Error?
Hype, Malpractice, and Scientific Misconduct in Organic Synthesis
The Absolute Bottom of the Publishing Barrel
Pharma Sales Corruption in India. And How.
When Is A Company Shading the Truth About Its Clinical Trials?
The Papers In This Journal Are Just So Darn Relevant
The GlaxoSmithKline Settlement
Merck Finds Its Phase II Candidates For Sale on the Internet
Laboratory Crime, Not Paying
Eight Billion Dollars Apparently Isn't Enough
Stem Cells in Texas: Quite the Business
Bias in Industry-Funded Trials in Rheumatoid Arthritis?
More Industrial Espionage
Selling Sanofi's Compounds on the Side
Defending Das' Resvertrol Research. Oh, Come On.
Dealing With Dishonesty
A Resveratrol Research Scandal. Oh, Joy.
More on Chinese Pharma Espionage
Chinese Pharma Espionage?
The XMRV Story Is Not Getting Any Saner
Faking Two Papers A Month. For Seven Years.
A Note About Identity Spoofing
So, How Come You're So Darn Lucky, Eh?
Honest Research in China
Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
The Finest Retraction Notice Ever?
Scientific Retractions: A Growth Industry?
What An Offer
What the Bottom of the Barrel Looks Like
Massive Piles of Faked Data - But Right On Time
Sezen / Sames: What Does it Say About Grad School?
The Sames / Sezen Fraud Case: Holy Cow
The Duke Cancer Scandal and Personalized Medicine
Fakery, As Revealed By Figures
An Unethical Clinical Trial
Even Worse Than Reality
More Insider Trading at the FDA?
Scientific Fraud: How Often and How Much?
Insider Trading at the FDA
Laboratory Sabotage?
Thallium Poisoning? In This Day and Age?
Whistleblowers: Paid Too Much?
Reboxetine Doesn't Work. But That's Not the Real Problem.
More On Homemade Street Drugs
MMR Vaccine and Autism: Lies, All Lies
The Sames-Sezen Case: The Feds Speak
99% Yield? That, Friends, Is Deception
Drugs At Home
Three Times Is Enemy Action
Cut-and-Paste Your Way to Publication
How Sleazy It Can Get
Avandia: Was the Evidence Buried?
That Schering-Plough Lawsuit Isn't Going Away
Sequenom: Faking It
Generex: Who Buys This Stuff, Anyway?
Benford's Law, Revisited
Stem Cell Politics
Steve Nissen's Meeting with GSK
Here's a Business Plan For You
Sequenom: Strike Up the Music, Bring On the Cream Pies
Extortion, Retractions, And More
GE Healthcare's Idiotic Libel Suit
Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
Pfizer's Pearl River Layoffs
Climategate and Scientific Conduct
Massaging the Data for Neurontin?
Selling It, And Selling It Hard
I'll See Your Conflicts, and Raise You?
Faked Data at the ETH
Pharma Whistleblowing: How It Works
A 2.3 Billion Dollar Attention-Getter
Ghostwriting
What's With Those People at Elsevier, Anyway?
Selling Zyprexa
Another Sack of Raving Nonsense Is Slated For Publication
Word For Word - But Why?
Perpetual Patents: A Nasty Thought Occurs
Competing (And Competing Unethically?)
Merck, Elsevier, and Fakery
No MAGIC Involved
What Results Did You Have In Mind?
Drug Industry Research: Reliable or Not?
Fraud: How, and Why, and How Again
The Merck Deal and the SEC: Not a Joke
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Ranbaxy in Trouble
Lilly Pays the Price
Insider Trading in Drug Stocks? Not Unknown. . .
Cut It Out. Cut It Out Now.
Vytorin: It's A Pity
Fakery And Its Ends
Big Steaming Heaps of Fraud
More On Merck and Taranabant
What You Become Known For
Recycle, Reuse, Republish
Visfatin: Real Or Not?
Pecunia Non Olet?
FDA Advisory Panels: Pay, No Play
The Great Plavix Disaster
The New England Journal And Its PR Flacks
Serono's Suitors
This Had Better Be Good
Ghostly Influences
So What's Wrong With A Little Money Changing Hands?
No Defense
No Better Than the Rest of Them
Silver Tongues, Golden Hands?
A Rake's Progress

The Scientific Literature
A Day of Irreproducibility In Cambridge
Big Journals, Big Retractions
There Must Have Been Multiple Chances to Catch This
Peer Review, Up Close and Personal
Are Your Compounds Ugly? Do You Know?
Life Is Too Short For Some Journal Feeds
Citable Garbage
My Imaginary Friends Would Be Glad to Serve as Referees
That Retracted Stressed Stem Cell Work
Scientific Journals: Who Pays What?
Varieties of Scientific Deception
The Robustness Test: Why Don't We Just Require It?
No More Acid Stem Cells
The Science Chemogenomics Paper is Revised
A Unique Correction
J. Appl. Drivel or Gibberish Lett.? Choices, Choices.
Molecular Printing of Drug Molecules. Say What?
Professor Fukuyama's Solvent Peaks
More on the Science Chemogenomic Signatures Paper
Biology Maybe Right, Chemistry Ridiculously Wrong
More Fukuyama Corrections
More on the UT-Austin Retraction Case
Dosing by Body Surface Area
Years Worth of the Stuff
More Things Synthetic Chemists Hate
What If Total Syntheses Had Only 25 Steps to Work In?
Going After Poor Published Research
We Are Pleased To Publish Your Senseless Ravings
Sydney Brenner on the State of Science
Changes in Papers
The NIH Takes a Look At How the Money's Spent
Robo-Combing the Chemistry Literature For Mistakes
Thoughts on Overpublishing
Not Again - Stem Cell Results in Trouble?
The Org Lett Spectral Hammer Falls Again
"It Is Not Hard to Peddle Incoherent Math to Biologists"
Genius, Sheer Genius
Pesticide Toxicity?
Today We Have Naming of Parts
A Timeline from Cell
Put Down That White-Out; Drop That Photoshop Cursor
Are There Good Writers In This Business?
Throwing Out the Files
A Long Fight Over Allegations of Fraud
Should Drug Industry Research All Get Rejected For Publication?
How Much Is Wrong?
It Just So Happens That I Have A Conference Right Here
Top Chemical Publications of 2013
Down With the Luxury Journals?
Shop Up Some Gels For the Paper
What You Can Publish After a Shamectomy
Authorship For Sale. Papers For Sale. Everything For Sale.
More on the Open Access Sting Article
It Doesn't Repeat? Who's Interested?
The Past Twenty Years of Drug Development, Via the Literature
ACSNano on Problematic Papers
The Reproducibility Initiative is Open
Holding Back Experimental Details, With Reason
An Open Access Trash Heap
RSS Readers: An Update
Results From the JACS Challenge
They'll Fake the Journal if You'll Fake the Papers
An Unknown Author With Someone Else's Work. Why?
What's An Important Paper? Take the JACS Challenge!
Thoughts on the Scientific Publishing Model, And Its Inverse
Great Papers That Have Been Rejected
What To Do About Chemistry Papers That Don't Work?
Exposing Faked Scientific Papers
Welcome to the Author's Brain. The "Fasten Seatbelts" Sign Is Illuminated
Not Sent Out For Review
Big Pharma And Its Research Publications
Nanorods? Or Photoshop?
Make Up the Elemental Analysis: An Update
New Frontiers in Analytical Chemistry
Touching Up the Spectra
Non-Reproducible Science: A Survey
19 Years to a Retraction. Bonus Midnight Camera Footage Included.
How Robust Is That New Reaction, Anyway?
The Perfect Papers For Each Journal
Watching DNA Polymerase Do Its Thing
The Overselling of Ionic Liquids
More on the GSK Shanghai Scandal
Mutato Nomine De Te Fabula Narratur
Five Minutes With Any Journal Article You Want?
Research Fraud at GSK Shanghai?
The Current Kudzu of Chemistry?
Why Not Share More Bioactivity Data?
Total Synthesis in Print
One Case of Plagiarism Down. Two Zillion to Go.
Is Glyphosate Poisoning Everyone?
Research Fraud, From A Master Fraud Artist
Towards Better Papers, With Real Results in Them
Scientific Posters, Heads on Platters, and Lawsuits
Fake Journals - But They'd Like Real Money
The Price of Publishing
Advertising in the Supplementary Information?
Scientists and Google Reader's Demise
Anonymity, Fakery, et al.
Open Access For ACS Articles?
Phil Baran at Blog Syn
What If the Journal Disappears?
An Incentive For Hype
The Wages of Copy-Pasting
More From Blog Syn
All Those Drug-Likeness Papers: A Bit Too Neat to be True?
A Word We Didn't Know We Needed
Coincidence, No Doubt. Well, Some Doubt.
Blog Syn: An Idea Whose Time Has Come?
Science Fraud and Legal Action
An Article That Shows What Med-Chem Is Like?
The Last Thing a Professor Wants to Hear
The Merck Index
Part Eleven? Really?
Your Press Release Has Already Been Written
Hexacyclinol Round-Up
Hexacyclinol Retracted. It Only Took Six Years.
How Much Fraud, As Opposed to Plain Old Error?
Hype, Malpractice, and Scientific Misconduct in Organic Synthesis
Oops. We Didn't Mean to Publish That.
Too Many Med Chem Journals?
The Absolute Bottom of the Publishing Barrel
Six Rule of Reproducibility
Various Links Of Stuff
Walking Away From the ACS
ENCODE And What It All Means
Graphical Abstract Tedium
A Synthetic Retraction
Chemistry's Mute Black Swans
More On Reproducing Scientific Results: Organic Chemistry Edition
Reproducing Scientific Results - On Purpose
Quick Links
The Papers In This Journal Are Just So Darn Relevant
If They Pretend to Read It, He'll Pretend to Write It
The Cream Rises to the Top, But So Does the Pond Scum
Publishing Without Consent
How Come?
The Breslow Chirality Paper Mess, Resolved
The UK Goes Open-Access
You're A Peer, Too, You Know
Flip That Glucose, Please
Different Worlds: A Last DHFR Paper Thought
Elsevier Picks Up the Pace
DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)
Breslow's Chirality Paper: More Than Just Alien Dinosaurs
That's Some Fine Editorial Work There
Harvard's Had Enough
How Do These Things Get Published?
More on the Federation of Independent Scientists: Journal Access
A Federation of Independent Researchers?
A New Journal (With Bonus Elsevier-Bashing)
Sloppy Science
Elsevier's RSS Feeds: Maybe a Not-So-Minor Complaint
Department of Lots of Nerve (Patent Applications Desk)
Bias in Industry-Funded Trials in Rheumatoid Arthritis?
Yes, The Research Works Act Is Dead
Is the Research Works Act Dead?
Imidazole-1-Sulfonyl Azide HCl: Look Out
An Elsevier Boycott
Every Methods Paper Has a Table
How the Andrulis Paper Got Published
The Andrulis Paper's Fallout
The Key to Everything? Not Quite.
The Research Works Act: One (Two!) Against and One For
Down With the Research Works Act
Defending Das' Resvertrol Research. Oh, Come On.
SciFinder Access For the Unemployed
Lead-Oriented Synthesis - What Might That Be?
The Changing Literature
Nowhere to Go But Up?
Best Paper You Read This Year?
Riding to the Rescue of Rhodanines
Nevirapine: Not Chiral. Paper: Not Right. Editorial Staff: Not Doing Their Job
Table Of Content Graphics, Mocked
The Scientific Literature Gets Kicked Around
Publishing, Perishing, Buying and Selling
The Finest Retraction Notice Ever?
Why Isn't There an ArXiv For Chemistry?
What Are Impact Factors Doing to Chinese Science?
Scientific Retractions: A Growth Industry?
Chinese Research: Not Quite the Juggernaut?
Fakery, As Revealed By Figures
Transcendental Meditation: Hold That Paper!
Even Worse Than Reality
Murine Viruses and Chronic Fatigue: Does the Story Continue
XMRV and Chronic Fatigue: Down For More Than the Third Time
Biomarkers, Revisited. Unfortunately.
Quis Custodiet Ipso Custodes?
A Google Oddity
Ups and Downs
What Medicinal Chemists Really Make
The Top 100 Chemists?
Great Moments in Journal Editing
Keep On Scrollin'
Just A Few More Month's Work, That's All I'm Asking Here
Graphical Crankiness
So Much For Natural-Product Nevirapine
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
Now, That's An Abstract
What The Referees Really Think
Retractions: Why The Secrecy?
The Life of a Paper
Putting Some Numbers on Peer Review
What A Paper Doesn't Have In It
Chiral What? Chiral How?
The Solid Phase
So What's Going On With Peer Review, Anyway?
Spending and Publishing
More Fraudulent Papers Coming From the US?
99% Yield? That, Friends, Is Deception
And Now, the Retractome
Peer Review's Problems
Trusting the Medical Literature?
Those Chemistry Bloggers
Conference Thoughts
Want To Make an Amide? Have I Got Good News For You!
Sodium Hydride As Oxidant, Again?
J. Whoozat Sci.
Put In Another Methyl Group: A Villanelle
Spread of the Pun Virus
Cut-and-Paste Your Way to Publication
Posters and Pickiness
Commenting On Scientific Papers: How Come No One Does It?
What To Do With The Not-Quite-Worthless
All Those Worthless Papers
California vs. Nature
A Word to the Wise
Great Moments in Heterocyclic Chemistry
Ang. Chem. Gets Weirder Every Day
Another Proposal For the Scientific Literature
ACS Med Chem Letters
A Brief and Not At All Intemperate Evaluation of the Current Literature
About Time
Darn It All
Animal Studies: Are Too Many Never Published At All?
The Referee Reports Are In
Terra Incognita
Stem Cell Politics
Two For One Sale
Twitter and Science, Revisited
Who Follows These Things?
Another New Med-Chem Journal
Polluting the Literature with PAINs
A Modest Literature Proposal
Literature Notes
Johnson May Have Been On to Something
Extortion, Retractions, And More
Run It Past the Chemists
Why Don't Chemists Communicate? (Or Do We?)
Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
What The Hey? (Abstract Abstracts, Part II)
Climategate and Scientific Conduct
Recommended Books For Medicinal Chemists, Part One
Massaging the Data for Neurontin?
Are You Now, Or Have You Ever Been. . .?
That Didn't Take Very Long
Those Zanies at Angewandte Chemie
I'll See Your Conflicts, and Raise You?
Ignoring Patents?
PNAS Shuts a Door
Abstract Abstracts
To What End?
Rings of the Future!
Ghostwriting
Farewell to Hard Copies
What's With Those People at Elsevier, Anyway?
Another Sack of Raving Nonsense Is Slated For Publication
Word For Word - But Why?
Merck, Elsevier, and Fakery
No MAGIC Involved
Dear Dr. Derek. . .
Your Paper (That Sack of Raving Nonsense) Has Been Accepted!
(Don't) Trust And (Don't) Verify
Don't Like It? Well, Just Don't Cite It!
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Hexacyclinol - Another Request
Hexacyclinol: A Forensic Case
A Long Tail Indeed
New Chemistry
Publish Your Work The Easy Way
My Compound Goes Where the Wild Goose Goes
Squinting At The Pictures, The Modern Way
Publish And Be Damned, Most Likely
Impact Factors: Can We Pretend That They Don't Exist?
PNAS: Read It, or Not?
Open Source Science?
Lowe's Law of Diurnal Distribution
Unknown - But You Can Buy It
Cut It Out. Cut It Out Now.
Writing It Down
Pfizer Loses, So Far
Pfizer vs. the NEJM: A Legal Showdown
Fakery And Its Ends
Big Steaming Heaps of Fraud
Recycle, Reuse, Republish
They Can Be Ranked - Somehow
Le Dernier Cri
Kids These Days!
Exciting Nonsense Wins Another One
Neat! Wish It Were True!
Let Us Now Turn To the Example of Yo' Mama
Expensive Reading
Sorting Through the Piles
Exalted Paper
Into The Trackless Wilderness
Cro-MagnonDraw
An Innocent Question
PLoS One
Take Your Shots (For Real, This Time?)
Ars Longa, But Instructions to Authors Say "Brevis"
German, Anyone?
Take Your Shots
Paper on a Shelf
Down the Chute: Your Call
Part Nine Hundred and Forty Two in a Series. . .
To The Third Darn Decimal Place
Hexacyclinol? Or Not?
The New England Journal And Its PR Flacks
Reading Our Own Press Releases
Don't Know. Don't Care?
Which World Do We Live In, Anyway?
Journal of Biological Chemical Biochemical Chemical Biology
NEJM vs. Its Contributors, Round Two
Plenty of Tar to Go Around
Complaints From a Fossil
Ranking the Journals - Try It at Home!
More Fun With Impact Factors
Our Friend the Impact Factor
Sitting Through Some Chemistry
Up There, and Down Here
Bonfire of the Wonder Drugs
Samuel Johnson Was Right
Success Has A Thousand Fathers
Housecleaning
Take it Off!
Around and About
Le Dernier Cri
The Dull Edge of Nanotech
The Agents Report Back
Meetings and Their Discontents
No Better Than the Rest of Them
Our Cheerful Buddy, The Cell Membrane
The Universe, Which Others Call the Library. . .
Catching Up
Back in the Stacks
The Library of Babel
Life of the Party
Cruel to Be Kind

Things I Won't Work With
Your Metal Azide Worries Are Over
Friendly, Welcoming Triazides. No, Really.
Mercury Azides. I'll Get Right On Those For You.
Things I Won't Work With: Dimethylcadmium
Chlorine Trifluoride: Some Empirical Findings
Things I Won't Work With: Azidoazide Azides, More Or Less
Things I Won't Work With: Selenophenol
Things I Won't Work With: Hexanitrohexaazaisowurtzitane
Things I Won't Work With: Chlorine Azide
Things I Won't Work With: Nitrotetrazole Oxides
Whoa! Time to Clean the Fishtank! Uh, Root Canal Appointment! Look at the Time!
Max Gergel's Memoirs
Things I Won't Work With: Small, Smelly Isocyanides
Things I Won't Work With: Dioxygen Difluoride
Things I Won't Work With: Straight Dimethyl Zinc
Things I Won't Work WIth: Thioacetone
Things I Won't Work With: Chalcogen Polyazides
Things I Won't Work With: Azidotetrazolate Salts
Things I Won't Work With: Triazadienyl Fluoride
Things I Won't Work With: Cyanogen Azide
Sand Won't Save You This Time
Things I Won't Work With: Frisky Perchlorates
Can't Buy These Thrills
Things I Won't Work With: Carbon Diselenide
Things I Won't Work With: Ozonides
Things I Won't Work With: Polyazides
Things I Won't Work With: A Nasty Condensed Gas
Thing I Won't Work WIth (2): Nickel Carbonyl
Things I Won't Touch (1)

Things I'm Glad I Don't Do
Max Gergel's Second Odd Book
"I Will Cherish the Personally Autographed Book Forever. . ."
Fun With Tunichromes
Things I'm Glad I Don't Do: Isolating Ciguatoxin

Toxicology
A Question: Monoclonal Antibodies in the Clinic
Why Not Bromine?
Thalidomide, Bound to Its Target
All Natural And Chemical Free
The Virtual Clinical Trial: Not Quite Around the Corner
Whack-A-Mole
A New Way to Study Hepatotoxicity
Pesticide Toxicity?
The West Virginia Formaldehyde Claim Is Nonsense
Parkinson's From the Environment?
The FDA: Too Loose, Or Appropriately Brave?
Ariad (And Its Drug) In Trouble
Ariad's Ponatinib Runs Into Big Trouble
Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
Eight Toxic Foods: The Aftermath
Eight Toxic Foods: A Little Chemical Education
Sulfa Side Effects, Decades Later
The Medical Periodic Table
Is Glyphosate Poisoning Everyone?
Trouble for a Whole Class of Diabetes Drugs?
Affymax In Trouble
Thallium Poisoning, Again
Suing A Generic Drug Maker: When And How?
ABT-199 Clinical Trial Suspended (Updated)
Eating A Whole Bunch of Random Compounds
Merck's Tredaptive Comes to a Halt
Sudden Onset of Promiscuity
Accelerated Approval And Its Discontents
The CETP Rogues Gallery
A Kinase Inhibitor Learns Something New
Live By The Bricks, Die By The Bricks
Predicting Toxicology
Antidepressant Drugs and Cell Membranes
The Artificial Intelligence Economy?
Side Effects - Lots of Side Effects
Statin Safety
Dapagliflozin Goes Down (For the Last Time?)
Do We Believe These Things, Or Not?
Pushing Onwards with CETP: The Big Money and the Big Risks
Cyclodextrin's Day in the Sun
siRNA - Toxicity in the Eye?
Predicting Toxicology On A Chip?
Alzheimer's: The News Is Not Getting Better
Generic Drug Warning Labels: The Supreme Court Speaks
The Supreme Court Slams Big Pharma? Not Exactly.
Potassium Iodide Pills
Thallium Poisoning? In This Day and Age?
Oh, And While You're At It. . .
More On Homemade Street Drugs
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Avandia: Was the Evidence Buried?
Natural Products: Not the Best Fit for Drugs?
Steve Nissen vs. GlaxoSmithKline
Vaccines in the Court
Steve Nissen's Meeting with GSK
Avandia: Off the Market or Not?
A Database of Side Effects
An Alzheimer's Compound Runs Into Big Trouble
GE Healthcare's Idiotic Libel Suit
Recommended Books For Medicinal Chemists, Part One
Side Effects, Predicted?
Statin Safety?
REACH for the Sky!
Arzoxifene: Not the Road to Big Profits?
Medarex, Ipilimumab, Prostate Cancer, And Reality
Into the Clinic. And Right Back Out.
Farewell to ACAT, and to Lots of Time and Money, Too
Niacin, No Longer Red-Faced?
Does Glucophage Make Alzheimer's Worse?
A Med-Chem Book Recommendation
Torcetrapib: What Was the Problem? And Does It Matter?
Avandia: Trouble, Run Head to Head
Liable For Generics? You Are Now!
Sticking It to Proteins
Down The Chute in Phase III
Taranabant Is No More
Vytorin: Another Round of Nasty Results
Merck, Vioxx: Seventeen and Three
Killing Proteins Wholesale
Cordaptive Q and A
Exubera, Safety, and No Guarantees
And You Thought Exubera Was A Disaster Before
Pre-emption For Real?
Pfizer vs. the NEJM: A Legal Showdown
Taranabant in Trouble?
Off Target? Which Target Did You Mean?
A Look Under the Hood
The Animal Testing Hierarchy
Avandia: Going Under for the Third Time?
Thimerosal. Again.
Avandia's Latest Round
Rimonabant: Down to Earth
Rimonabant, Out In the Light
Avandia: Trouble or Not?
A New FDA?
There's Toxicity and There's Toxicity
Bigger And Greasier
Too Near the Sun?
The Litvinenko Case: More On Polonium and Alpha Particles
Polonium Poisoning
Ah, the Heck With the Error Bars
Touch Me Not
Merck: Unfigure-outable
Vioxx: 18 Months to Trouble?
Formally Undecideable
Rats Rule, Right?
Merck's Latest Underwhelming Data
The New England Journal And Its PR Flacks
NEJM vs. Its Contributors, Round Two
Mice, Humans, and Cancer
Pemoline Problems
Old Standbys
Remind Me Not to Do This Again
Once And For All
Tysabri's Fall
Waiting for the FDA
A Trial Too Far
Back Under the Sheets For Me
No Drug Is An Island
The FDA Weighs In
The Other COX-2 Shoe Drops
Die-oxin?
Safe, And Other Four-Letter Words
Cox-2 Confusion
How Bad Are the Cox-2 Inhibitors, Anyway?
More on Merck
A Day With All the Bark Left On It
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
The Dose Makes the Poison
Next on the Food Channel. . .
Odd Elements in Drugs
Osmium Tetroxide, Of All Things
A Mechanism for Thimerosal
How Drugs Die
Back on the Air
Clearance Sale
Neurotoxins
And While We're On the Subject - Mercury?
The Ames Test and the Real World
The Ames Test
Our Buddies at the FDA
What to Do When the Rats Die on You
And Always Keep Ahold of Nurse, For Fear of Finding Something Worse
Rats, For Fear of Worse
Toxicolottery

Who Discovers and Why
Peter Thiel's Uncomplimentary Views of Big Pharma
The NIH Takes a Look At How the Money's Spent
Drug Discovery in India
NIH Taking on More RIsk?
Standards of Proof
Organizing Research
Creativity Training For Creative Creators
An Inspirational Quote from Bernard Munos
Reworking Big Pharma
The GSK Jackpot
One. . .Million. . .Pounds (For a New Antibiotic?)
E. O. Wilson's "Letters to a Young Scientist"
Just Work on the Winners
AstraZeneca's Move To Hot, Happening Cambridge
Thought for the Day, On Interdisciplinary Research
Yuri Milner's Millions, And Where They're Going
An Anniversary
Whitesides on Discovery and Development
A Broadside Against The Way We Do Things Now
Nassim Taleb on Scientific Discovery
The Age of Nobel Chemistry Laureates
Chemistry's Mute Black Swans
Biotech Clusters
Scientific Literacy: Where Do You Stop?
More "More Scientists" Debate
How Not to Do Science Education
Drug Company Culture: It's Not Helping
Nobel Prizes in Chemistry For People Who Aren't Chemists
Roger Boisjoly and the Management Hat
Smugness as a Warning Sign
Of Drug Research and Moneyball
Ray Firestone's Take On Pharma's Plight
"You Guys Don’t Do Innovation. The iPad. That’s Innovative"
Hard, Hard Work in the Lab
The Economics of the Drug Industry: Big Can't Be Big Enough?
Bernard Munos Rides Again
Chinese Research: Not Quite the Juggernaut?
Right Up Next to Academia
Funding People, Not Projects?
Translation Needed
The Fox's Lament
Hedgehogs and Foxes Holding Erlenmeyer Flasks
Science: Good For Anything Else?
Where Drugs Come From: By Country
Peer Review's Problems
Where Drugs Come From: The Numbers
More on Garage Biotech
The Hours You Put In
Synthetic Chemistry: All Mined Out?
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
Columns Outside The Doors
Scientia Est Experientia
Not The End. Not At All
Alzheimer's Markers and Collaboration
Maybe We Should Make It More of a Game
Organic Chemistry: A Lack of Challenges?
Joy
Why Close One Research Site Over Another?
GSK's Biotechy World
What To Do With The Not-Quite-Worthless
All Those Worthless Papers
The Truth Shall Make Ye. . .Unhappy?
Scientific Discovery: Getting Older (And Less Lonely)
India's Research Culture
Prediction Markets, Idea Sharing, and So On
Garage Biotech
Biology By the Numbers
Munos On Big Companies and Small Ones
That Didn't Take Very Long
Fifty Years of Scientific History For You
The Best Ones Aren't Over Here Any More?
The Grant Application Treadmill
Industrial Research: More Grounded in Reality, or Not?
A Deuterium Deal
Competing (And Competing Unethically?)
Takeda Evaluating Scientists on "Quality"?
Genentech: Let's Hope He's Right
Roche Starts to Manage Things
Genentech's Culture: At Risk or Not?
Autism and Vaccines: Boiling Over Yet Again
10,000 Hours To Drug Discovery?
Science and Its Values
The Perils of Poor Equipment
New Year - I Hope!
Cheese Dip and Hydrochloric Acid
Neil Bartlett, 1932-2008
US and UK Biotech: Growth and Form
Open Source Science?
The Gates Foundation: Dissatisfied With Results?
Funding in the EU: The Simple Way
(No) Anarchy in the EU: A Report From Inside
Anarchy in the EU
An Eye For the Numbers
O Pioneers!
Rainbows and Fishing Expeditions
Winterize Your Ideas
Exciting Nonsense Wins Another One
And Speaking of Discovering Things. . .
Maybe Not Improved, But Definitely New
One Year
Three Things You Need
Why Now, And Not Before?
European Drugs, American Drugs
Little, Big
The Doctorate and Its Discontents
Deep Breaths
Failure: Not Your Friend, But Definitely Your Companion
Scientists, All Over
Hedgehogs in Stockholm
Inspirational Reading?
Where Do They Come From?
Now With the Great Taste of Fish!
Ask Not
Too Big to Discover Anything
You Can't Win If You Don't Play
Men and Women and Science and Jobs
Because I Never Lie, and I'm Always Right
A Scientific Aptitude Test?
Time and Chance
Needs and Wants
Pretty Much the Reason You'd Think
Crossing Your Fingers, Authoritatively
As Thin As a Soap Bubble
Very Wrong, or Very Right
Don't Talk To Yourself So Much
Progress Through Craziness
The Next Science
Right In Front of You
Research, The Right Way
The Root of All Results?
The Best Bad News He Ever Had
. . .Your Huddled Pharmas Yearning to Breath Free
Weinberg's "Golden Lessons"
Easy Parts and Hard Parts
Attitude
Europe, Again
The Future and Its Friends
So What's A Worthwhile Problem, Anyway?
Anything Worth Doing. . .
Giordano Bruno

Why Everyone Loves Us
Thiola, Retrophin, Martin Shkrell, Reddit, and More
The Most Unconscionable Drug Price Hike I Have Yet Seen
Incomprehensible Drug Prices? Think Again.
The Hep C Field Gets Nastier By the Minute
The Real Numbers on Tamiflu
Pfizer Seeks Respect
Should Drug Industry Research All Get Rejected For Publication?
More Behind-the-Scenes Maneuvering. How Wonderful.
Another Look At Marketing Vs. R&D In Pharma
The Atlantic on Drug R&D
Merck's Liptruzet: A Cause For Shame?
Costing Just Too Much
PhRMA And Why People Dislike the Drug Industry
A New Book on the Drug Industry And Its Image
LaMattina on Angell
Off-Label Promotion Is Legal, You Say?
Marcia Angell's Interview: I Just Can't
GSK Opens Up Its Trial Data
Getting Drug Research Really, Really Wrong
Merck's Madagascar Marketing Mess
DTC Advertising: Is That Where Things Fell Apart?
The NIH and Conflicts of Interest
Even Worse Than Reality
The Ethics of Avastin
How Others See Us (And How We See Them)
Excel and Exceed, Y'all
More on KV and Makena's Pricing
Makena's Price: What to Do?
Public Outreach
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Use Avastin! Don't Use Avastin!
Ahem: "Sell Gobs of Dope"?
Ghostwriting On the Larger Scale
Avandia Goes Down: A Research Rant
The Life of a Key Opinion Leader
Steve Nissen vs. GlaxoSmithKline
A Tiny Little Presentation Tip
Colchicine's Price Goes Through the Roof
Two Doses of Crazy
Selling It, And Selling It Hard
Fall From Grace
Lexapro, Forest Labs, and the Hard Sell
Spray-Painted For Success
Animal Rights, You Say?
Ghostwriting
And While We're Talking About Industry-Sponsored Studies. . .
Drug Industry Research: Reliable or Not?
Greedy Biotechs?
Cut It Out. Cut It Out Now.
Vytorin: It's A Pity
Pfizer Loses, So Far
Now Your Liver Doesn't Have to Make It For You
A Solution, Courtesy of the MIT Faculty
Pfizer vs. the NEJM: A Legal Showdown
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Arsenic, Patents, and the World
Incomprehension, Out For A Stroll
Now With Ethyl Mesylate!
Pecunia Non Olet?
More Avandia, And More on Marketing
Amgen: The Pythian Oracle Laughs Again
FDA Advisory Panels: Pay, No Play
Love and Anger
Vox Populi
There Is a Tide. . .
Garnier Strikes Back
Science Marches On
Let's See What the Sharks Think of These Steaks!
Angell's Book
So What's Wrong With A Little Money Changing Hands?
No Defense
Play It Again
Getting the Word Out, For Once
More From the Me-Too Front
Putting A Price on Proving It
One Of Us Is Hallucinating
A Rough Business
Voluntary. . .For Now
As Others See Us
Adam Smith Goes Pharmaceutical


Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 26724

Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 26724

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/footer.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/cat_index.php on line 26724